<SEC-DOCUMENT>0001193125-25-177024.txt : 20250808
<SEC-HEADER>0001193125-25-177024.hdr.sgml : 20250808
<ACCEPTANCE-DATETIME>20250808163053
ACCESSION NUMBER:		0001193125-25-177024
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20250808
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250808
DATE AS OF CHANGE:		20250808

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ImmunityBio, Inc.
		CENTRAL INDEX KEY:			0001326110
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				431979754
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37507
		FILM NUMBER:		251198932

	BUSINESS ADDRESS:	
		STREET 1:		3530 JOHN HOPKINS COURT
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		(844) 696-5235

	MAIL ADDRESS:	
		STREET 1:		3530 JOHN HOPKINS COURT
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NantKwest, Inc.
		DATE OF NAME CHANGE:	20150713

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Conkwest, Inc.
		DATE OF NAME CHANGE:	20140416

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ZelleRx Corp
		DATE OF NAME CHANGE:	20050504
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d29656d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ibrx="http://www.immunitybio.com/20250808" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2025-08-08_to_2025-08-08" id="ixv-281">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2025-08-08_to_2025-08-08">0001326110</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xlink:type="simple" xlink:href="ibrx-20250808.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase"/> </ix:references> <ix:resources> <xbrli:context id="duration_2025-08-08_to_2025-08-08"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-08-08</xbrli:startDate> <xbrli:endDate>2025-08-08</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div> <div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, D.C. 20549</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <ix:nonNumeric name="dei:DocumentType" contextRef="duration_2025-08-08_to_2025-08-08" id="ixv-292">8-K</ix:nonNumeric></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section 13 OR 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of The Securities Exchange Act of 1934</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2025-08-08_to_2025-08-08" format="ixt:datemonthdayyearen" id="ixv-293">August 8, 2025</ix:nonNumeric></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2025-08-08_to_2025-08-08" id="ixv-294">ImmunityBio, Inc.</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2025-08-08_to_2025-08-08" format="ixt-sec:stateprovnameen" id="ixv-295">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2025-08-08_to_2025-08-08" id="ixv-296">001-37507</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2025-08-08_to_2025-08-08" id="ixv-297">43-1979754</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or other jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(IRS Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2025-08-08_to_2025-08-08" id="ixv-298">3530 John Hopkins Court</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2025-08-08_to_2025-08-08" id="ixv-299">San Diego</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2025-08-08_to_2025-08-08" format="ixt-sec:stateprovnameen" id="ixv-300">California</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2025-08-08_to_2025-08-08" id="ixv-301">92121</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Address of principal executive offices, including zip code)</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s telephone number, including area code: <ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2025-08-08_to_2025-08-08" id="ixv-302">(844)</ix:nonNumeric> <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2025-08-08_to_2025-08-08" id="ixv-303">696-5235</ix:nonNumeric></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Not Applicable</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former name or former address, if changed since last report.)</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2025-08-08_to_2025-08-08" format="ixt-sec:boolballotbox" id="ixv-304">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2025-08-08_to_2025-08-08" format="ixt-sec:boolballotbox" id="ixv-305">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2025-08-08_to_2025-08-08" format="ixt-sec:boolballotbox" id="ixv-306">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2025-08-08_to_2025-08-08" format="ixt-sec:boolballotbox" id="ixv-307">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section 12(b) of the Act:</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2025-08-08_to_2025-08-08" id="ixv-308">Common Stock, par value $0.0001 per share</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2025-08-08_to_2025-08-08" id="ixv-309">IBRX</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2025-08-08_to_2025-08-08" format="ixt-sec:exchnameen" id="ixv-310">The Nasdaq Global Select Market</ix:nonNumeric></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2025-08-08_to_2025-08-08" format="ixt-sec:boolballotbox" id="ixv-311">&#9744;</ix:nonNumeric></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div> <div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;8.01.</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Other Events. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As previously disclosed in the Company&#8217;s Form <span style="white-space:nowrap">10-Q</span> filed on August&#160;5, 2025, on July&#160;29, 2025 the United States District Court for the Southern District of California (the &#8220;Court&#8221;) issued an order (the &#8220;Order&#8221;) providing for preliminary approval of a proposed settlement of the claims asserted nominally on behalf of ImmunityBio, Inc. (the &#8220;Company&#8221;) against the individual defendants named in the previously disclosed stockholder derivative actions entitled <span style="font-style:italic">Van Luven v. Soon-Shiong et al</span>., Case No. <span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">3:24-cv-02014-GPC-VET,</span></span></span></span> <span style="font-style:italic">Barbieri v. Soon-Shiong, et al</span>., Case No. <span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">3:25-cv-00416-AGS-JLB</span></span></span></span> and <span style="font-style:italic">Shin v. Soon-Shiong, et al</span>., Case No. <span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">3:25-cv-00423-JAH-DDL,</span></span></span></span> pending before the Court in accordance with the Stipulation and Settlement Agreement entered in May 2025 (the &#8220;Stipulation&#8221;). The proposed settlement calls for the Company to adopt certain corporate governance reforms as described further in the Stipulation, and pay attorneys&#8217; fees, which the Company expects to be funded by its insurance carrier, in exchange for a full and complete release and dismissal of the derivative actions. The Order set a final approval hearing for November&#160;4, 2025. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As required by the Order, the Company has posted a copy of the Notice of Proposed Derivative Settlement (the &#8220;Notice&#8221;) and the Stipulation to the Investor Relations section of the Company&#8217;s website, and on August&#160;8, 2025 is filing this Current Report on Form <span style="white-space:nowrap">8-K</span> and attaching the Notice and Stipulation as exhibits hereto, copies of which are attached as Exhibit 99.1 and 99.2, respectively. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;9.01</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">(d)</span>&#8195;<span style="font-style:italic">Exhibits</span>. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:5%"/>
<td style="width:92%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"><span style="font-weight:bold">Exhibit</span><br/><span style="font-weight:bold">Number</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Description of Exhibit</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d29656dex991.htm">Notice of Proposed Derivative Settlement. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.2*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d29656dex992.htm">Stipulation and Settlement Agreement. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document).</td></tr>
</table> <div style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</div>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:2%;vertical-align:top;text-align:left">*</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Filed herewith. </p></td></tr></table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0">


<tr>

<td style="width:45%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:4%"/>

<td style="vertical-align:bottom"/>
<td style="width:3%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:45%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">IMMUNITYBIO, INC.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">Registrant</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Date: August&#160;8,&#160;2025</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jason R. Liljestrom</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Jason R. Liljestrom</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">General Counsel and Corporate Secretary</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d29656dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES DISTRICT COURT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SOUTHERN DISTRICT OF CALIFORNIA </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IN RE IMMUNITYBIO, INC.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SHAREHOLDER
DERIVATIVE</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">LITIGATION</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTICE OF PROPOSED DERIVATIVE</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>SETTLEMENT</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Lead Case No.: <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">3:24-cv-02014-GPC-VET</FONT></FONT></FONT></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(Consolidated with</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">3:25-cv-00416-GPC-VET</FONT></FONT></FONT></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">3:25-cv-00423-GPC-VET)</FONT>
</FONT></FONT></FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Judge: Hon. Gonzalo P. Curiel</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Magistrate Judge:
Hon. Valerie E. Torres</P></TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>NOTICE OF PROPOSED SETTLEMENT OF SHAREHOLDER DERIVATIVE</U> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>MATTERS, HEARING THEREON, AND RIGHT TO APPEAR</U> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>TO:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>ALL CURRENT RECORD HOLDERS AND BENEFICIAL OWNERS OF COMMON STOCK OF IMMUNITYBIO, INC.
(&#147;IMMUNITYBIO&#148; OR &#147;THE COMPANY&#148;) AS OF JULY&nbsp;31, 2025 (THE &#147;RECORD DATE&#148;).</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>PLEASE READ THIS NOTICE CAREFULLY AND IN ITS ENTIRETY. THIS NOTICE RELATES TO A PROPOSED SETTLEMENT AND DISMISSAL OF LITIGATION AND
CONTAINS IMPORTANT INFORMATION REGARDING YOUR RIGHTS. YOUR RIGHTS MAY BE AFFECTED BY THESE LEGAL PROCEEDINGS. IF THE COURT APPROVES THE SETTLEMENT, YOU WILL BE FOREVER BARRED FROM CONTESTING THE APPROVAL OF THE PROPOSED SETTLEMENT AND FROM PURSUING
THE SETTLED CLAIMS. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>IF YOU HOLD IMMUNITYBIO COMMON STOCK FOR THE BENEFIT OF ANOTHER, PLEASE PROMPTLY TRANSMIT THIS DOCUMENT TO
SUCH BENEFICIAL OWNER. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>THE COURT HAS MADE NO FINDINGS OR DETERMINATIONS CONCERNING THE MERITS OF THE DERIVATIVE MATTERS. THE
RECITATION OF THE BACKGROUND AND CIRCUMSTANCES OF THE SETTLEMENT CONTAINED HEREIN DOES NOT CONSTITUTE THE FINDINGS OF THE COURT. IT IS BASED ON REPRESENTATIONS MADE TO THE COURT BY COUNSEL FOR THE PARTIES. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>THE DERIVATIVE MATTERS ARE NOT &#147;CLASS ACTIONS.&#148; THUS, THERE IS NO COMMON FUND UPON WHICH YOU CAN MAKE A </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>CLAIM FOR A MONETARY PAYMENT. THERE IS NO PROOF OF CLAIM FORM FOR SHAREHOLDERS TO SUBMIT
IN CONNECTION WITH THIS SETTLEMENT, AND SHAREHOLDERS ARE NOT REQUIRED TO TAKE ANY ACTION IN RESPONSE TO THIS NOTICE. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notice is hereby
provided to you of the proposed Settlement<SUP STYLE="font-size:75%; vertical-align:top">1</SUP> of the above-captioned consolidated derivative action and certain other Derivative Matters. This Notice is provided by order of the U.S. District Court
for the Southern District of California (the &#147;Court&#148;). It is not an expression of any opinion by the Court. It is to notify current shareholders of the terms of the proposed Settlement of the Derivative Matters. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>I.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>WHY THIS NOTICE HAS BEEN POSTED AND FILED WITH THE U.S. SECURITIES AND EXCHANGE COMMISSION
</B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This notice is intended to notify all ImmunityBio shareholders affected by the settlement of the derivative action
styled <I>In re ImmunityBio Inc. Shareholder Derivative Litigation</I>, Lead Case No. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">3:24-cv-02014</FONT></FONT> (S.D. Cal.) (S.D. Cal.) (the &#147;Derivative Action&#148;) and all
related Derivative Matters (as defined below) of the Proposed Settlement of Shareholder Derivative Matters, Hearing Thereon, and Right to Appear (the &#147;Notice&#148;). The following Settling Parties (defined herein) through their respective
counsel have agreed upon terms to settle the Derivative Matters and have signed the written Stipulation setting forth the terms of the Settlement: (i)&nbsp;plaintiffs Gary Van Luven (&#147;Van Luven&#148;), Angelo Barbieri (&#147;Barbieri&#148;),
and Bong Shin (&#147;Shin&#148;) (the &#147;Plaintiffs&#148;) and demand-made shareholders Roland Davies (&#147;Davies&#148;) and Chris Pallas (&#147;Pallas&#148;) (and together with Plaintiffs, the &#147;Shareholders&#148;), derivatively on behalf
of ImmunityBio, Inc. (&#147;ImmunityBio&#148; or the &#147;Company&#148;); (ii) nominal defendant ImmunityBio, a Delaware corporation; and (iii)&nbsp;individual defendants Patrick Soon-Shiong, Richard Adcock, Cheryl L. Cohen, Michael D. Blaszyk,
John Owen Brennan, Linda Maxwell, Wesley Clark, Christobel Selecky, Barry J. Simon, and David C. Sachs (the &#147;Individual Defendants,&#148; together with ImmunityBio, the &#147;Defendants,&#148; and together with ImmunityBio and the Shareholders,
the &#147;Parties&#148;). Subject to the approval of the Court and the terms and conditions expressly provided </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><SUP STYLE="font-size:75%; vertical-align:top">1</SUP> The capitalized terms used in this Notice and not otherwise defined are defined in the Stipulation and
Agreement of Settlement (&#147;Stipulation&#148;) (dated May&nbsp;19, 2025). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">therein, the Stipulation is intended by the Settling Parties to fully, finally, and forever resolve,
discharge, and settle the Released Claims. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;4, 2025, at 1:30 p.m., the Court will hold a hearing (the &#147;Settlement
Hearing&#148;). The purpose of the Settlement Hearing is to determine: (i)&nbsp;whether the Settlement of the Derivative Matters on the terms and conditions provided for in the Stipulation is fair, reasonable, and adequate to ImmunityBio and Current
ImmunityBio Shareholders, and should be finally approved by the Court; (ii)&nbsp;whether a Judgment as provided in, and attached as Exhibit E to the Stipulation should be entered; (iii)&nbsp;whether to approve Shareholders&#146; Counsel request for
attorneys&#146; fees and reimbursement of expenses, inclusive of requested Service Awards for Shareholders; and (iv)&nbsp;such other matters as may be necessary or proper in the circumstances. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>II.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>SUMMARY OF THE LITIGATION </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>A. Background </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ImmunityBio
is a vertically integrated biotechnology company developing next-generation therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. The Company&#146;s lead biologic product, Anktiva, is a novel <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> <FONT STYLE="white-space:nowrap">IL-15</FONT> agonist antibody-cytokine fusion protein. In May 2023, the Company announced that the FDA had rejected its BLA for
Anktiva, not because of any problems with Anktiva&#146;s safety and efficacy, but because of cGMP deficiencies identified during a <FONT STYLE="white-space:nowrap">pre-license</FONT> inspection of its CMOs. On April&nbsp;22, 2024, upon the
Company&#146;s submission of a second BLA, the FDA approved Anktiva with BCG for the treatment of <FONT STYLE="white-space:nowrap">BCG-unresponsive</FONT> <FONT STYLE="white-space:nowrap">non-muscle</FONT> invasive bladder cancer with carcinoma in
situ. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Derivative Matters allege that from March&nbsp;10, 2021 to May&nbsp;10, 2023, the Individual Defendants&#150;all of whom are
current or former Company officers and/or members of the Company&#146;s Board of Directors (the &#147;Board&#148;)&#150;breached their fiduciary duties to the Company and its shareholders and committed other alleged misconduct by failing to conduct
adequate oversight and making or causing the Company to make false and misleading statements that failed to disclose: (1)&nbsp;current Good Manufacturing Practices (&#147;cGMP&#148;) deficiencies at the Company&#146;s </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">third-party contract manufacturing organizations (&#147;CMOs&#148;) for Anktiva; (2)&nbsp;that one or more
of the Company&#146;s CMOs for Anktiva did in fact suffer from cGMP deficiencies; (3)&nbsp;that the foregoing deficiencies were likely to cause the U.S. Food and Drug Administration (the &#147;FDA&#148;) to reject the Company&#146;s Biologics
License Application (&#147;BLA&#148;) for Anktiva; and (4)&nbsp;that the Company overstated the regulatory approval prospects for the Anktiva BLA. The Derivative Matters allege that, as a result of the foregoing, the Company&#146;s stock price
declined, precipitating the filing of a related federal securities fraud class action lawsuit captioned <I>In re ImmunityBio, Inc. Securities Litigation</I>, No.
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">23-cv-01216</FONT></FONT> (S.D. Cal.) by a class of ImmunityBio investors against the Company and certain of its officers (the &#147;Securities Class&nbsp;Action&#148;). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>B. Procedural History </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
February&nbsp;9, 2024, Davies issued a demand to ImmunityBio to inspect the Company&#146;s books and records pursuant to 8 <I>Del. C.</I> &#167; 220 (&#147;Section&nbsp;220&#148;) in connection with the alleged misconduct described above.
Thereafter, pursuant to a confidentiality agreement, the Company produced <FONT STYLE="white-space:nowrap">non-public,</FONT> Board-level, internal corporate documents totaling over 600 pages to Davies that were responsive to his Section&nbsp;220
inspection demand (the &#147;220 Documents&#148;). After reviewing and analyzing the 220 Documents, on September&nbsp;17, 2024, Davies served the Board with a <FONT STYLE="white-space:nowrap">pre-suit</FONT> demand under Delaware law requesting that
the Board commence an investigation into the wrongdoing described above and alleged in the Derivative Matters, and/or file a lawsuit against the Individual Defendants regarding the same. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;24, 2024, Pallas made a substantially similar demand to inspect the Company&#146;s books and records pursuant to
Section&nbsp;220 in connection with the misconduct described above and alleged in the Derivative Matters. Thereafter, pursuant to a confidentiality agreement, the Company produced the 220 Documents to Pallas. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;29, 2024, plaintiff Van Luven filed in the Court a shareholder derivative complaint on behalf of nominal defendant ImmunityBio
against the Individual Defendants, asserting claims for violation of the Securities Exchange Act of 1934 (&#147;Exchange Act&#148;), for breach of fiduciary duty, unjust enrichment, and waste of corporate assets under Delaware law (the &#147;<I>Van
</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Luven</I> Action&#148;). On February&nbsp;25, 2025, plaintiff Barbieri filed a substantially similar
shareholder derivative complaint in the Court on behalf of nominal defendant ImmunityBio against certain of the Individual Defendants for breach of fiduciary duty and unjust enrichment under Delaware law, and for violations of the Exchange Act (the
&#147;<I>Barbieri</I> Action&#148;). On February&nbsp;26, 2025, plaintiff Shin filed a third substantially similar shareholder derivative complaint in the Court on behalf of nominal defendant ImmunityBio against the Individual Defendants asserting
claims for violation of the Exchange Act, and for breach of fiduciary duty, unjust enrichment, and waste of corporate assets under Delaware law (the &#147;<I>Shin</I> Action&#148;). These lawsuits are predicated on the same underlying factual
allegations and alleged wrongdoing as the Securities Class&nbsp;Action. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;2, 2025, the parties to the <I>Van Luven</I>,
<I>Barbieri</I>, and <I>Shin</I> Actions jointly moved to consolidate these actions and to appoint Kuehn Law, PLLC as Lead Counsel for Plaintiffs, which the Court granted that same day. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>C. Settlement Negotiations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Parties, by and through their undersigned attorneys, engaged in months of good-faith,
<FONT STYLE="white-space:nowrap">arm&#146;s-length</FONT> discussions and negotiations with regard to the possible settlement of the Derivative Matters. On December&nbsp;27, 2024, following initial discussions, certain of Shareholders&#146; Counsel
sent a detailed settlement demand to Defendants&#146; Counsel, including numerous proposed corporate governance reforms. On February&nbsp;14, 2025, Defendants&#146; Counsel responded to the settlement demand with a detailed counteroffer of proposed
corporate governance reforms. Shareholders&#146; Counsel and Defendants&#146; Counsel then continued to negotiate a potential settlement, exchanging numerous proposals and information and engaging in frank discussions regarding the strengths and
weaknesses of the claims and defenses at issue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;21, 2025, the Parties reached an agreement as to the material terms of the
proposed settlement and executed a confidential settlement term sheet (&#147;Term Sheet&#148;). Pursuant to the Term Sheet, the Company will adopt the corporate governance reforms (&#147;Corporate Governance Reforms&#148;) described in Section III
(below), that were subsequently approved by the Board on April&nbsp;4, 2025, subject to the Court&#146;s approval. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Parties did not discuss or negotiate the amount or payment of any attorneys&#146; fees
for Shareholders&#146; Counsel prior to executing the Term Sheet containing the Corporate Governance Reforms. In an attempt to facilitate a negotiation of an attorneys&#146; fee award, the Parties agreed, and did, participate in a private mediation
on April&nbsp;23, 2025 overseen by Jed Melnick, Esq., the same JAMS mediator who mediated the resolution of the Securities Class&nbsp;Action. The Parties were unable to reach an agreement as to Shareholders&#146; Counsel&#146;s attorneys&#146; fees.
The Parties have finalized the Stipulation without an attorneys&#146; fees component. Shareholders&#146; Counsel will file a fee and expense application to the Court simultaneously with Plaintiffs&#146; separate motion for final settlement approval,
to which Defendants may respond and/or oppose. The Court will determine whether to approve Shareholders&#146; Counsel&#146;s requested award of attorneys&#146; fees or some other amount the Court deems appropriate. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>III.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>TERMS OF THE PROPOSED DERIVATIVE SETTLEMENT </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The principal terms, conditions and other matters that are part of the Settlement, which is subject to approval by the Court, are summarized
below. This summary should be read in conjunction with, and is qualified in its entirety by reference to, the text of the Stipulation, which has been filed with the Court and is also available for viewing on the Investor Relations page of
ImmunityBio&#146;s website at <U>https://ir.immunityBio.com/</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Settlement and in consideration of the releases
set forth therein, ImmunityBio shall implement the corporate governance reforms, consistent with the terms and timing set forth below and in Exhibit A of the Stipulation and its subparts (the &#147;Reforms&#148;). The Company and its Board
acknowledge and agree that the Settlement and Reforms confer substantial and material benefits on the Company and Current ImmunityBio Shareholders, and that the Derivative Matters and Shareholders&#146; and Shareholders&#146; Counsel&#146;s efforts
were a substantial and material factor in causing ImmunityBio to adopt, implement, and/or maintain the Reforms. Specifically, the Company shall adopt and maintain the below described Reforms for a period of at least four (4)&nbsp;years: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>A.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>New Board Member </B>- On or before December&nbsp;31, 2025, the Board shall refresh itself by appointing one
(1)&nbsp;new independent director to the Board. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>B.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Enhancements to the Disclosure Committee Charter </B>&#150; Within (30)&nbsp;days of Final Approval of the
Settlement, the Board shall amend the Disclosure Committee Charter as set forth in Exhibit <FONT STYLE="white-space:nowrap">A-1</FONT> to the Stipulation. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>C.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Enhancements to the Audit Committee Charter </B>&#150; Within (30)&nbsp;days of Final Approval of the
Settlement, the Board shall amend the Disclosure Committee Charter as set forth in Exhibit <FONT STYLE="white-space:nowrap">A-2</FONT> to the Stipulation. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>D.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Public Posting of Corporate Governance Guidelines and Board Committee Charters </B>&#150; The Company will
continue to post on the Investor Relations/Governance Documents portion of the Company&#146;s public website the Company&#146;s Corporate Governance Guidelines, Code of Global Business Conduct and Ethics, Audit Committee Charter, Compensation
Committee Charter, Disclosure Committee Charter, Nominating and Corporate Governance Committee Charter, and the Related Party Transaction Committee Charter. If such documents are amended or revised, the Company will post these updated documents on
the Investor Relations portion of the Company&#146;s public website within a reasonable time after they have been adopted. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>E.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Quarterly Board Discussion Concerning Business Topics Relevant to Allegations in Derivative Matters
</B>&#150; Within (30)&nbsp;days of Final Approval of the Settlement, Company management shall ensure that they report to the Board at least quarterly concerning: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company&#146;s compliance with FDA regulations, the Company&#146;s compliance with cGMP, and the
Company&#146;s CMOs&#146; compliance with cGMP, identify any material risks relating thereto, and make any recommendations to mitigate any of these identified material risks; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Whether the Company&#146;s disclosures comport with the Company&#146;s compliance </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#8194;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">with FDA regulations, the Company&#146;s compliance with cGMP, and the Company&#146;s CMOs&#146; compliance
with cGMP, and identify material risks relating thereto, and whether the Company&#146;s disclosures require modification. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>F.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Annual Legal Department Review and Report on Effectiveness </B>&#150; The Company&#146;s Legal Department
will review and report to the Board of Directors at least annually with respect to the effectiveness of the Company&#146;s policies, procedures, and practices related to compliance with FDA regulations. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>G.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Employee Training </B>&#150; Within ninety (90)&nbsp;days of Final Approval of the Settlement, the Company
shall establish and/or maintain training program(s) that adhere to the following conditions: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company&#146;s Human Resources and Legal Departments shall be charged with primary responsibility for
developing, implementing, and/or maintaining annual employee training program(s) focused on compliance, internal controls policies and procedures, compliance risk assessment, and complaint reporting and investigation. The Company&#146;s Human
Resources and Legal Departments shall be authorized and provided the resources necessary to retain external consultants and vendors as they deem necessary to develop, implement, and/or maintain the training program(s). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The training shall be mandatory, in whole or in part, for Company employees based on their role in the Company
as determined by the Company&#146;s Human Resources and Legal Departments. Training shall be annual for all such persons, and in the event a person is appointed or hired after the annual training for a particular year, a special training session
shall be held for such individual within ninety (90)&nbsp;days of their appointment or hiring. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Training shall include coverage of risk assessment and compliance, the Company&#146;s Code of Conduct, the
Company&#146;s Insider Trading Policy, and all other manuals, policies, rules, or procedures established by the Company </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
concerning legal, ethical, or regulatory standards of conduct applicable to and to be observed in connection with work performed by such employee for the Company. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The training shall be mandatory for employees involved in (a)&nbsp;preparing the Company&#146;s financial
statements; (b)&nbsp;manufacturing the Company&#146;s products; (c) communicating with the FDA; (d)&nbsp;communicating with the Company&#146;s independent external auditor; and (e)&nbsp;and drafting, disseminating or producing the Company&#146;s
public statements, in each case as appropriate based on their role in the Company as determined by the Company&#146;s Human Resources and Legal Departments. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>IV.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>SHAREHOLDERS&#146; COUNSELS&#146; FEE AND EXPENSE AWARD AND SHAREHOLDERS&#146; SERVICE AWARDS
</B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to discussing attorneys&#146; fees and reimbursement of expenses for Shareholders&#146; Counsel, the Settling
Parties negotiated and agreed upon the Reforms to be adopted as part of theSettlement.Defendants acknowledge that the Settlement confers substantial benefits upon ImmunityBio and Current ImmunityBio Shareholders and, in recognition of those
substantial benefits, that Shareholders&#146; Counsel are entitled to an award of attorneys&#146; fees and expenses.Shareholders&#146; Counsel intend to petition the Court for an award of attorneys&#146; fees and litigation expenses not to exceed
$1,400,000 to Shareholders&#146; Counsel (the &#147;Fee and Expense Award&#148;). Defendants have not and do not agree to a Fee and Expense Award of $1,400,000 or that such an award is appropriate. Defendants are permitted to respond and/or oppose
the Fee and Expense Award application. ImmunityBio and its insurers are responsible for the payment of any Fee and Expense Award, and the Parties agree that no other person or entity shall have any responsibility to contribute to or pay the Fee and
Expense Award. To date, Shareholders&#146; Counsel have not received any payments for their efforts on behalf of ImmunityBio shareholders, nor have Shareholders&#146; Counsel been reimbursed for their <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> litigation expenses. The Fee and Expense Amount will compensate Shareholders&#146; Counsel for the substantial benefits achieved in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">the Derivative Matters, and the risks of undertaking the prosecution of the Derivative Matters on a
contingent basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Defendants agree not to oppose reasonable service awards in the amount up to $2,500 to each of the Shareholders to be
paid out of the Fee and Expense Amount in recognition of Shareholders&#146; efforts to achieve the Settlement&#146;s benefits to the Company, subject to Court approval (the &#147;Service Awards&#148;). </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>V.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>REASONS AND BENEFITS OF THE SETTLEMENT </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Counsel for the Settling Parties believe that the Settlement is in the best interests of ImmunityBio, and its shareholders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>A. Why Did the Shareholders Agree to Settle? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Shareholders and Shareholders&#146; Counsel brought the claims in good faith and continue to believe that the claims asserted in the
Derivative Matters have merit. However, the Shareholders and Shareholders&#146; Counsel recognize and acknowledge the expense, time, and uncertainty inherent in the continued prosecution of their claims in the Derivative Matters through trial and
any subsequent appeal(s). Shareholders and Shareholders&#146; Counsel also have taken into account the uncertain outcome and the risk of any litigation, especially in complex actions such as the Derivative Matters, as well as the difficulties and
delays inherent in such litigation. The Shareholders and Shareholders&#146; Counsel also are mindful of the inherent problems of proof of, and possible defenses to, the claims asserted in the Derivative Matters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based upon their investigation, Shareholders and Shareholders&#146; Counsel have concluded that the terms and conditions of the Stipulation
are fair, reasonable and adequate to Shareholders, Current ImmunityBio Shareholders, and ImmunityBio, and in their best interests, and have agreed to settle the claims raised in the Derivative Matters pursuant to the terms and provisions of the
Stipulation after considering, among other things: (a)&nbsp;the substantial benefits that Current ImmunityBio Shareholders and ImmunityBio have received or will receive from the Settlement; (b)&nbsp;the attendant risks of continued litigation; and
(c)&nbsp;the desirability of permitting the Settlement </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">to be consummated. In particular, Shareholders and Shareholders&#146; Counsel considered the significant
litigation risk inherent in shareholder derivative litigation. The law imposes significant burdens on plaintiffs for pleading and proving a shareholder derivative claim. While Shareholders believe their claims are meritorious, Shareholders
acknowledge that there is a substantial risk that the Derivative Matters may not succeed in producing a recovery in light of the applicable legal standards and possible defenses. Shareholders and Shareholders&#146; Counsel believe that, under the
circumstances, they have obtained the best possible relief for ImmunityBio and Current ImmunityBio Shareholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>B. Why Did the
Defendants Agree to Settle? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Defendants deny any and all allegations of wrongdoing, liability, violations of law, or damages arising
out of or related to any of the conduct, statements, acts, or omissions alleged in the Derivative Matters, and maintain that their conduct was at all times proper, in the best interests of ImmunityBio and its shareholders, and in compliance with
applicable law. They further deny any breach of fiduciary duties or violation of federal securities laws. The Defendants also deny that ImmunityBio or its shareholders were harmed by any conduct or lack thereof alleged in the Derivative Matters or
that could have been alleged therein. The Defendants assert that, at all relevant times, they acted in good faith and in a manner they reasonably believed to be in the best interests of ImmunityBio and all of its shareholders. Nevertheless,
Defendants wish to eliminate the uncertainty, distraction, risk, burden, and expense of further litigation, and to permit the operation of ImmunityBio without further distraction and diversion of its Board and personnel with respect to the
Derivative Matters. The Defendants have therefore determined to settle the Derivative Matters on the terms and conditions set forth in this Stipulation solely to put the Released Claims (as defined below) to rest, finally and forever, without in any
way acknowledging any wrongdoing, fault, liability, or damages. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>VI.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>SETTLEMENT HEARING </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;4, 2025, at 1:30 p.m., the Court will hold the Settlement Hearing either in person at the James M. Carter and Judith N. Keep
United States Courthouse, Courtroom 12A, 333 West Broadway, San Diego, California 92101 or by telephone or videoconference (at the discretion of the Court). At the Settlement Hearing, the Court will consider whether the Settlement is fair,
reasonable and adequate and thus should be finally approved and whether the Derivative Matters should be dismissed with prejudice pursuant to the Stipulation. The Court also will rule upon Shareholders&#146; Counsel&#146;s request for approval of
the Fee and Expense Amount to Shareholders&#146; Counsel and Shareholders&#146; Service Awards. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>VII.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>RIGHT TO ATTEND SETTLEMENT HEARING </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any Current ImmunityBio Shareholder may, but is not required to, appear in person at the Settlement Hearing. If you want to be heard at the
Settlement Hearing in opposition to the Settlement, the Fee and Expense Amount or the Service Award, then you must first comply with the procedures for objecting, which are set forth below. The Court has the right to change the hearing dates or
times without further notice. Thus, if you are planning to attend the Settlement Hearing, you should confirm the date and time before going to the Court. CURRENT IMMUNITYBIO SHAREHOLDERS WHO HAVE NO OBJECTION TO THE SETTLEMENT DO NOT NEED TO APPEAR
AT THE SETTLEMENT HEARING OR TAKE ANY OTHER ACTION. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>VIII.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>RIGHT TO OBJECT TO THE SETTLEMENT AND PROCEDURES FOR DOING SO </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You have the right to object to any aspect of the Settlement. You must object in writing, and you may request to be heard at the Settlement
Hearing. If you choose to object, then you must follow these procedures. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>A. You Must Make Detailed Objections in Writing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any objections must be presented in writing and must contain the following information: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notice of intent to appear at the Settlement Hearing; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Your name, legal address, and telephone number; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Proof of being a Current ImmunityBio Shareholder as of the Record Date and representation that you will
continue to own ImmunityBio common stock as of the date of the Settlement Hearing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The date(s) you acquired your ImmunityBio shares and the number of ImmunityBio shares held;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A <U>detailed statement</U> of your specific position with respect to the matters to be heard at the Settlement
Hearing, including a statement of each objection being made; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The grounds for each objection or the reasons for your desire to appear and to be heard. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Court will not consider any objection that does not substantially comply with these requirements. Any counsel retained by a purported
objector for the purpose of asserting an objection must make a notice of appearance on the Court by October&nbsp;21, 2025, which is fourteen (14)&nbsp;days prior to the Settlement Hearing. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>B. You Must Timely Deliver Written Objections to the Court and to Lead Counsel for Plaintiffs </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">YOUR WRITTEN OBJECTIONS MUST BE FILED WITH THE COURT AND SENT BY HAND OR BY FIRST CLASS MAIL, POSTAGE
<FONT STYLE="white-space:nowrap">PRE-PAID</FONT> TO SHAREHOLDERS&#146; COUNSEL. THE WRITTEN OBJECTIONS MUST BE FILED WITH THE COURT AND POSTMARKED NO LATER THAN OCTOBER&nbsp;7, 2025, WHICH IS TWENTY-EIGHT (28)&nbsp;CALENDAR DAYS PRIOR TO THE
SETTLEMENT HEARING to the following address: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Shareholders&#146; Counsel:</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Clerk of the Court:</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">Justin A. Kuehn<BR>KUEHN LAW, PLLC<BR>53 Hill Street, Suite 605<BR>Southampton, NY 11968<BR>Telephone: (833) <FONT STYLE="white-space:nowrap">672-0814</FONT><BR>justin@kuehn.law</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">United States District Court<BR>Southern District of California<BR>333 West Broadway, Suite 420<BR>San Diego, CA 92101</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Court will not consider any objection that is not timely filed with the Court and delivered to
Shareholders&#146; Counsel. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any person or entity who fails to object or otherwise requests to be heard in the manner </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">prescribed above will be deemed to have waived the right to object to any aspect of the Settlement or
otherwise request to be heard (including the right to appeal) and will be forever barred from raising such objection or request to be heard in this or any other action or proceeding, but shall otherwise be bound by the Judgment to be entered and the
releases to be given. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>IX.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>HOW TO OBTAIN ADDITIONAL INFORMATION </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Notice summarizes the Settling Parties&#146; Stipulation. It is not a complete statement of the events of the Derivative Matters or the
Stipulation. Although the Settling Parties believe that the descriptions about the Settlement that are contained in this Notice are accurate in all material respects, in the event of any inconsistencies between the descriptions in this Notice and
the Stipulation, the Stipulation will control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You may inspect the Stipulation and other papers at https://ir.immunityBio.com/. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">PLEASE DO NOT CALL, WRITE, OR OTHERWISE DIRECT QUESTIONS TO EITHER THE COURT OR THE CLERK&#146;S OFFICE. Any questions you have about matters
in this Notice should be directed by telephone or in writing to Shareholders&#146; Counsel at the address set forth above. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>X.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>NOTICE TO PERSONS OR ENTITIES HOLDING OWNERSHIP ON BEHALF OF OTHERS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Brokerage firms, banks and/or other persons or entities who held shares of ImmunityBio common stock for the benefit of others are requested to
immediately send this Notice to all of their respective beneficial owners. If Current ImmunityBio Shareholders have questions or comments about the Settlement, they should follow the procedures listed above. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated: July&nbsp;29, 2025</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">BY ORDER OF THE UNITED STATES<BR>DISTRICT COURT FOR THE SOUTHERN<BR>DISTRICT OF CALIFORNIA</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>d29656dex992.htm
<DESCRIPTION>EX-99.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES DISTRICT COURT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SOUTHERN DISTRICT OF CALIFORNIA </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IN RE IMMUNITYBIO, INC.</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">SHAREHOLDER DERIVATIVE
<B></B>LITIGATION</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>STIPULATION AND SETTLEMENT AGREEMENT</B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lead Case No.:
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">3:24-cv-02014-GPC-VET</FONT></FONT></FONT></FONT></P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(Consolidated with</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">3:25-cv-00416-GPC-VET</FONT>
</FONT></FONT></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">3:25-cv-00423-GPC-VET)</FONT>
</FONT></FONT></FONT></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Judge: Hon. Gonzalo P. Curiel</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Magistrate Judge: Hon. Valerie E. Torres<B> </B></P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">3:24-cv-02014-GPC-VET
</P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STIPULATION AND SETTLEMENT
AGREEMENT </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Stipulation and Settlement Agreement (the &#147;Stipulation&#148;) is made and entered
into as of May&nbsp;19, 2025, by and among: (i)&nbsp;plaintiffs Gary Van Luven (&#147;Van Luven&#148;), Angelo Barbieri (&#147;Barbieri&#148;), and Bong Shin (&#147;Shin&#148;) (the &#147;Plaintiffs&#148;) and demand-made shareholders Roland Davies
(&#147;Davies&#148;) and Chris Pallas (&#147;Pallas&#148;) (and together with Plaintiffs, the &#147;Shareholders&#148;), derivatively on behalf of ImmunityBio, Inc. (&#147;ImmunityBio&#148; or the &#147;Company&#148;); (ii) nominal defendant
ImmunityBio, a Delaware corporation; and (iii)&nbsp;individual defendants Patrick Soon-Shiong, Richard Adcock, Cheryl L. Cohen, Michael D. Blaszyk, John Owen Brennan, Linda Maxwell, Wesley Clark, Christobel Selecky, Barry J. Simon, and David C.
Sachs (the &#147;Individual Defendants,&#148; together with ImmunityBio, the &#147;Defendants,&#148; and together with ImmunityBio and the Shareholders, the &#147;Parties&#148;).<SUP STYLE="font-size:75%; vertical-align:top">1</SUP> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Parties, by and through their undersigned attorneys, have reached an agreement for the settlement of claims asserted or that could have
been asserted in in the above-captioned consolidated shareholder derivative matters&#151;<I>Van Luven v. Soon-Shiong, et al</I>., No. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">3:24-cv-02014</FONT></FONT> (S.D. Cal.),
<I>Barbieri v. Soon-Shiong, et al</I>., No. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">3:25-cv-00416</FONT></FONT> (S.D. Cal.), and <I>Shin v. Soon-Shiong, et al</I>., No. <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">3:25-cv-00423</FONT></FONT> (S.D. Cal.) (the &#147;Derivative Actions&#148;)&#151;and the related claims and allegations set forth in respective <FONT STYLE="white-space:nowrap">pre-suit</FONT> stockholder demands made
under Delaware law by Roland Davies and Chris Pallas (the &#147;Demands,&#148; collectively with the Derivative Actions, the &#147;Derivative Matters&#148;) on the terms set forth below (the &#147;Settlement&#148;), and subject to Court approval
pursuant to Rule 23.1 of the Federal Rules of Civil Procedure (&#147;Rule 23.1&#148;). This Stipulation is intended to fully, finally, and forever compromise, resolve, discharge, and settle all Released Claims (defined below), and to result in the
dismissal of the Derivative Actions with prejudice as against the Released Persons (defined below). </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><SUP STYLE="font-size:75%; vertical-align:top">1</SUP> Defendants in the <I>Van Luven</I>, <I>Barbieri</I>, and <I>Shin</I> actions are the
same, with the exception of Wesley Clark, John Owen Brennan, and Barry J. Simon, who are not named as defendants in the <I>Barbieri </I>action. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">3:24-cv-02014-GPC-VET </P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STIPULATION AND SETTLEMENT AGREEMENT </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>I.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>The Derivative Matters </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>A. Background </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ImmunityBio
is a vertically integrated biotechnology company developing next-generation therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. The Company&#146;s lead biologic product, Anktiva, is a novel <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> <FONT STYLE="white-space:nowrap">IL-15</FONT> agonist antibody-cytokine fusion protein. In May 2023, the Company announced that the FDA had rejected its BLA for
Anktiva, not because of any problems with Anktiva&#146;s safety and efficacy, but because of cGMP deficiencies identified during a <FONT STYLE="white-space:nowrap">pre-license</FONT> inspection of its CMOs. On April&nbsp;22, 2024, upon the
Company&#146;s submission of a second BLA, the FDA approved Anktiva with BCG for the treatment of <FONT STYLE="white-space:nowrap">BCG-unresponsive</FONT> <FONT STYLE="white-space:nowrap">non-muscle</FONT> invasive bladder cancer with carcinoma in
situ.&#8195; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Derivative Matters allege that from March&nbsp;10, 2021 to May&nbsp;10, 2023, the Individual Defendants&#150;all of whom
are current or former Company officers and/or members of the Company&#146;s Board of Directors (the &#147;Board&#148;)&#150;breached their fiduciary duties to the Company and its shareholders and committed other alleged misconduct by failing to
conduct adequate oversight and making or causing the Company to make false and misleading statements that failed to disclose: (1)&nbsp;current Good Manufacturing Practices (&#147;cGMP&#148;) deficiencies at the Company&#146;s third-party contract
manufacturing organizations (&#147;CMOs&#148;) for Anktiva; (2)&nbsp;that one or more of the Company&#146;s CMOs for Anktiva did in fact suffer from cGMP deficiencies; (3)&nbsp;that the foregoing deficiencies were likely to cause the U.S. Food and
Drug Administration (the &#147;FDA&#148;) to reject the Company&#146;s Biologics License Application (&#147;BLA&#148;) for Anktiva; and (4)&nbsp;that the Company overstated the regulatory approval prospects for the Anktiva BLA. The Derivative
Matters allege that, as a result of the foregoing, the Company&#146;s stock price declined, precipitating the filing of a related federal securities fraud class action lawsuit in this Court captioned <I>In re ImmunityBio, Inc. Securities
Litigation</I>, No. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">23-cv-01216</FONT></FONT> (S.D. Cal.) by a class of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">3:24-cv-02014-GPC-VET </P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STIPULATION AND SETTLEMENT AGREEMENT </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ImmunityBio investors against the Company and certain of its officers (the &#147;Securities
Class&nbsp;Action&#148;).<SUP STYLE="font-size:75%; vertical-align:top">2</SUP> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>B. Procedural History </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&nbsp;9, 2024, Davies issued a demand to ImmunityBio to inspect the Company&#146;s books and records pursuant to 8 <I>Del. C.</I>
&#167; 220 (&#147;Section&nbsp;220&#148;) in connection with the alleged misconduct described above. Thereafter, pursuant to a confidentiality agreement, the Company produced <FONT STYLE="white-space:nowrap">non-public,</FONT> Board-level, internal
corporate documents totaling over 600 pages to Davies that were responsive to his Section&nbsp;220 inspection demand (the &#147;220 Documents&#148;). After reviewing and analyzing the 220 Documents, on September&nbsp;17, 2024, Davies served the
Board with a <FONT STYLE="white-space:nowrap">pre-suit</FONT> demand under Delaware law requesting that the Board commence an investigation into the wrongdoing described above and alleged in the Derivative Matters, and/or file a lawsuit against the
Individual Defendants regarding the same. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;24, 2024, Pallas made a substantially similar demand to inspect the
Company&#146;s books and records pursuant to Section&nbsp;220 in connection with the misconduct described above and alleged in the Derivative Matters. Thereafter, pursuant to a confidentiality agreement, the Company produced the 220 Documents to
Pallas. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;29, 2024, plaintiff Van Luven filed in this Court a stockholder derivative complaint on behalf of nominal
defendant ImmunityBio against the Individual Defendants, asserting claims for violation of the Securities Exchange Act of 1934 (&#147;Exchange Act&#148;), for breach of fiduciary duty, unjust enrichment, and waste of corporate assets under Delaware
law (the &#147;<I>Van Luven</I> Action&#148;). On February&nbsp;25, 2025, plaintiff Barbieri filed a substantially similar stockholder derivative complaint in this Court on behalf of nominal </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><SUP STYLE="font-size:75%; vertical-align:top">2</SUP> On June&nbsp;20, 2024, the Court entered an Order granting in part and denying in part
the defendants&#146; motion to dismiss the Securities Class&nbsp;Action. On March&nbsp;17, 2025, the Court granted a motion for preliminary approval of a proposed $10.5&nbsp;million settlement of the Securities Class&nbsp;Action. A final settlement
approval hearing for the proposed Securities Class&nbsp;Action settlement is set for June&nbsp;13, 2025. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">3:24-cv-02014-GPC-VET </P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STIPULATION AND SETTLEMENT AGREEMENT </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">defendant ImmunityBio against certain of the Individual Defendants for breach of fiduciary duty and unjust
enrichment under Delaware law, and for violations of the Exchange Act (the &#147;<I>Barbieri</I> Action&#148;). On February&nbsp;26, 2025, plaintiff Shin filed a third substantially similar stockholder derivative complaint in this Court on behalf of
nominal defendant ImmunityBio against the Individual Defendants asserting claims for violation of the Exchange Act, and for breach of fiduciary duty, unjust enrichment, and waste of corporate assets under Delaware law (the &#147;<I>Shin</I>
Action&#148;). These lawsuits are predicated on the same underlying factual allegations and alleged wrongdoing as the Securities Class&nbsp;Action. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;2, 2025, the parties to the <I>Van Luven</I>, <I>Barbieri</I>, and <I>Shin</I> Actions jointly moved to consolidate these actions
and to appoint Kuehn Law as Lead Counsel for Plaintiffs, which the Court granted the same day. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>C. Settlement Negotiations&#8195;
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Parties, by and through their undersigned attorneys, engaged in months of good-faith,
<FONT STYLE="white-space:nowrap">arm&#146;s-length</FONT> discussions and negotiations with regard to the possible settlement of the Derivative Matters. On December&nbsp;27, 2024, following initial discussions, certain of Shareholders&#146; Counsel
sent a detailed settlement demand to Defendants&#146; Counsel, including numerous proposed corporate governance reforms. On February&nbsp;14, 2025, Defendants&#146; Counsel responded to the settlement demand with a detailed counteroffer of proposed
corporate governance reforms. Shareholders&#146; Counsel and Defendants&#146; Counsel then continued to negotiate a potential settlement, exchanging numerous proposals and information and engaging in frank discussions regarding the strengths and
weaknesses of the claims and defenses at issue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;21, 2025, the Parties reached an agreement as to the material terms of the
proposed settlement and executed a confidential settlement term sheet (&#147;Term Sheet&#148;). Pursuant to the Term Sheet, the Company will adopt the corporate governance reforms (&#147;Corporate Governance Reforms&#148;) attached hereto as Exhibit
A, that were subsequently approved by the Board on April&nbsp;4, 2025, subject to the Court&#146;s approval.&#8195; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">3:24-cv-02014-GPC-VET </P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STIPULATION AND SETTLEMENT AGREEMENT </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Parties did not discuss or negotiate the amount or payment of any attorneys&#146; fees
for Shareholders&#146; Counsel prior to executing the Term Sheet containing the Corporate Governance Reforms. In an attempt to facilitate a negotiation of an attorneys&#146; fee award, the Parties agreed, and did, participate in a private mediation
on April&nbsp;23, 2025 overseen by Jed Melnick, Esq., the same JAMS mediator who mediated the resolution of the Securities Class&nbsp;Action. The Parties were unable to reach an agreement as to Shareholders&#146; Counsel&#146;s attorneys&#146; fees.
As set forth in the Term Sheet, the Parties have finalized this Stipulation without an attorneys&#146; fees component. If the Settlement is preliminarily approved by the Court, Shareholders&#146; Counsel will file a fee and expense application to
the Court simultaneously with Plaintiffs&#146; separate motion for final settlement approval, to which Defendants may respond and/or oppose. The Court will determine whether to approve Shareholders&#146; Counsel&#146;s requested award of
attorneys&#146; fees or some other amount the Court deems appropriate. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>II.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>The Shareholders&#146; Claims and Reasons for Settlement </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Shareholders believe that the claims asserted in the Derivative Matters have merit, but also believe that the Settlement set forth below
provides substantial and material benefits for ImmunityBio and Current ImmunityBio Shareholders. In addition to these benefits, Shareholders and Shareholders&#146; Counsel have considered: (i)&nbsp;the attendant risks of continued litigation and the
uncertainty of the outcome of the Derivative Matters; (ii)&nbsp;the probability of success on the merits; (iii)&nbsp;the inherent problems of proof associated with, and possible defenses to, the claims asserted in the Derivative Matters;
(iv)&nbsp;the desirability of permitting the Settlement to be consummated according to its terms; (v)&nbsp;the expense and length of continued proceedings necessary to prosecute the Derivative Matters through trial(s) and appeal(s); and
(vi)&nbsp;the conclusion of Shareholders and Shareholders&#146; Counsel that the terms and conditions of the Settlement are fair, reasonable, and adequate, and that it is in the best interests of ImmunityBio and Current ImmunityBio Shareholders to
settle the Derivative Matters on the terms set forth herein. Shareholders&#146; entry into this </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">3:24-cv-02014-GPC-VET </P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STIPULATION AND SETTLEMENT AGREEMENT </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stipulation is not intended to be and shall not be construed as an admission or concession concerning the
relative strength or merit of the claims alleged in the Derivative Matters. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>III.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Defendants&#146; Denials of Wrongdoing or Liability and Reasons for Settlement </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Defendants deny any and all allegations of wrongdoing, liability, violations of law, or damages arising out of or related to any of the
conduct, statements, acts, or omissions alleged in the Derivative Matters, and maintain that their conduct was at all times proper, in the best interests of ImmunityBio and its shareholders, and in compliance with applicable law. They further deny
any breach of fiduciary duties or violation of federal securities laws. The Defendants also deny that ImmunityBio or its shareholders were harmed by any conduct or lack thereof alleged in the Derivative Matters or that could have been alleged
therein. The Defendants assert that, at all relevant times, they acted in good faith and in a manner they reasonably believed to be in the best interests of ImmunityBio and all of its shareholders.&#8195; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Nevertheless, Defendants wish to eliminate the uncertainty, distraction, risk, burden, and expense of further litigation, and to permit the
operation of ImmunityBio without further distraction and diversion of its Board and personnel with respect to the Derivative Matters. The Defendants have therefore determined to settle the Derivative Matters on the terms and conditions set forth in
this Stipulation solely to put the Released Claims (as defined below) to rest, finally and forever, without in any way acknowledging any wrongdoing, fault, liability, or damages.&#8195; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Nothing in this Stipulation shall be construed as any admission by the Defendants of any wrongdoing, fault, liability, or damages whatsoever.
This Stipulation is not a finding or evidence of the validity or invalidity of any claims or defenses in the Derivative Matters, any wrongdoing by the Defendants, or any damages or injury to ImmunityBio or its shareholders.&#8195; </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>IV.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Board Approval of the Settlement </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&nbsp;4, 2025, the Board reviewed the proposed Settlement and the Corporate Governance Reforms (Ex. A), and in the exercise of its
business judgment, unanimously </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">3:24-cv-02014-GPC-VET </P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STIPULATION AND SETTLEMENT AGREEMENT </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">determined that the proposed Settlement provides a substantial and material benefit to, and is in the best
interests of, the Company and its shareholders. The Board supports the Settlement as fair, reasonable, and adequate. If approved by the Court, the Board will cause ImmunityBio to adopt, implement, and maintain the Corporate Governance Reforms in the
time and manner specified. The Board acknowledges that the Derivative Matters and Shareholders&#146; and Shareholders&#146; Counsel&#146;s efforts were a substantial and material factor in causing ImmunityBio to agree to adopt, implement, and
maintain the Corporate Governance Reforms. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>V.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Terms of the Settlement </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, IT IS HEREBY STIPULATED AND AGREED, by and among the Parties subject to the approval of the Court pursuant to Rule 23.1, that
the Derivative Matters shall be fully and finally compromised and settled, the Released Claims shall be released as against the Released Persons, and the Derivative Actions shall be dismissed with prejudice as against the Released Persons, upon and
subject to the following terms and conditions of the Settlement: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>A. Definitions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.1. &#147;Current ImmunityBio Shareholders&#148; means any Person or Persons (as defined below) who are record or beneficial owners of
ImmunityBio common stock as of the close of business on the date of this Stipulation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.2. &#147;Defendants&#146; Counsel&#148; means
Wilson Sonsini Goodrich&nbsp;&amp; Rosati, P.C. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.3. &#147;Effective Date&#148; means Final Approval of Settlement, as defined below.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.4. &#147;Final&#148; means, with respect to any judgment or order, that (i)&nbsp;if no appeal is filed, the expiration date of the time
for filing or noticing of any appeal of the judgment or order; or (ii)&nbsp;if there is an appeal from the judgment or order, the date of (a)&nbsp;final dismissal of all such appeals, or the final dismissal of any proceeding on certiorari or
otherwise to review the judgment or order, or (b)&nbsp;the date the judgment or order is finally affirmed on an appeal, the expiration of the time to file a petition for a writ of certiorari or other form of review, or the denial of a writ of
certiorari or other form of review of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">3:24-cv-02014-GPC-VET </P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STIPULATION AND SETTLEMENT AGREEMENT </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">judgment or order, and, if certiorari or other form of review is granted, the date of final affirmance of
the judgment or order following review pursuant to that grant. However, any appeal or proceeding seeking subsequent judicial review pertaining solely to an order issued with respect to attorneys&#146; fees or expenses shall not in any way delay or
preclude the Judgment from becoming Final. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.5. &#147;Final Approval of Settlement&#148; means that (i)&nbsp;the Court has entered the
Judgment&#151;with no material modification to the form of Judgment&#151;approving the Settlement, dismissing Defendants from the Derivative Actions with prejudice on the merits and without costs to any party (except any costs specifically
identified in this Stipulation), and providing for the Releases set forth below; and (ii)&nbsp;such Judgment is Final; provided, however, and notwithstanding any provision to the contrary in this Stipulation, Final Approval of Settlement shall not
include (and the Settlement is expressly not conditioned on) the award of attorneys&#146; fees or the payment of expenses to counsel for any Person, including any appeal related to any such award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.6. &#147;Judgment&#148; means the Order and Final Judgment to be entered by the Court, substantially in the form annexed hereto as Exhibit
E, dismissing the Released Claims with prejudice as against the Released Persons. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.7. &#147;Notice&#148; means the Notice of Pendency
and Proposed Settlement of Action, substantially in the form annexed hereto as Exhibit D. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.8. &#147;Person&#148; means a natural person,
individual, corporation, partnership, limited partnership, limited liability partnership, limited liability company, association, joint venture, joint stock company, estate, legal representative, trust, unincorporated association, government, or any
political subdivision or agency thereof, or any other business or legal entity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.9. &#147;Shareholders&#146; Counsel&#148; means
(i)&nbsp;Kuehn Law, PLLC, (ii)&nbsp;Wolf Haldenstein Adler Freeman&nbsp;&amp; Herz LLP, (iii)&nbsp;The Rosen Law Firm, P.A., (iv) Schubert Jonckheer&nbsp;&amp; Kolbe LLP, (v)&nbsp;Shuman, Glenn&nbsp;&amp; Stecker, and (vi)&nbsp;Rigrodsky Law, P.A.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">3:24-cv-02014-GPC-VET </P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STIPULATION AND SETTLEMENT AGREEMENT </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.10. &#147;Released Claims&#148; means any and all manner of claims, demands, rights,
liabilities, losses, obligations, duties, damages, costs, debts, expenses, interest, penalties, sanctions, fees, attorneys&#146; fees, actions, potential actions, causes of action, suits, agreements, judgments, decrees, matters, issues and
controversies of any kind, nature, or description whatsoever, whether disclosed or undisclosed, accrued or unaccrued, apparent or not apparent, direct or derivative, foreseen or unforeseen, matured or not matured, suspected or unsuspected,
liquidated or not liquidated, fixed or contingent, including known claims and Unknown Claims (as defined below), whether based on state, local, foreign, federal, statutory, regulatory, common, or other law or rule (including claims within the
exclusive jurisdiction of the federal courts), that are, have been, could have been, could now be, or in the future could, can, or might be asserted, in the Derivative Matters or in any other court, tribunal, or proceeding (a)&nbsp;by the
Shareholders or any other Current ImmunityBio Stockholder directly or derivatively on behalf of ImmunityBio, or by ImmunityBio directly, against any of the Released Persons or (b)&nbsp;by the Released Persons against ImmunityBio or any other
Released Person, which, now or hereafter, are based upon, arise out of, or relate to any of the actions or inactions, transactions, occurrences, statements, representations, misrepresentations, omissions, allegations, facts, practices, events,
claims, or any other matters related to: (i)&nbsp;the allegations, claims, and events described in the complaints filed in the Derivative Actions; (ii)&nbsp;the allegations, claims, and events described in the Demands; and (iii)&nbsp;the Derivative
Actions and the institution, prosecution and settlement thereof; provided, however, &#147;Released Claims&#148; shall not include, and neither the Stipulation nor any aspect of the Settlement shall affect claims relating to enforcement of the
Settlement, the Stipulation, or any other agreement among any or all of the Parties and relevant insurers in connection with the Settlement. For the avoidance of doubt, Released Claims do not include the derivative claims asserted on behalf of
ImmunityBio, Inc. in an unrelated shareholder derivative lawsuit pending in the Delaware Court of Chancery captioned <I>Carlson v. Soon-Shiong, et al</I>., C.A. No. <FONT STYLE="white-space:nowrap">2024-1185-JTL.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">3:24-cv-02014-GPC-VET </P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STIPULATION AND SETTLEMENT AGREEMENT </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.11. &#147;Released Persons&#148; means ImmunityBio, the Individual Defendants, the
Shareholders, and their respective past, present, or future heirs, trusts, trustees, estates, beneficiaries, distributees, agents, employees, fiduciaries, partners, subsidiaries, affiliates, associated entities, stockholders, principals, officers,
directors, predecessors, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">predecessors-in-interest,</FONT></FONT> successors, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">successors-in-interest,</FONT></FONT>
assigns, advisors, attorneys, personal or legal representatives, associates and insurers, <FONT STYLE="white-space:nowrap">co-insurers</FONT> and <FONT STYLE="white-space:nowrap">re-insurers.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.12. &#147;Releases&#148; means the releases set forth in Section B below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.13. &#147;Preliminary Approval Order&#148; means an order preliminarily approving the Settlement, scheduling a Settlement final approval
hearing, and approving the form of notice and method of giving notice, substantially in the form annexed hereto as Exhibits B and C. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.14. &#147;Settlement Hearing&#148; means the hearing (or hearings) at which the Court will review and assess the adequacy, fairness, and
reasonableness of the Settlement, and the appropriateness and amount of the award of attorneys&#146; fees and expenses to be awarded by the Court (as set forth in Sections C and D, below). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.15. &#147;Summary Notice&#148; means the Summary Notice in the form annexed as Exhibit C. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.16. &#147;Unknown Claims&#148; means any claims that the Shareholders, any Released Person, ImmunityBio, or any other Current ImmunityBio
Stockholder does not know or suspect to exist in his, her, or its favor at the time of the release of the Released Claims against any of the Released Persons, including those which, if known by him, her, or it, might have affected his, her, or its
decision(s) with respect to the Settlement. With respect to any of the Released Claims, the Parties stipulate and agree that upon Final Approval of the Settlement, they shall be deemed to have, and by operation of the Judgment shall have, expressly
waived, relinquished, and released any and all provisions, rights, and benefits conferred by or under California Civil Code &#167; 1542, and any law of any state or territory of the United States, or principle of common law or foreign law, that is
similar, comparable, or equivalent to California Civil Code &#167; 1542. The Parties acknowledge that they may </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">3:24-cv-02014-GPC-VET </P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STIPULATION AND SETTLEMENT AGREEMENT </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">hereafter discover facts in addition to or different from those now known or believed to be true by them,
with respect to the subject matter of the Released Claims, but it is the intention of the Parties to completely, fully, finally, and forever compromise, settle, release, discharge, and extinguish any and all Released Claims without regard to the
subsequent discovery of additional or different facts. The Parties acknowledge that the foregoing waiver was separately bargained for and is a key element of the Settlement, and was relied upon by each and all of the Parties in entering into the
Settlement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>B. Settlement, Settlement Consideration, and Releases </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.1. In consideration for the full and final release, settlement, and discharge of any and all Released Claims against the Released Persons,
and notwithstanding the existence of any timely filed objections to the Settlement, or any collateral attack on the Settlement or any part thereof, or any appeal or potential for appeal from the Settlement or the Judgment, ImmunityBio shall
implement the Corporate Governance Reforms, consistent with the terms and timing set forth in Exhibit A and its subparts. The Company and its Board acknowledge and agree that the Settlement and Corporate Governance Reforms confer substantial and
material benefits on the Company and Current ImmunityBio Shareholders, and that the Derivative Matters and Shareholders&#146; and Shareholders&#146; Counsel&#146;s efforts were a substantial and material factor in causing ImmunityBio to adopt,
implement, and/or maintain the Corporate Governance Reforms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.2. Upon the Effective Date, the Shareholders, any Current ImmunityBio
Stockholder, the Defendants, and all of their respective <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">successors-in-interest,</FONT></FONT> predecessors, representatives, trustees, executors, administrators, heirs, assigns or
transferees, immediate and remote, and any person or entity acting for or on behalf of, or claiming under, any of them, and each of them, shall be deemed to have, and by operation of the Judgment approving this Settlement shall have, completely
discharged, dismissed with prejudice on the merits, released and settled, to the fullest extent permitted by law, the Released Claims against the Released Persons and shall be forever barred and enjoined </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">3:24-cv-02014-GPC-VET </P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STIPULATION AND SETTLEMENT AGREEMENT </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">from commencing, instituting, prosecuting, or continuing to prosecute any of the Released Claims against any
of the Released Persons. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.3. The Settlement shall eliminate all further risk and liability relating to the Released Claims, and the
Settlement shall be a final and complete resolution of all disputes asserted or that could be or could have been asserted with respect to the Released Claims. All such claims shall be enjoined from further prosecution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.4. Unless separately set forth herein, the Parties shall bear their own fees, costs, and expenses related to the Derivative Matters and the
Settlement, provided that nothing herein shall affect any claims that ImmunityBio or any of the Defendants may have against any of their respective insurers, <FONT STYLE="white-space:nowrap">co-insurers,</FONT> or reinsurers, to the extent such
claims are not otherwise released pursuant to other documentation. For the avoidance of doubt, this section is not intended to release and expressly does not release any claims by or among ImmunityBio, any Defendant, and their respective insurers, <FONT
STYLE="white-space:nowrap">co-insurers,</FONT> or reinsurers related to indemnification or advancement of defense costs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>C. Procedure
for Approval </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.1. As promptly as practical after execution of this Stipulation, the Plaintiffs shall move for a Preliminary Approval
Order that preliminarily approves the Settlement, authorizes notice of the Settlement, and schedules a date and time for the Settlement Hearing, substantially in the form attached hereto as Exhibit B.&#8195; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.2. Within ten (10)&nbsp;business days after the entry of the Preliminary Approval Order, ImmunityBio shall: (i)&nbsp;post the Notice and the
Stipulation (and exhibits thereto) on the Investor Relations page of ImmunityBio&#146;s website and maintain the documents there until after the Settlement Hearing; (ii)&nbsp;publish the Summary Notice in <I>Investors Business Daily</I> with a link
to the Company&#146;s Investor Relations webpage where the Notice and Stipulation (and exhibits thereto) will be posted and available; and (iii)&nbsp;file with the U.S. Securities and Exchange Commission (the &#147;SEC&#148;) the Notice and
Stipulation (and exhibits thereto) as exhibits to a Current Report on Form <FONT STYLE="white-space:nowrap">8-K.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">3:24-cv-02014-GPC-VET </P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STIPULATION AND SETTLEMENT AGREEMENT </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.3. ImmunityBio shall be solely responsible for all costs and expenses related to
disseminating the notices of the proposed Settlement (&#147;Notice Costs&#148;), regardless of whether the Court declines to approve the Settlement or the Effective Date otherwise fails to occur. In no event shall the Shareholders, any other
ImmunityBio stockholder, the Defendants, or any of their attorneys (including Shareholders&#146; Counsel) be responsible for any Notice Costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.4. The Parties submit that the proposed content and manner of notice, including the Summary Notice (Ex. C) and the Notice (Ex. D),
constitutes adequate and reasonable notice to Current ImmunityBio Shareholders pursuant to Rule 23.1, applicable law, and due process requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.5. The Plaintiffs shall move for final approval of the Settlement. As set forth in the Preliminary Approval Order, Plaintiffs shall
simultaneously submit papers in support of final approval of the Settlement and an application for a Fee and Expense Award for Shareholders&#146; Counsel (defined below). Defendants may, but are under no obligation to, submit additional papers in
support of the final approval of the Settlement. Defendants may respond and/or oppose the application for a Fee and Expense Award for Shareholders&#146; Counsel. No later than <FONT STYLE="white-space:nowrap">twenty-one</FONT> (21)&nbsp;days before
the Settlement Hearing, Defendants&#146; Counsel shall serve on Plaintiffs&#146; counsel in the Derivative Actions and file with the Court an appropriate declaration with respect to the notices. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.6. The Parties and their attorneys agree to use their individual and collective best efforts and to cooperate with one another to obtain
Court approval of the Settlement. The Parties and their attorneys further agree to use their individual and collective best efforts to effect, take, or cause to be taken all actions, and to do, or cause to be done, all things reasonably necessary,
proper, or advisable under applicable laws, regulations, and agreements to consummate and make effective, as promptly as practicable, the Settlement provided for hereunder and the dismissal of the Derivative Actions as to the Released Persons with
prejudice.&#8195; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">3:24-cv-02014-GPC-VET </P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STIPULATION AND SETTLEMENT AGREEMENT </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.7. If the Settlement embodied in this Stipulation is approved by the Court, the Parties
shall request that the Court enter the Judgment, substantially in the form attached hereto as Exhibit E. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>D. Attorneys&#146; Fees and
Expenses </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.1. Defendants acknowledge that the Settlement confers substantial benefits upon ImmunityBio and Current ImmunityBio
Shareholders and, in recognition of those substantial benefits, that Shareholders&#146; Counsel are entitled to an award of attorneys&#146; fees and expenses. Shareholders&#146; Counsel intend to petition the Court for an award of attorneys&#146;
fees and litigation expenses not to exceed $2,500,000 to Shareholders&#146; Counsel (the &#147;Fee and Expense Award&#148;). By this Stipulation, Defendants have not and do not agree to a Fee and Expense Award of $2,500,000 or that such an award is
appropriate. Defendants are permitted to respond and/or oppose the Fee and Expense Award application. Subject to Court approval, the Fee and Expense Award in the amount to be approved by the Court shall be paid to Shareholders&#146; Counsel,
notwithstanding the existence of any timely filed objections to the Fee and Expense Award or any appeal or potential for appeal therefrom, or any collateral attack on the Settlement or any part thereof or any appeal or potential appeal from the
Settlement or the Judgment, within twenty (20)&nbsp;business days after both of the following events have occurred: (i)&nbsp;the Court enters an order awarding the Fee and Expense Award; and (ii)&nbsp;Shareholders&#146; Counsel provides to
Defendants&#146; Counsel wire payment instructions, bank information on bank letterhead, an Internal Revenue Service (&#147;IRS&#148;) Form <FONT STYLE="white-space:nowrap">W-9,</FONT> and the name and contact information at the bank to confirm
instructions and receipt of payment. ImmunityBio and its insurers are responsible for the payment of any Fee and Expense Award, and the Parties agree that no other person or entity shall have any responsibility to contribute to or pay the Fee and
Expense Award.&#8195; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.2. If, after payment of any Fee and Expense Award, the Fee and Expense Award is reversed or reduced and such
order reducing or reversing the award has become Final, or the Settlement is terminated in accordance with the terms of this Stipulation, Shareholders&#146; Counsel shall, within ten (10)&nbsp;business days of any order from a court of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">3:24-cv-02014-GPC-VET </P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STIPULATION AND SETTLEMENT AGREEMENT </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">appropriate jurisdiction terminating the Settlement or reducing the Fee and Expense Award, return to the
payor(s) the difference between the Fee and Expense Award paid to Shareholders&#146; Counsel, on the one hand, and any attorneys&#146; fees and expenses ultimately and finally awarded on appeal, further proceedings on remand, or otherwise on the
other hand. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.3. The Fee and Expense Award shall be the sole compensation for Shareholders&#146; Counsel in connection with the
Derivative Matters and the Settlement and shall be allocated pursuant to agreement among Shareholders&#146; Counsel. Defendants and the Released Persons shall have no responsibility or liability whatsoever with respect to that allocation of the Fee
and Expense Award to or among Shareholders&#146; Counsel or any other counsel to any stockholder or plaintiff in another matter with whom Shareholders&#146; Counsel has agreed to allocate a portion of the Fee and Expense Award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.4. The Individual Defendants shall not be liable or have any personal payment obligations in connection with the Settlement. Defendants
shall not be liable for or obligated to pay any fees, expenses, costs, or disbursements, or to incur any expense on behalf of, any person or entity (including, without limitation, the Shareholders or Shareholders&#146; Counsel), directly or
indirectly, in connection with the Derivative Matters or the Settlement, except as expressly provided for in this Stipulation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.5. This
Stipulation, the Settlement, the Judgment, and whether the Judgment becomes Final, are not conditioned upon the approval of an award of attorneys&#146; fees, costs, or expenses, either at all or in any particular amount, by the Court.
Shareholders&#146; Counsel warrants that no portion of any such award of attorneys&#146; fees or expenses shall be paid to Shareholders, except as may be approved by the Court. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.6. The Parties further stipulate that Plaintiffs&#146; Counsel may apply to the Court for service awards up to twenty-five hundred dollars
($2,500.00) for each of the Shareholders, only to be paid upon Court approval, and to be paid from the Fee and Expense Amount in recognition of the Shareholders&#146; participation and efforts in the initiation, prosecution, and settlement of the
Derivative Matters. The failure of the Court </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">3:24-cv-02014-GPC-VET </P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STIPULATION AND SETTLEMENT AGREEMENT </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">to approve any requested service award(s), in whole or in part, shall have no effect on the Settlement.
Neither the Company nor any of the Individual Defendants shall be liable for any portion of any service award(s). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>E. Stay Pending
Court Approval </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.1. Pending Court approval of the Stipulation, the Parties agree to stay any and all proceedings in the Derivative
Actions other than those incident to the Settlement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.2. Except as necessary to pursue the Settlement and determine Shareholders&#146;
Counsel&#146;s Fee and Expense Award (if any), until the earlier of the Effective Date or an order of the Court substantially denying or declining to approve the Settlement in accordance with the Stipulation, the Parties agree not to institute,
commence, prosecute, continue, or in any way participate in, whether directly or indirectly, representatively, individually, derivatively on behalf of ImmunityBio, or in any other capacity, any action or other proceeding asserting any Released
Claims. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.3. Notwithstanding Paragraphs 5.1 and 5.2, nothing herein shall in any way impair or restrict the rights of any Party to defend
this Stipulation or to otherwise respond in the event any Person objects to the Stipulation, the proposed Judgment to be entered, and/or Plaintiffs&#146; fee and expense application. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>F. Effect of Disapproval, Cancellation, or Termination </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.1. The Shareholders, ImmunityBio, and the Individual Defendants (provided, with respect to Defendants, that Defendants unanimously agree
amongst themselves) shall each have the right to terminate the Settlement and this Stipulation solely by providing written notice of their election to do so (&#147;Termination Notice&#148;) to the other Parties within thirty (30)&nbsp;days of:
(i)&nbsp;the Court&#146;s refusal to approve this Stipulation or any part of it that materially affects any Party&#146;s rights or obligations hereunder; (ii)&nbsp;the Court&#146;s declining to enter the Judgment in any material respect; or
(iii)&nbsp;the date upon which the Judgment is modified or reversed in any material respect by an appellate court. Neither a modification nor a reversal on appeal of the amount of fees, costs, and expenses awarded by the Court </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">3:24-cv-02014-GPC-VET </P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STIPULATION AND SETTLEMENT AGREEMENT </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">to Shareholders&#146; Counsel shall be deemed a material modification of the Judgment or this Stipulation.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.2. In the event that the Settlement is terminated pursuant to its terms or the Effective Date otherwise fails to occur for any other
reason, then: (i)&nbsp;the Settlement and this Stipulation (other than this Section F and Paragraph 3.3 above) shall be canceled and terminated; (ii)&nbsp;any judgment entered in the Derivative Actions and any related orders entered by the Court
shall in all events be treated as vacated, <I>nunc pro tunc</I>; (iii)&nbsp;the Releases provided under the Settlement shall be null and void; (iv)&nbsp;to the extent the Fee and Expense Award has been paid, it shall be repaid to the persons who
paid on behalf of any Defendants within ten (10)&nbsp;business days after termination of the Settlement; (v)&nbsp;the fact of the Settlement shall not be admissible in any proceeding before any court or tribunal; (vi)&nbsp;all proceedings in the
Derivative Matters shall revert to their status as of immediately prior to the filing of this Stipulation, and no materials created by or received from another party that were used in, obtained during, or related to settlement discussions shall be
admissible for any purpose in any court or tribunal, or used, absent consent from the disclosing party, for any other purpose or in any other capacity, except to the extent that such materials are otherwise required to be produced during discovery
in any other litigation; (vii)&nbsp;the Parties shall jointly petition the Court for a revised schedule for further proceedings; and (viii)&nbsp;the Parties shall proceed in all respects as if the Settlement and this Stipulation (other than this
Section F and Paragraph 3.3 above) had not been entered into by the Parties. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>G. No Admission of Liability </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.1. It is expressly understood and agreed that neither the Settlement nor any act or omission in connection therewith is intended or shall be
deemed or argued to be evidence of or to constitute an admission or concession by: (a)&nbsp;the Defendants as to (i)&nbsp;the truth of any fact alleged by the Shareholders, (ii)&nbsp;the validity of any claims or other issues raised, or which might
be or might have been raised, in the Derivative Matters or in any other litigation, (iii)&nbsp;the deficiency of any defense that has been or could have been asserted in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">3:24-cv-02014-GPC-VET </P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STIPULATION AND SETTLEMENT AGREEMENT </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">the Derivative Matters or in any litigation, or (iv)&nbsp;any wrongdoing, fault, or liability of any kind by
any of them, which each of them expressly denies; or (b)&nbsp;the Shareholders that any of their claims are without merit, that any of the Defendants or Released Persons had meritorious defenses, or that damages or other relief recoverable in the
Derivative Matters would not have exceeded the terms of the Settlement. The Parties or any Released Persons may file this Stipulation and/or Judgment in any action that has been or may be brought against them in order to support a claim or defense
based on principles of <I>res judicata</I>, collateral estoppel, release, good faith settlement, judgment bar or reduction, or any other theory of claim preclusion or issue preclusion or similar defense or counterclaim or in connection with any
insurance litigation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>H Miscellaneous Provisions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.1. This Stipulation shall be deemed to have been mutually prepared by the Parties and shall not be construed against any of them by reason of
authorship. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.2. The Parties agree that in the event of any breach of this Stipulation, all of the Parties&#146; rights and remedies at
law, equity, or otherwise, are expressly reserved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.3. The Parties agree there will be no public announcements regarding the specific
terms of this Settlement until ImmunityBio has announced or disclosed it or the Stipulation has been filed with the Court. To the extent permitted by law, all agreements made and orders entered during the course of the Derivative Matters relating to
the confidentiality of documents or information shall survive this Stipulation.&#8195; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.4. This Stipulation, its exhibits and any
related agreement executed between ImmunityBio, the Individual Defendants, and the relevant insurers, embody the entire agreement and understanding of the Parties and supersede all prior agreements and understandings, if any, in respect of the
subject matter contained herein. No representations, warranties, or statements of any nature whatsoever, whether written or oral, have been made to or relied upon by any Party concerning the subject matter of this Stipulation, other than the
representations, warranties and covenants expressly set forth in such documents. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">3:24-cv-02014-GPC-VET </P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STIPULATION AND SETTLEMENT AGREEMENT </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.5. This Stipulation may be executed in one or more counterparts, each of which shall be
deemed to be an original and all of which shall constitute one and the same document. Any signature to the Stipulation by means of facsimile or electronic scanning shall be treated in all manner and respects as an original signature and shall be
considered to have the same binding legal effect as if it were the original signed version thereof and without any necessity for delivery of the originally signed signature pages in order for this to constitute a binding agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.6. The headings herein are used for the purpose of convenience only and are not meant to have legal effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.7. Each counsel or other person executing this Stipulation on behalf of any Party warrants that he or she has the full authority to bind his
or her principal to this Stipulation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.8. The Shareholders represent and warrant that none of the Shareholders&#146; claims referred to
in this Stipulation or that could have been alleged in the Derivative Matters have been assigned, encumbered, or in any manner transferred in whole or in part. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.9. This Stipulation shall not be modified or amended, nor shall any provision of this Stipulation be deemed waived, unless such
modification, amendment, or waiver is in writing and executed by or on behalf of the Party(ies) against whom such modification, amendment, or waiver is sought to be enforced.&#8195; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.10. Any failure by any Party to insist upon the strict performance by any other Party of any of the provisions of this Stipulation shall not
be deemed a waiver of any of the provisions hereof, and such party, notwithstanding such failure, shall have the right thereafter to insist upon the strict performance of any and all of the provisions of this Stipulation to be performed by such
other Party. Waiver by any Party of any breach of this Stipulation by any other Party shall not be deemed a waiver of any other prior or subsequent breach of this Stipulation, and failure by any Party to assert any claim for breach of this
Stipulation shall not be deemed to be a waiver as to that or any other breach and will not preclude any Party from seeking to remedy a breach and enforce the terms of this Stipulation. Each of the Parties&#146; respective obligations hereunder are
several and not joint, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">3:24-cv-02014-GPC-VET </P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STIPULATION AND SETTLEMENT AGREEMENT </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">and the breach or default by one Party shall not be imputed to, nor shall any Party have any liability or
responsibility for, the obligations of any other Party herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.11. This Stipulation shall be binding upon, and inure to the benefit of,
the successors and assigns of the Parties hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.12. Notwithstanding the entry of the Judgment, the Court shall retain jurisdiction
with respect to the implementation, enforcement, and interpretation of the terms of the Stipulation, and all Parties submit to the jurisdiction of the Court for all matters relating to the administration, enforcement, and consummation of the
Settlement and the implementation, enforcement, and interpretation of the Stipulation, including, without limitation, any matters relating to awards of attorneys&#146; fees and expenses to Plaintiffs&#146; Counsel. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.13. The construction and interpretation of this Stipulation shall be governed by and construed in accordance with the laws of the State of
Delaware and without regard to the laws that might otherwise govern under principles of conflicts of law applicable hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.14. Without
further order of the Court, the Parties hereto may agree to reasonable extensions of time to carry out any of the provisions of the Stipulation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.16. The following exhibits are annexed hereto and incorporated herein by reference: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Exhibit A: Corporate Governance Reforms; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Exhibit B: Preliminary Approval Order; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Exhibit C: Summary Notice; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Exhibit D: Notice of Pendency and Proposed Settlement of Action; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Exhibit E: Final Order and Judgment. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, IT IS HEREBY AGREED by the undersigned as of the date noted above. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">3:24-cv-02014-GPC-VET </P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STIPULATION AND SETTLEMENT AGREEMENT </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="49%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated: May&nbsp;19, 2025</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">By<SUP STYLE="font-size:75%; vertical-align:top">:</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Gregory L. Watts</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Gregory L. Watts, State Bar No.&nbsp;197126</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">W<SMALL>ILSON</SMALL> S<SMALL>ONSINI</SMALL> G<SMALL>OODRICH</SMALL>&nbsp;&amp; R<SMALL>OSATI</SMALL>, P.C.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">701 Fifth Avenue, Suite 5100</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Seattle, WA 98104-7036</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Telephone: (206) <FONT STYLE="white-space:nowrap">883-2500</FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">gwatts@wsgr.com</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Natalie J. Morgan, State Bar No.&nbsp;211143</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">W<SMALL>ILSON</SMALL> S<SMALL>ONSINI</SMALL> G<SMALL>OODRICH</SMALL>&nbsp;&amp; R<SMALL>OSATI</SMALL>, P.C.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">12235 El Camino Real</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">San Diego, CA 92130-3002</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Telephone: (858) <FONT STYLE="white-space:nowrap">350-2300</FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">nmorgan@wsgr.com</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Counsel for Individual Defendants and</I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Nominal Defendant ImmunityBio, Inc.</I></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Betsy C. Manifold</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Betsy C. Manifold, State Bar No.&nbsp;182450</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Rachele R. Byrd, State Bar No.&nbsp;190634</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Alex J. Tramontano,
State Bar No.&nbsp;276666</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">WOLF HALDENSTEIN ADLER FREEMAN</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&amp; HERZ LLP</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">750 B Street, Suite 1820</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">San Diego, CA 92101</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Telephone: (619) <FONT STYLE="white-space:nowrap">239-4599</FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">manifold@whafh.com</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">byrd@whafh.com</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">tramontano@whafh.com</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Justin A. Kuehn (admitted <I>pro hac vice</I>)</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">KUEHN LAW, PLLC</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">53 Hill Street, Suite 605</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Southampton, NY 11968</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Telephone: (833) <FONT STYLE="white-space:nowrap">672-0814</FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">justin@kuehn.law</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>Counsel for Plaintiff Gary Van Luven</I></P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">3:24-cv-02014-GPC-VET </P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STIPULATION AND SETTLEMENT AGREEMENT </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="49%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Robert C. Schubert</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Robert C. Schubert, State Bar No.&nbsp;62684</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dustin L. Schubert, State Bar No.&nbsp;254876</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SCHUBERT
JONCKHEER&nbsp;&amp; KOLBE LLP</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">2001 Union St., Suite 200</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">San Francisco, CA 94123</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Telephone: (415) <FONT STYLE="white-space:nowrap">788-4220</FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">rschubert@sjk.law</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">dschubert@sjk.law</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Counsel for Plaintiff-Angelo Barbieri</I></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Laurence M. Rosen</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Laurence M. Rosen, State Bar No.&nbsp;219683</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">THE ROSEN LAW FIRM, P.A.</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">355 S. Grand Avenue, Suite
2450</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Los Angeles, CA 90071</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Telephone: (213) <FONT STYLE="white-space:nowrap">785-2610</FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">lrosen@rosenlegal.com</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Counsel for plaintiff Bong Shin</I></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Brett D. Stecker</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Brett D. Stecker</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SHUMAN, GLENN, &amp; STECKER</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">326 W. Lancaster
Ave.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Ardmore, PA 19003</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Telephone: (303) <FONT STYLE="white-space:nowrap">861-3003</FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">brett@shumanlawfirm.com</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Counsel for Shareholder Roland Davies</I></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Seth D. Rigrodsky</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Seth D. Rigrodsky</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Vincent A. Licata</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">RIGRODSKY LAW, P.A.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">825 East Gate Boulevard,
Suite 300</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Garden City, NY 11530</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(516) <FONT
STYLE="white-space:nowrap">683-3519</FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">sdr@rl-legal.com</FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">vl@rl-legal.com</FONT></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><I>Counsel for Shareholder Chris Pallas</I></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">3:24-cv-02014-GPC-VET </P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STIPULATION AND SETTLEMENT AGREEMENT </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Exhibit A </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>ImmunityBio, Inc. Corporate Governance Reforms </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:Times New Roman">The Board of Directors (the &#147;Board&#148;) of ImmunityBio, Inc. (&#147;ImmunityBio&#148; or the &#147;Company&#148;) has agreed to adopt
or maintain the following corporate governance reforms (the &#147;Reforms&#148;). The Company shall implement and/or maintain, where applicable, the Reforms described below for four (4)&nbsp;years from the effective date of the settlement and
resolution of the Derivative Matters. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">I.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">New Board Member </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:Times New Roman">After execution of this term sheet concerning the Derivative Matters but on or before December&nbsp;31, 2025, the Board shall refresh itself by
appointing one (1)&nbsp;new independent director to the Board of Directors. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">II.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Enhancements to the Disclosure Committee Charter </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:Times New Roman">No later than thirty (30)&nbsp;days after issuance of an order approving the final settlement and resolution of the Derivative Matters, the
Board shall amend the Disclosure Committee Charter as set forth in Exhibit 1 attached hereto. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">III.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Enhancements to the Audit Committee Charter </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:Times New Roman">No later than thirty (30)&nbsp;days after issuance of an order approving the final settlement and resolution of the Derivative Matters, the
Board shall amend the Audit Committee Charter as set forth in Exhibit 2 attached hereto. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">IV.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Public Posting of Corporate Governance Guidelines and Board Committee Charters </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:Times New Roman">The Company will continue to post on the Investor Relations/Governance Documents portion of the Company&#146;s public website the
Company&#146;s Corporate Governance Guidelines, Code of Global Business Conduct and Ethics, Audit Committee Charter, Compensation Committee Charter, Disclosure Committee Charter, Nominating and Corporate Governance Committee Charter, and the Related
Party Transaction Committee Charter. If such documents are amended or revised, the Company will post these updated documents on the Investor Relations portion of the Company&#146;s public website within a reasonable time after they have been
adopted. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">V.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Quarterly Board Discussion Concerning Business Topics Relevant to Allegations in Derivative Claims
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:Times New Roman">No later than thirty (30)&nbsp;days after issuance of an order approving the final settlement and resolution of the
Derivative Matters, Company management shall ensure that they report to the Board at least quarterly: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-6- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company&#146;s compliance with FDA regulations, the Company&#146;s compliance with Current Good
Manufacturing Practices (&#147;cGMP&#148;), and the Company&#146;s contract manufacturing organizations&#146; (&#147;CMOs&#148;) compliance with cGMP, identify any material risks relating thereto, and make any recommendations to mitigate any of
these identified material risks. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Whether the Company&#146;s disclosures comport with the Company&#146;s compliance with FDA regulations, the
Company&#146;s compliance with cGMP, and the Company&#146;s CMOs&#146; compliance with cGMP, and identify material risks relating thereto, and whether the Company&#146;s disclosures require modification. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">VI.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Annual Legal Department Review and Report on Effectiveness </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:Times New Roman">The Company&#146;s Legal Department will review and report to the Board of Directors at least annually with respect to the effectiveness of the
Company&#146;s policies, procedures, and practices related to compliance with FDA regulations. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">VII.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Employee Training </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:Times New Roman">No later than ninety (90)&nbsp;days after issuance of an order approving the final settlement of the Derivative Actions and resolution of the
Derivative Claims, the Company shall establish and/or maintain training program(s) that adhere to the following conditions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company&#146;s Human Resources and Legal Departments shall be charged with primary responsibility for
developing, implementing, and/or maintaining annual employee training program(s) focused on compliance, internal controls policies and procedures, compliance risk assessment, and complaint reporting and investigation. The Company&#146;s Human
Resources and Legal Departments shall be authorized and provided the resources necessary to retain external consultants and vendors as they deem necessary to develop, implement, and/or maintain the training program(s). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The training shall be mandatory, in whole or in part, for Company employees based on their role in the Company
as determined by the Company&#146;s Human Resources and Legal Departments. Training shall be annual for all such persons, and in the event a person is appointed or hired after the annual training for a particular year, a special training session
shall be held for such individual within ninety (90)&nbsp;days of their appointment or hiring. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Training shall include coverage of risk assessment and compliance, the Company&#146;s Code of Conduct, the
Company&#146;s Insider Trading Policy, and all other manuals, policies, rules, or procedures established by the Company concerning legal, ethical, or regulatory standards of conduct applicable to and to be observed in connection with work performed
by such employee for the Company. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-7- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The training shall be mandatory for employees involved in (a)&nbsp;preparing the Company&#146;s financial
statements; (b)&nbsp;manufacturing the Company&#146;s products; (c)&nbsp;communicating with the FDA; (d)&nbsp;communicating with the Company&#146;s independent external auditor; and (e)&nbsp;and drafting, disseminating or producing the
Company&#146;s public statements, in each case as appropriate based on their role in the Company as determined by the Company&#146;s Human Resources and Legal Departments. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">*** </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:Times New Roman">The Company and the
Company&#146;s Board will acknowledge that the Derivative Matters and the efforts of counsel for Van Luven, Barbieri, Shin, Pallas, and Davies in connection therewith were a substantial and material factor in causing the Company to adopt, implement,
and/or maintain the Reforms, and that the Reforms provide substantial and material benefits to the Company and are in the best interests of the Company and its shareholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-8- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT 1 </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>IMMUNITYBIO, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DISCLOSURE COMMITTEE CHARTER </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PURPOSE</B>: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purpose of the Disclosure
Committee (the &#147;<B>Committee</B>&#148;) of ImmunityBio, Inc. (the &#147;<B>Company</B>&#148;) is to consider the materiality of information and to determine disclosure obligations and to report such matters to the Chief Executive Officer
(&#147;<B>CEO</B>&#148;) and Chief Financial Officer (&#147;<B>CFO</B>&#148; and, together with the CEO, &#147;<B>Certifying Officers</B>&#148;) with the
goal<FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">s</U></FONT><FONT STYLE="font-family:Times New Roman"> of ensuring that</FONT><FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt"> (i)</U></FONT><FONT STYLE="font-family:Times New Roman">&nbsp;the information required in the Company&#146;s reports
filed</FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt"> with the U.S. Securities and Exchange Commission (&#147;SEC&#148;)</U></FONT><FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt"> </U></FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#ff0000"><STRIKE>under the Securities Exchange
Act of 1934, as amended, </STRIKE></FONT><FONT STYLE="font-family:Times New Roman">is recorded, processed, summarized and reported on a timely and accurate
basis</FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">; and (ii)&nbsp;other information communicated in the Company&#146;s SEC reports, quarterly earnings press
releases, and prepared statements for quarterly earnings calls, and other press releases and public statements, including but not limited to information concerning the Company&#146;s drug development, clinical trials, compliance with Current Good
Manufacturing Practices (&#147;cGMP&#148;), and interactions with the U.S. Food and Drug Administration (&#147;FDA&#148;) and similar foreign regulators, is not materially false or misleading</U></FONT><FONT STYLE="font-family:Times New Roman">. In
furtherance of this purpose, the Committee shall design, adopt and implement procedures and policies in connection with the information-gathering and reporting process, including those set forth below. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>COMMITTEE MEMBERSHIP AND ORGANIZATION</B>: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE;padding-bottom:2pt; margin-bottom:-1pt; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Committee is established pursuant to the authority of the Certifying Officers and is intended to follow the
suggestion of the<FONT COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt"> SEC</U></FONT> <FONT COLOR="#ff0000"><STRIKE>Securities and Exchange Commission (&#147;<B>SEC</B>&#148;) </STRIKE></FONT>that is contained in SEC Release
No.&nbsp;33-8124, 34-46427 &#147;Certification of Disclosure in Companies&#146; Quarterly and Annual Reports&#148; to establish a disclosure committee. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE;padding-bottom:2pt; margin-bottom:-1pt; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Committee shall be chaired by the
<FONT COLOR="#ff0000"><STRIKE>CFO</STRIKE></FONT><FONT COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">General Counsel (&#147;GC&#148;)</U></FONT>, <FONT COLOR="#ff0000"><STRIKE>(</STRIKE></FONT>or as otherwise determined by
the <FONT COLOR="#ff0000"><STRIKE>President </STRIKE></FONT><FONT COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">CEO </U></FONT>and CFO<FONT COLOR="#ff0000"><STRIKE>)</STRIKE></FONT>. The Committee
Chair<FONT COLOR="#ff0000"><STRIKE>person</STRIKE></FONT>&#146;s responsibilities shall be to<FONT COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt"> (a)&nbsp;preside over Committee meetings, (b)</U></FONT>&nbsp;coordinate the
activities and internal communication of the Committee, <FONT COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">(c)</U></FONT>&nbsp;<FONT COLOR="#ff0000"><STRIKE>to </STRIKE></FONT>call meetings of the Committee as appropriate,
<FONT COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">(d)</U></FONT>&nbsp;<FONT COLOR="#ff0000"><STRIKE>to </STRIKE></FONT>coordinate communication with
<FONT COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">inside and/or</U></FONT><FONT COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt"> </U></FONT>outside legal counsel in a manner consistent with
preserving the attorney-client privilege, <FONT COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">(e)&nbsp;meet with the Audit Committee Chair, as deemed necessary by the Audit Committee Chair or the Disclosure Committee
Chair,</U></FONT> and<FONT COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt"> (</U></FONT>f<FONT COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">)</U></FONT>&nbsp;<FONT COLOR="#ff0000"><STRIKE>to
</STRIKE></FONT>serve as the principal liaison between the Committee and the <FONT COLOR="#ff0000"><STRIKE>President </STRIKE></FONT><FONT COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">CEO</U></FONT> and CFO, while
implementing the information gathering <FONT COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">and review</U></FONT> processes in accordance with the requirements of this charter within the various business units or departments
of the Company. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-1- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE;padding-bottom:2pt; margin-bottom:-1pt; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The members of the Committee shall be no fewer than <FONT COLOR="#ff0000"><STRIKE>three</STRIKE></FONT><FONT
 COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt"> four</U></FONT> (<FONT COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">4</U></FONT><FONT COLOR="#ff0000"><STRIKE>3</STRIKE></FONT>)&nbsp;officers of
the Company from relevant developmental backgrounds, including the Company&#146;s <FONT COLOR="#ff0000"><STRIKE>President</STRIKE></FONT><FONT COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt"> CEO,</U></FONT> <FONT
 COLOR="#ff0000"><STRIKE>and </STRIKE></FONT>CFO<FONT COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">, </U></FONT><FONT COLOR="#ff0000"><STRIKE>General
Counsel</STRIKE></FONT><FONT COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">GC, and Chief Compliance Officer</U></FONT>. Committee members shall consult with the Company&#146;s
management<FONT COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt"> (including the Company&#146;s Chief Operating Officer, Chief Medical Officer, and Senior Vice President of Regulatory Affairs)</U></FONT>, investor relations
function, <FONT COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">internal audit function,</U></FONT> independent auditors,<FONT COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt"> inside and
outside</U></FONT> legal counsel, Audit Committee<FONT COLOR="#ff0000"><STRIKE> (in particular, the financial expert members of the Audit Committee)</STRIKE></FONT>, and Board of Directors, as appropriate. Representatives of the Company&#146;s
outside counsel, representatives of the Company&#146;s independent auditors and other personnel of the Company or representatives of its outside advisors may be invited to attend meetings of the Committee, as the Committee deems necessary or
appropriate in performing its functions. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE;padding-bottom:2pt; margin-bottom:-1pt; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Changes to the membership of the Committee shall be determined by the
<FONT COLOR="#ff0000"><STRIKE>President</STRIKE></FONT> <FONT COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">CEO</U></FONT> and CFO as necessary in light of changes in the Company&#146;s business, operations, organization or
management. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>COMMITTEE<FONT STYLE="font-family:Times New Roman" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt"> AUTHORITY</U></FONT> </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE;padding-bottom:2pt; margin-bottom:-1pt; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">1.</U></FONT></TD>
<TD ALIGN="left" VALIGN="top">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt"></U></FONT><FONT COLOR="#008000"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">The
 Committee reports to the Certifying Officers, who, in consultation with legal counsel, maintain ultimate decision- making authority regarding
</U></FONT><FONT COLOR="#008000"><strike><u>our</u></strike></FONT><FONT COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">the
Company&#146;s</U></FONT><FONT COLOR="#008000"><U STYLE="border-bottom:1pt double; padding-bottom:1pt"> external disclosures.</U></FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE;padding-bottom:2pt; margin-bottom:-1pt; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">2.</U></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; " ALIGN="left"><FONT COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">The Committee has the authority to retain
separate and independent advisors at the Company&#146;s expense to provide advice and counsel concerning the Company&#146;s disclosure practices and public disclosure obligations.</U></FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="font-family:Times New Roman" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">COMMITTEE</U></FONT> RESPONSIBILITIES<FONT
STYLE="font-family:Times New Roman" COLOR="#ff0000"><STRIKE> AND AUTHORITY</STRIKE></FONT>: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#008000"><STRIKE>The Committee reports to the Certifying Officers, who, in consultation with legal counsel, maintain ultimate decision making authority regarding our external
disclosures.</STRIKE></FONT><FONT STYLE="font-family:Times New Roman"> The Committee&#146;s responsibilities are to assist the Certifying Officers in: </FONT></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE;padding-bottom:2pt; margin-bottom:-1pt; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Establishing and maintaining a process (&#147;<B>Disclosure Controls</B>&#148;) designed to ensure that<FONT
 COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt"> (a)</U></FONT>&nbsp;information required to be disclosed by the Company in its filings with the SEC <FONT COLOR="#ff0000"><STRIKE>and other information that the Company
discloses to the investment community </STRIKE></FONT>is recorded, processed<FONT COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">,</U></FONT><FONT COLOR="#ff0000"><STRIKE> and</STRIKE></FONT> summarized and reported <FONT
 COLOR="#ff0000"><STRIKE>accurately and</STRIKE></FONT><FONT COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">on a</U></FONT> timely<FONT COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt"> and accurate
basis; and (b)&nbsp;that other information communicated</U></FONT><FONT COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt"> in the Company&#146;s SEC reports, quarterly earnings press releases, prepared statements for quarterly
earnings calls, and other press releases and public statements, including but not limited to information concerning the Company&#146;s drug development, clinical trials, compliance with cGMP, and interactions with the FDA and similar foreign
regulators, is not materially false or misleading</U></FONT>. Disclosure<FONT COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt"> C</U></FONT><FONT COLOR="#ff0000"><STRIKE>c</STRIKE></FONT>ontrols will include sub-certifications
in such form and to be executed by such persons determined by the Committee to be appropriate<FONT COLOR="#ff0000"><STRIKE> and policies and procedures to assess the effectiveness of the Disclosure
Controls</STRIKE></FONT><FONT COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">.</U></FONT>; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE;padding-bottom:2pt; margin-bottom:-1pt; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consulting with the Company&#146;s internal audit function (if any) regarding the Company&#146;s internal
controls<FONT COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">.</U></FONT><FONT COLOR="#ff0000"><STRIKE>;</STRIKE></FONT> </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-2- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE;padding-bottom:2pt; margin-bottom:-1pt; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Preparing<FONT COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt"> and
reviewing</U></FONT> the<FONT COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt"> Company&#146;s periodic filings with the SEC, including</U></FONT>
quarterly<FONT COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt"> reports</U></FONT>, annual <FONT COLOR="#ff0000"><STRIKE>and current
</STRIKE></FONT>reports<FONT COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">,</U></FONT> and proxy statements<FONT COLOR="#ff0000"><STRIKE>, including the preparation of time and responsibility schedules for such
documents</STRIKE></FONT><FONT COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">.</U></FONT><FONT COLOR="#ff0000"><STRIKE>;</STRIKE></FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE;padding-bottom:2pt; margin-bottom:-1pt; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Evaluating<FONT COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt"> and
assessing</U></FONT> the Company&#146;s Disclosure Controls as of the end of each fiscal quarter<FONT COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">.</U></FONT><FONT COLOR="#ff0000"><STRIKE>;</STRIKE></FONT>
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE;padding-bottom:2pt; margin-bottom:-1pt; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT COLOR="#ff0000"><STRIKE>5.</STRIKE></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT COLOR="#ff0000"><STRIKE></STRIKE></FONT>Documenting the procedures taken in preparing the quarterly,
annual and current reports and proxy statements and evaluating the Company&#146;s<FONT COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt"> D</U></FONT><FONT COLOR="#ff0000"><STRIKE>d</STRIKE></FONT>isclosure
<FONT COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">C</U></FONT><FONT COLOR="#ff0000"><STRIKE>c</STRIKE></FONT>ontrols<FONT COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">.</U></FONT> <FONT
 COLOR="#ff0000"><STRIKE>and procedures; and</STRIKE></FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE;padding-bottom:2pt; margin-bottom:-1pt; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT COLOR="#ff0000"><STRIKE>6.</STRIKE></FONT><FONT COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">5.</U></FONT></TD>
<TD ALIGN="left" VALIGN="top">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt"></U></FONT><FONT COLOR="#ff0000"><STRIKE>Certifying the
Company&#146;s quarterly and annual reports. In addition, the Committee shall:</STRIKE></FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE;padding-bottom:2pt; margin-bottom:-1pt; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Design<FONT COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">ing</U></FONT>, adopt<FONT
 COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">ing,</U></FONT> and implement<FONT COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">ing</U></FONT> appropriate procedures and policies, and monitor<FONT
 COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">ing</U></FONT> these procedures and policies, to ensure<FONT COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt"> (a)</U></FONT>&nbsp;accurate and timely
collection of information <FONT COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">required to be disclosed by the SEC</U></FONT><FONT COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt"> </U></FONT><FONT
 COLOR="#ff0000"><STRIKE>for inclusion </STRIKE></FONT>in<FONT COLOR="#ff0000"><STRIKE>to</STRIKE></FONT> the Company&#146;s periodic and current SEC reports and
<FONT COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">(b)&nbsp;other information communicated in</U></FONT> the Company&#146;s <FONT COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">SEC
reports,</U></FONT> quarterly earnings press releases<FONT COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">, and prepared statements for quarterly earnings calls is not materially false or misleading</U></FONT>.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE;padding-bottom:2pt; margin-bottom:-1pt; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Establish<FONT COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">ing
responsibilities</U></FONT> and review timelines relating to the preparation and filing of the Company&#146;s quarterly earnings press releases and periodic SEC reports. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE;padding-bottom:2pt; margin-bottom:-1pt; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Establish<FONT COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">ing</U></FONT> as
appropriate policies and procedures to ensure relevant Company personnel timely report to the Committee information potentially requiring disclosure. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE;padding-bottom:2pt; margin-bottom:-1pt; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Establish<FONT COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">ing</U></FONT>
responsibility and lines of communication throughout the Company&#146;s operations and business units for collecting relevant information on a timely basis, including making periodic inquiries with relevant Company personnel possessing information
potentially requiring disclosure. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT COLOR="#ff0000"><STRIKE>10.</STRIKE></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT COLOR="#ff0000"><STRIKE>Review drafts of quarterly earnings press releases and periodic and current SEC
reports undergoing preparation for filing, including final drafts.</STRIKE></FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE;padding-bottom:2pt; margin-bottom:-1pt; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT COLOR="#ff0000"><STRIKE>11.</STRIKE></FONT><FONT COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">10.</U></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; " ALIGN="left">Meet<FONT COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">ing</U></FONT> periodically during the
preparation of quarterly earnings press releases and periodic SEC reports to discuss disclosure matters and filings made by the Company to ensure completeness and accuracy of content. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE;padding-bottom:2pt; margin-bottom:-1pt; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT COLOR="#ff0000"><STRIKE>12.</STRIKE></FONT><FONT COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">11.</U></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; " ALIGN="left">Meet<FONT COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">ing</U></FONT> at regular intervals to
discuss matters potentially requiring disclosure, in periodic SEC reports (including but not limited to prior to annual and quarterly SEC filings), current SEC reports or otherwise. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-3- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE;padding-bottom:2pt; margin-bottom:-1pt; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT COLOR="#ff0000"><STRIKE>13.</STRIKE></FONT><FONT COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">12.</U></FONT></TD>
<TD ALIGN="left" VALIGN="top">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; " ALIGN="left">Coordinat<FONT COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">ing</U></FONT><FONT COLOR="#ff0000"><STRIKE>e</STRIKE></FONT>, as
necessary, the review of quarterly earnings press releases and periodic and current SEC reports with the Certifying Officers, the Company&#146;s independent accountants, internal auditors (if any), outside counsel and the
<FONT COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">A</U></FONT><FONT COLOR="#ff0000"><STRIKE>a</STRIKE></FONT>udit<U> <FONT COLOR="#0000ff">C</FONT></U><FONT COLOR="#ff0000"><STRIKE>c</STRIKE></FONT>ommittee.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT COLOR="#ff0000"><STRIKE>14.</STRIKE></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT COLOR="#ff0000"><STRIKE>Periodically report to the Certifying Officers (in the event the CEO and/or the
CFO are members of the Committee, then to the chairperson of audit committee of the board of directors) on disclosure issues and the Committee&#146;s findings regarding the effectiveness of its procedures and policies, including any weaknesses
identified therein or in the Company&#146;s disclosure controls and procedures generally.</STRIKE></FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE;padding-bottom:2pt; margin-bottom:-1pt; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT COLOR="#ff0000"><STRIKE>15.</STRIKE></FONT><FONT COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">13.</U></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; " ALIGN="left">Report<FONT COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">ing</U></FONT> quarterly to the Audit
Committee regarding<FONT COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt"> the Company&#146;s Disclosure</U></FONT><FONT COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt"> Controls and the
Committee&#146;s effectiveness,</U></FONT> <FONT COLOR="#ff0000"><STRIKE>its </STRIKE></FONT>activities<U>,</U> and recommendations. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE;padding-bottom:2pt; margin-bottom:-1pt; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT COLOR="#ff0000"><STRIKE>16.</STRIKE></FONT><FONT COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">14.</U></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; " ALIGN="left">Report<FONT COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">ing</U></FONT> annually to the Board
regarding <FONT COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">the adequacy of the
Company&#146;s</U></FONT><FONT COLOR="#ff0000"><STRIKE>its</STRIKE></FONT><FONT COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt"> Disclosure Controls and the Disclosure Committee&#146;s effectiveness,</U></FONT> activities<FONT
 COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">,</U></FONT> and recommendations. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE;padding-bottom:2pt; margin-bottom:-1pt; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT COLOR="#ff0000"><STRIKE>17.</STRIKE></FONT><FONT COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">15.</U></FONT><FONT COLOR="#ff0000"><STRIKE></STRIKE></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT COLOR="#ff0000"><STRIKE>Review, as appropriate, other material press releases of the Company, as
applicable.</STRIKE></FONT><FONT COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">Reviewing the Disclosure Committee Charter annually.</U></FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>MEETINGS</B>: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is anticipated that the
Committee will hold regular meetings as directed by the Certifying Officers or as the Committee otherwise deems appropriate, but in no event shall the
Committee<FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt"> shall</U></FONT><FONT STYLE="font-family:Times New Roman"> meet </FONT><FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#ff0000"><STRIKE>less than</STRIKE></FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">at
least</U></FONT><FONT STYLE="font-family:Times New Roman"> four times per calendar year</FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt"> in connection with each
annual and quarterly filing required by the Securities Exchange Act of 1934</U></FONT><FONT STYLE="font-family:Times New Roman">. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-4- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT 2 </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CHARTER OF THE AUDIT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COMMITTEE OF THE BOARD </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF DIRECTORS OF </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>IMMUNITYBIO, INC. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PURPOSE </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purpose of the Audit Committee (the &#147;<B>Committee</B>&#148;) is to assist the Board of Directors (the &#147;<B>Board</B>&#148;) of
ImmunityBio, Inc. (the &#147;<B>Company</B>&#148;) in fulfilling its responsibilities for overseeing: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Company&#146;s accounting and financial reporting processes and internal control over financial reporting, as
well as the audit and integrity of the Company&#146;s financial statements. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The qualifications, independence and performance of the Company&#146;s independent registered public accounting
firm (the &#147;<B>independent auditor</B>&#148;). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Company&#146;s compliance with applicable law (including U.S. federal securities laws and other legal and
regulatory requirements). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Risk assessment and risk management. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Such other matters as provided in this charter. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>COMPOSITION </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE;padding-bottom:2pt; margin-bottom:-1pt; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Membership and Appointment</U>. The Audit Committee shall consist of at least three
<FONT COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">(3)</U></FONT> members of the Board. Members of the Audit Committee shall be appointed by the Board and may be removed by the Board in its discretion.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE;padding-bottom:2pt; margin-bottom:-1pt; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Qualifications</U>. Members of the Audit Committee must meet the following criteria as well as any
additional criteria required by applicable law or the rules and regulations of the <FONT COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">U.S.</U></FONT> Securities and Exchange Commission (the &#147;<B>SEC</B>&#148;) or the
securities exchange on which the Company&#146;s securities are listed (the &#147;<B>Exchange Rules</B>&#148;) and such other qualification as are established by the Board from time to time; provided, however, that the Company may avail of itself of
any applicable exemptions under the Exchange Rules: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Each member of the Audit Committee shall meet the independence standards established by the SEC and the Exchange
Rules, and will also satisfy the enhanced independence requirements for members of the audit committee under the Exchange Rules. The determination of independence will be made by the Board. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Each member of the Audit Committee shall be financially literate (as determined by the Board in its business
judgment in accordance with applicable law) and shall have a practical knowledge of finance and accounting and the ability to read and understand financial statements, in each case either from the time of such member&#146;s appointment to the Audit
Committee or within a reasonable period of time after appointment to the Audit Committee. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">At least one member of the Audit Committee will be an &#147;audit committee financial expert,&#148; as that term
is defined in Item&#8201;407(d)(5)(ii) of Regulation S-K and the rules and regulations of the Nasdaq Global Select Market. An audit committee financial expert is not required to be the chairperson of the Committee. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">At least one member of the Audit Committee must have past employment experience in finance or accounting,
requisite professional certification in accounting or other comparable experience or background that leads to financial sophistication. A person who satisfies the definition of &#147;audit committee financial expert&#148; will also be presumed to
have the requisite financial sophistication. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">No member of the Committee shall have participated in the preparation of the financial statements of the Company
or any of its current subsidiaries at any time during the prior three (3)&nbsp;years. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Chairperson</U>. The Board may designate a chairperson of the Committee. In the absence of that designation,
the Committee may designate a chairperson by majority vote of the Committee members. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>RESPONSIBILITIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following are the principal recurring responsibilities of the Committee. The Committee may perform such other functions as are consistent
with its purpose and applicable law, rules and regulations or as the Board may request. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Select and Hire the Independent Auditor</U>. The Committee shall be directly responsible for appointing,
compensating, retaining, overseeing and, where appropriate, replacing any independent auditor engaged by the Company to prepare or issue an audit report or perform any other audit, review or attestation services for the Company. The independent
auditor will report directly to the Committee and be ultimately accountable to the Board. The Committee has sole authority to approve the hiring and discharging of the independent auditor, all audit engagement fees and terms and all permissible
non-audit engagements with the independent auditor. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Supervise and Evaluate the Independent Auditor</U>. The Committee will: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Oversee and, at least annually, evaluate the work of the independent auditor or any other registered public
accounting firm engaged for the purpose of preparing or issuing an audit report or performing other audit, review or attest services for the Company, which evaluation shall include a review and evaluation of the lead partner of the independent
auditor. The Committee shall review, in consultation with the independent auditor, the annual audit plan and scope of audit activities. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">At least annually, obtain and review a report by the independent auditor that describes (i)&nbsp;the independent
auditor&#146;s internal quality control review procedures, and (ii)&nbsp;any material issues raised by the most recent internal quality-control review, or peer review, of the independent auditor or by any inquiry or investigation by governmental or
professional authorities, within the preceding five years, regarding any independent audit performed by the independent auditor, and any steps taken to deal with any such issues. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Evaluate the Independence of the Independent Auditor</U>. The Committee will: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Review and discuss with the independent auditor the written independence disclosures required by the applicable
requirements of the Public Company Accounting Oversight Board or other regulatory body. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Review and discuss with the independent auditor at least annually any relationships or services (including
permissible non-audit services) that may affect its objectivity and independence. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE;padding-bottom:2pt; margin-bottom:-1pt; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">&#149;</U></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt"></U></FONT>Review the rotation of
the independent auditor&#146;s lead audit and concurring partners and the rotation of other audit partners, with applicable time-out periods, in accordance with applicable law. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Take appropriate action to oversee the independence of the independent auditor. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Approve Audit and Non-Audit Services and Fees</U>. The Committee shall (i)&nbsp;review and approve, in
advance, the scope and plans for the audits and the audit fees and (ii)&nbsp;approve in advance (or, where permitted under the rules and regulations of the SEC, subsequently) all non-audit and tax services to be performed by the independent auditor
that are not otherwise prohibited by law or regulations and any associated fees. The Committee shall also approve all audit and permitted non-audit and tax services that may be provided by other registered public accounting firms. The Committee may,
in accordance with applicable law, establish pre-approval policies and procedures for the engagement of independent accountants and any other registered public accounting firm to render services to the Company, including, but not limited to,
policies that would allow the delegation of pre-approval authority to one or more members of the Committee. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Review Financial Statements</U>. The Committee shall review and discuss the following with management, the
internal auditors, if applicable, and the independent auditor, as applicable: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The scope and timing of the annual audit of the Company&#146;s financial statements. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE;padding-bottom:2pt; margin-bottom:-1pt; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company&#146;s annual audited and quarterly unaudited financial statements and
<FONT COLOR="#ff0000"><STRIKE>annual </STRIKE></FONT><FONT COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">Annual </U></FONT>and <FONT COLOR="#ff0000"><STRIKE>quarterly
</STRIKE></FONT><FONT COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">Quarterly </U></FONT><FONT COLOR="#ff0000"><STRIKE>reports
</STRIKE></FONT><FONT COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">Reports </U></FONT>on<FONT COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt"> SEC </U></FONT>Form<FONT COLOR="#ff0000"><STRIKE>
</STRIKE></FONT><FONT COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">s </U></FONT>10-K and 10-Q, including the disclosures in &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of
Operations&#148;, and recommend to the Board whether the audited financial statements and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; should be included in the Company&#146;s<FONT
 COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt"> SEC </U></FONT>Form 10-K. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The results of the independent audit and the quarterly reviews of the Company&#146;s financial statements, and
the independent auditor&#146;s opinion on the audited financial statements. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The reports and certifications regarding internal control over financial reporting and disclosure controls and
procedures. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Major issues regarding accounting principles and financial statement presentation, including any significant
changes in the Company&#146;s selection or application of accounting principles. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Analyses prepared by management or the independent auditor setting forth significant financial reporting issues
and judgments made in connection with the preparation of the financial statements. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The effect of regulatory and accounting initiatives, as well as off-balance sheet structures, on the
Company&#146;s financial statements. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any significant changes required or taken in the audit plan as a result of any material control deficiency.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any problems or difficulties the independent auditor encountered in the course of its audit work, including any
restrictions on the scope of the auditor&#146;s activities or on access to requested information, and management&#146;s response. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any significant disagreements between management and the independent auditor. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Reports and Communications from the Independent Auditor</U>. The Committee shall review and discuss reports
from the independent auditor concerning the following: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Critical accounting policies and practices to be used by the Company. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE;padding-bottom:2pt; margin-bottom:-1pt; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Alternative treatments of financial information within
G<FONT COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">enerally Accepted Accounting Principles (&#147;G</U></FONT>AAP<FONT COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">&#148;)</U></FONT> that the
auditor has discussed with management, ramifications of the use of these alternative disclosures and treatments, and the treatment preferred by the independent auditor if different from that used by management. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Any material written communications between the independent auditor and management, such as any management letter
or schedule of unadjusted differences. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Any matters required to be communicated to the Committee under generally accepted auditing standards and other
legal or regulatory requirements. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Audit Committee Report</U>. The Committee will prepare the report of the Audit Committee that SEC rules
require to be included in the Company&#146;s annual proxy statement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Earnings Press Releases and Earnings Guidance</U>. The Committee will review, in general, earnings press
releases (including any use of pro forma or other non-GAAP information), and review and discuss with management and the independent auditors policies with respect to earnings press releases, financial information and earnings guidance provided to
the public, analysts and ratings agencies. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">9.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Internal Controls</U>. The Committee shall, as appropriate, review and discuss with management, the internal
auditors, if applicable, and the independent auditor the adequacy and effectiveness of the Company&#146;s internal controls, including any changes, significant deficiencies or material weaknesses in those controls reported by the independent
auditor, the internal auditors, if applicable, or management and any special audit steps adopted in light of any material control deficiencies, and any fraud, whether or not material, that involves management or other Company employees who have a
significant role in the Company&#146;s internal controls. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE;padding-bottom:2pt; margin-bottom:-1pt; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">10.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Disclosure Controls and Procedures</U>. The
<FONT COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">Committee shall receive a quarterly report from the Disclosure Committee regarding the adequacy of the Company&#146;s Disclosure Controls and the Disclosure
Committee&#146;s effectiveness, activities, and recommendations. The </U></FONT>Committee <FONT COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">Chair</U></FONT> shall
<FONT COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">also meet with the Disclosure Committee Chair, as deemed appropriate by the Committee Chair or Disclosure Committee Chair to </U></FONT><FONT COLOR="#ff0000"><STRIKE>as
appropriate review and </STRIKE></FONT>discuss the adequacy and effectiveness of the Company&#146;s<FONT COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt"> D</U></FONT><FONT COLOR="#ff0000"><STRIKE>d</STRIKE></FONT>isclosure<FONT
 COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt"> C</U></FONT><FONT COLOR="#ff0000"><STRIKE>c</STRIKE></FONT>ontrols<FONT COLOR="#ff0000"><STRIKE> and procedures</STRIKE></FONT>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Legal and Regulatory Compliance</U>. The Committee shall: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Review and discuss with management, the internal auditors, if applicable, and the independent auditor
(i)&nbsp;the overall adequacy and effectiveness of the Company&#146;s legal, regulatory and ethical compliance programs, including the Company&#146;s Code of Business Conduct and Ethics, compliance with anti-bribery and anti-corruption laws and
regulations, and compliance with export control regulations and (ii)&nbsp;reports regarding compliance with applicable laws, regulations and internal compliance programs. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Discuss with management and the independent auditor any correspondence with regulators or governmental agencies
and any published reports that raise material issues regarding the Company&#146;s financial statements or accounting policies. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Discuss with the Company&#146;s senior legal officer any legal matters that may have a material impact on the
financial statements or the Company&#146;s compliance procedures. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">12.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Complaints</U>. The Committee shall establish and oversee procedures for the receipt, retention and
treatment of complaints on accounting, internal accounting controls or audit matters, as well as for confidential and anonymous submissions by the Company&#146;s employees of concerns regarding questionable accounting or auditing matters.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">13.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Risk Assessment and Risk Management</U>. The Committee shall review and discuss with management, the
internal auditors, if applicable, and the independent auditor the Company&#146;s major risk exposures (whether financial, operating or otherwise) and the steps management has taken to monitor, control and report those exposures, including the
Company&#146;s guidelines and procedures to govern the process by which risk assessment and risk management are handled. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">14.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Hiring of Auditor Personnel</U>. The Committee shall set hiring policies with regard to employees and former
employees of the independent auditor and oversee compliance with such policies. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">15.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Committee Charter Review</U>. The Committee shall review and reassess, at least annually, the adequacy of
this charter annually and shall submit any recommended changes to the charter to the Board for approval. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">16.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Performance Review</U>. The Committee shall review and assess, at least annually, the performance of the
Committee on an annual basis. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">17.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Related Party Transactions</U>. The Committee shall receive a list and a briefing from the Chair of the
Related Party Transaction Committee, or his or her designee, of all transactions approved by the Related Party Transaction Committee that would require disclosure pursuant to Item&#8201;404 of Regulation S-K or any other transaction between the
Company and any other person where the parties&#146; relationship is not arms&#146;- length including, without limitation, any transaction between the Company and (i)&nbsp;any director or executive officer of the Company; (ii)&nbsp;any nominee for
election as a director; (iii)&nbsp;any holder of Company securities owning more than 5% of any class of Company stock and (iv)&nbsp;any member of the immediate family of any of the foregoing; provided, however, that the Committee does not need to
review compensatory arrangements between the Company and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
its directors or executive officers if (i)&nbsp;such arrangements are reported pursuant to Item&#8201;402 of Regulation S-K or (ii)&nbsp;in the case of arrangements that are not reported because
the executive officer is not a named executive officer as defined in Item&#8201;402(a)(3) of Regulation S-K, such arrangements are reviewed and approved by the Compensation Committee. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">18.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Budget Review</U>. The Committee shall review and discuss with management the Company&#146;s proposed budget
and then recommend the budget to the Board for approval. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">19.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Cybersecurity and Data Privacy</U>. The Committee shall periodically review and discuss with management
risks relating to significant cybersecurity matters and concerns involving the Company, including information security, data privacy, backup of information systems and related regulatory matters and compliance. Management will provide periodic
reports to the Committee on information security matters, including the adequacy and effectiveness of the Company&#146;s information security policies and practices and the internal controls regarding information security, and will notify the
chairperson of the Committee as soon as practicable of significant information security matters and concerns as they arise. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The function of the Committee is primarily one of oversight. The Company&#146;s management is responsible for preparing the Company&#146;s
financial statements, and the independent auditor is responsible for auditing and reviewing those financial statements. The Committee is responsible for assisting the Board in overseeing the conduct of these activities by management and the
independent auditor. The Committee is not responsible for providing any expert or special assurance as to the financial statements or the independent auditor&#146;s work. It is recognized that the members of the Committee are not full-time employees
of the Company, that it is not the duty or responsibility of the Committee or its members to conduct &#147;field work&#148; or other types of auditing or accounting reviews or procedures or to set auditor independence standards, and that each member
of the Committee shall be entitled to rely on (i)&nbsp;the integrity of those persons and organizations within and outside the Company from which the Committee receives information and (ii)&nbsp;the accuracy of the financial and other information
provided to the Committee, in either instance absent actual knowledge to the contrary. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>MEETINGS AND PROCEDURES </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Meetings</U>. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Committee will meet at least quarterly at such times and places as the Committee determines. The chairperson
of the Committee shall preside at each meeting. The chairperson will approve the agenda for the Committee&#146;s meetings and any member may suggest items for consideration. If a chairperson is not designated or present, an acting chair may be
designated by the Committee members present. The Committee may act by unanimous written consent (which may include electronic consent) in lieu of a meeting in accordance with the Company&#146;s bylaws. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Committee will maintain written minutes of its meetings, which minutes will be filed with the minutes of the
meeting of the Board. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Committee shall meet periodically with members of management as deemed appropriate and the independent
auditor in separate executive sessions. Each regularly scheduled meeting of the Committee will conclude with an executive session of the Committee absent members of management. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Committee may invite to its meetings any director, officer or employee of the Company and such other persons
as it deems appropriate in order to carry out its responsibilities. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Reporting to the Board of Directors</U>. The Committee shall report regularly to the Board with respect to
the Committee&#146;s activities and recommendations, including any material issues that arise with respect to the quality or integrity of the Company&#146;s financial statements, the Company&#146;s compliance with legal or regulatory requirements,
the performance of the finance team and the performance and independence of the Company&#146;s independent auditor, as applicable. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Authority to Retain Advisors</U>. The Committee shall have the authority to engage independent counsel or
other advisors as it deems necessary or appropriate to carry out its duties. The Committee shall set the compensation, and oversee the work of, any independent counsel or other advisors retained by it. The Company will provide appropriate funding,
as determined by the Committee, to pay the independent auditor, any other registered public accounting firm and any independent counsel and any other outside advisors hired by the Committee and any administrative expenses of the Committee that are
necessary or appropriate in carrying out its activities. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Subcommittees</U>. The Committee may form subcommittees for any purpose that the Committee deems appropriate
and may delegate to such subcommittees such power and authority as the Committee deems appropriate. If designated, each such subcommittee will establish its own schedule and maintain written minutes of its meetings, which minutes will be filed with
the minutes of the meetings of the Board. The Committee shall not delegate to a subcommittee any power or authority required by law, regulation or listing standard to be exercised by the Committee as a whole. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Access</U>. The Committee shall be given full access to the chairperson of the Board, management, the
independent auditor and, if applicable, the internal auditors, if applicable, as well as the Company&#146;s books, records, facilities and other personnel. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Compensation</U>. Members of the Committee shall receive such fees, if any for their service as Committee
members as may be determined by the Board in its sole discretion. Members of the Committee may not receive any compensation from the Company except the fees that they receive for service as a member of the Board or any committee thereof or as
otherwise permitted by the applicable law, the rules of the SEC and the Exchange Rules. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT B </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES DISTRICT COURT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SOUTHERN DISTRICT OF CALIFORNIA </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>IN RE IMMUNITYBIO, INC.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SHAREHOLDER DERIVATIVE</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>LITIGATION</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No.&nbsp;3:24-cv-02014-GPC-VET</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(Consolidated with</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3:25-cv-00416-GPC-VET</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3:25-cv-00423-GPC-VET)</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>This Document Relates to:</B></P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>ALL ACTIONS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>[PROPOSED] ORDER GRANTING PRELIMINARY APPROVAL OF DERIVATIVE SETTLEMENT, APPROVING FORM AND MANNER OF NOTICE, AND SETTING DATE FOR HEARING ON FINAL APPROVAL OF SETTLEMENT</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Judge: Hon. Gonzalo P. Curiel</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Magistrate: Hon.
Judge Valerie E. Torres</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">3:24-cv-02014-GPC-VET </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[PROPOSED]
PRELIMINARY APPROVAL ORDER RE SETTLEMENT </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, a consolidated shareholder derivative action is pending in this Court titled <I>In
re ImmunityBio, Inc. Shareholder Derivative Litigation</I>, No.&nbsp;3:24-cv-02014-GPC-VET; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, a Stipulation and Settlement
Agreement (the &#147;Stipulation&#148;) was made and entered into as of May&nbsp;19, 2025, by and among (i)&nbsp;plaintiffs Gary Van Luven (&#147;Van Luven&#148;), Angelo Barbieri (&#147;Barbieri&#148;), and Bong Shin (&#147;Shin&#148;) (the
&#147;Plaintiffs&#148;) and demand-made shareholders Roland Davies (&#147;Davies&#148;) and Chris Pallas (&#147;Pallas&#148;) (and together with Plaintiffs, the &#147;Shareholders&#148;), derivatively on behalf of ImmunityBio, Inc.
(&#147;ImmunityBio&#148; or the &#147;Company&#148;); (ii)&nbsp;nominal defendant ImmunityBio, a Delaware corporation; and (iii)&nbsp;individual defendants Patrick Soon-Shiong, Richard Adcock, Cheryl L. Cohen, Michael D. Blaszyk, John Owen Brennan,
Linda Maxwell, Wesley Clark, Christobel Selecky, Barry J. Simon, and David C. Sachs (the &#147;Individual Defendants,&#148; together with ImmunityBio, the &#147;Defendants,&#148; and together with ImmunityBio and the Shareholders, the
&#147;Parties&#148;), which sets forth the terms and conditions for the proposed settlement (the &#147;Settlement&#148;) of the above-captioned action (the &#147;Action&#148;), subject to review and approval by this Court pursuant to Rule 23.1 of
the Federal Rules of Civil Procedure upon notice to Current ImmunityBio Shareholders (as defined below); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW</B>, upon application of
the parties to the Action, after review and consideration of the Stipulation filed with the Court and the exhibits annexed thereto, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IT
IS HEREBY ORDERED</B> this <U>&#8195;&#8195;</U> day of <U>&#8195;&#8195;&#8195;&#8195;&#8195;</U>, 2025, as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. Except for terms
defined herein, the Court adopts and incorporates the definitions in the Stipulation for the purposes of this order. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">3:24-cv-02014-GPC-VET </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[PROPOSED]
PRELIMINARY APPROVAL ORDER RE SETTLEMENT </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. The Court hereby preliminarily approves the Settlement, as embodied in the Stipulation
and the exhibits attached thereto, subject to further consideration at the Settlement Hearing to be held as described below. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. A hearing
(the &#147;Settlement Hearing&#148;) shall be held on <U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U>, 2025, at <U>&#8195;&#8195;&#8195;&#8195;</U> a.m./p.m., at the United States District Court for the Southern District of California to,
among other things: (a)&nbsp;determine whether the proposed Settlement, on the terms and conditions provided for in the Stipulation, is fair, reasonable, and adequate and in the best interests of ImmunityBio and all Current ImmunityBio Shareholders;
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) determine whether the Court should finally approve the Settlement and enter the Judgment, substantially in the form attached as Exhibit E to the
Stipulation, dismissing the Action with prejudice against Defendants, and extinguishing and releasing the Released Claims as against the Released Persons; (c)&nbsp;consider Shareholders&#146; Counsel&#146;s application for an award of
attorneys&#146; fees and litigation expenses (the &#147;Fee and Expense Award&#148;); and (d)&nbsp;consider any other matters that may properly be brought before the Court in connection with the Settlement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. The Settlement Hearing may be adjourned by the Court from time to time without further notice to Current ImmunityBio Shareholders other than
by announcement at the Settlement Hearing or other adjournment thereof, or a notation on the docket in the Action. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. The Court reserves
the right to approve the Settlement at or after the Settlement Hearing, with such modifications as may be consented to by the Parties, and without further notice to the Current ImmunityBio Shareholders. The Court retains jurisdiction over this
Action to consider further applications arising out of or connected with the proposed Settlement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">3:24-cv-02014-GPC-VET </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[PROPOSED]
PRELIMINARY APPROVAL ORDER RE SETTLEMENT </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. The Court approves, as to form and content, the Summary Notice attached as Exhibit C to
the Stipulation and the Notice of Proposed Settlement of Shareholder Derivative Matters, Hearing Theron, and Right to Appear (the &#147;Notice&#148;) attached as Exhibit D to the Stipulation as (i)&nbsp;the best notice practicable under the
circumstances; (ii)&nbsp;notice that is reasonably calculated, under the circumstances, to apprise Current ImmunityBio Shareholders of the pendency of the Action, the effect of the proposed Settlement (including the Releases to be provided
thereunder), Shareholders&#146; Counsel&#146;s Fee and Expense Award in connection with the Settlement, Current ImmunityBio Shareholders&#146; rights to object to any aspect of the Settlement, and to appear at the Settlement Hearing; (iii)&nbsp;due,
adequate, and sufficient notice to all persons and entities entitled to receive notice of the proposed Settlement; and (iv)&nbsp;satisfies the requirements of Rule 23.1 of the Federal Rules of Civil Procedure and due process, and all other
applicable law and rules. The date and time of the Settlement Hearing shall be included in the Summary Notice and Notice when they are distributed. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. No later than ten (10)&nbsp;business days after the entry of this Preliminary Approval Order (the &#147;Notice Date&#148;), ImmunityBio
shall: (i)&nbsp;post the Notice and the Stipulation (and exhibits thereto) on the Investor Relations page of ImmunityBio&#146;s website and maintain the documents there until after the Settlement Hearing; (ii)&nbsp;publish the Summary Notice in
<I>Investors Business Daily</I> with a link to the Company&#146;s Investor Relations webpage where the Notice and Stipulation (and exhibits thereto) will be posted and available; and (iii)&nbsp;file with the U.S. Securities and Exchange Commission
(the &#147;SEC&#148;) the Notice and Stipulation (and exhibits thereto) as exhibits to a Current Report on Form 8-K. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">3:24-cv-02014-GPC-VET </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[PROPOSED]
PRELIMINARY APPROVAL ORDER RE SETTLEMENT </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. ImmunityBio shall pay any and all costs and expenses related to providing notice of the
proposed Settlement (&#147;Notice Costs&#148;) regardless of whether the Court declines to approve the Settlement or the Effective Date otherwise fails to occur. In no event shall Plaintiffs, any other ImmunityBio shareholder, the Defendants, or any
of their attorneys (including Shareholders&#146; Counsel) be responsible for any Notice Costs. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. No later than twenty-one (21)&nbsp;days
before the Settlement Hearing, Defendants&#146; Counsel shall serve on Plaintiffs&#146; counsel in the Derivative Actions and file with the Court an appropriate declaration with respect to the notices. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. As set forth in the Notice, any Current ImmunityBio Shareholder who continues to own shares of ImmunityBio common stock through the date of
the Settlement Hearing and who objects to the proposed Settlement, the proposed Judgment to be entered in connection with the Settlement, or Shareholders&#146; Counsel&#146;s application for a Fee and Expense Award, or who otherwise wishes to be
heard (&#147;Objector&#148;), may appear in person or by his, her, or its attorney at the Settlement Hearing and present any evidence or argument that may be proper and relevant; <U>provided</U>, <U>however</U>, that no Objector shall be heard or
entitled to contest the approval of the terms and conditions of the Settlement, or, if approved, the Judgment to be entered thereon, or Shareholders&#146; Counsel&#146;s application for a Fee and Expense Award, unless he, she, or it has, no later
than fourteen (14)&nbsp;days before the Settlement Hearing (unless the Court in its discretion shall thereafter otherwise direct, upon application of such person and for good cause shown), filed written objections with the Court and sent by hand or
by first class mail, postage pre-paid to Shareholders&#146; Counsel and the Clerk of Court at the following addresses: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">3:24-cv-02014-GPC-VET </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[PROPOSED]
PRELIMINARY APPROVAL ORDER RE SETTLEMENT </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Shareholders&#146; Counsel </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Justin A. Kuehn </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">KUEHN LAW, PLLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">53 Hill Street, Suite 605 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Southampton, NY 11968 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Telephone: (833)&nbsp;672-0814 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">justin@kuehn.law</U></FONT><FONT STYLE="font-family:Times New Roman"> </FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Clerk of Court </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">United States District Court </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Southern District of California </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">333 West Broadway, Suite 420
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Diego, CA 92101 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. Any objections
must: (i)&nbsp;state whether the Objector intends to appear at the Settlement Hearing; (ii)&nbsp;provide the Objector&#146;s name, legal address, and telephone number; (iii) provide proof of being a Current ImmunityBio Shareholder as of the Record
Date and representation that the Objector will continue to own ImmunityBio stock as of the date of the Settlement Hearing; (iv)&nbsp;the dates the Objector acquired ImmunityBio shares and the number of shares held; (v)&nbsp;a detailed statement of
the Objector&#146;s specific position with respect to the matters to be hear at the Settlement Hearing, including a statement of each objection being made; and (vi)&nbsp;provide the grounds for each objection or the reason for the Objector&#146;s
desire to appear and to be heard. The Parties are authorized to request from any Objector additional information or documentation sufficient to prove his, her, or its holdings of ImmunityBio common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">3:24-cv-02014-GPC-VET </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[PROPOSED]
PRELIMINARY APPROVAL ORDER RE SETTLEMENT </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. Any Person who fails to object in the manner prescribed above shall be deemed to have
waived such objection (including the right to appeal), unless the Court in its discretion allows such objection to be heard at the Settlement Hearing, and shall forever be barred from raising such objection in this Action or any other action or
proceeding or otherwise contesting the Settlement, Shareholders&#146; Counsel&#146;s application for a Fee and Expense Award, or any other matter related to the Settlement, in the Action or any other action or proceeding, and will otherwise be bound
by the Judgment to be entered and the releases to be given. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13. The Plaintiffs shall file and serve a motion for final approval of the
Settlement and any application for a Fee and Expense Award on or before forty-five (45)&nbsp;days prior to the date set herein for the Settlement Hearing. If Defendants respond to Plaintiffs&#146; final approval motion or the application for a Fee
and Expense Award, they shall do so on or before twenty-one (21)&nbsp;days before the Settlement Hearing. If Objectors seek to file objections to the Settlement, they shall do so on or before fourteen (14)&nbsp;days before the Settlement Hearing.
Any reply papers in support of the motion for final approval, Fee and Expense Award, or in response to any objections are to be filed with the Court no later than seven (7)&nbsp;days prior to the Settlement Hearing. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14. If the Settlement is approved by the Court following the Settlement Hearing, the Court shall enter the Judgment substantially in the form
attached to the Stipulation as Exhibit E. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15. In the event that the Settlement is terminated in its entirety pursuant to the terms of
Stipulation or the Effective Date otherwise fails to occur for any reason, the Settlement and the Stipulation shall be canceled and terminated; this Order (except as otherwise provided by the Stipulation) shall become null and void and be without
prejudice to the rights of the Parties and Current ImmunityBio Shareholders; and all proceedings in, and parties to, the Action shall revert to their status in this Action before the Stipulation was filed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">3:24-cv-02014-GPC-VET </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[PROPOSED]
PRELIMINARY APPROVAL ORDER RE SETTLEMENT </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16. All discovery and other proceedings in this Action (except as may be necessary to carry
out the terms and conditions of the proposed Settlement) are hereby stayed and suspended until further order of the Court. Except as provided in the Stipulation, pending final determination of whether the Stipulation should be approved, all parties
to the Action are hereby enjoined against instituting, commencing, prosecuting, continuing, or in any way participating in, whether directly, representatively, individually, derivatively on behalf of ImmunityBio, or in any other capacity, any action
or other proceeding asserting any Released Claims against the Released Persons, and all Current ImmunityBio Shareholders to the extent they are acting, or purporting to act, derivatively on behalf of ImmunityBio, are hereby enjoined against
instituting, commencing, prosecuting, continuing, or in any way participating in any action or other proceeding asserting any Released Claims against the Released Persons. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17. The Court may, for good cause shown, extend any of the deadlines set forth in this Order without further notice to anyone other than the
parties to the Action and any Objectors. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated: <U>&#8195;&#8195;&#8195;&#8195;&#8195;</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">THE HONORABLE GONZALO P. CURIEL UNITED STATES DISTRICT JUDGE</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">3:24-cv-02014-GPC-VET </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[PROPOSED]
PRELIMINARY APPROVAL ORDER RE SETTLEMENT </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT C </B></P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES DISTRICT COURT </B></P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SOUTHERN DISTRICT OF CALIFORNIA </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="53%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">IN RE IMMUNITYBIO, INC. SHAREHOLDER DERIVATIVE LITIGATION</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTICE OF PROPOSED DERIVATIVE SETTLEMENT</B></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lead Case No.: 3:24-cv-02014-GPC-VET</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(Consolidated with</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3:25-cv-00416-GPC-VET</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3:25-cv-00423-GPC-VET)</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Judge: Hon. Gonzalo P. Curiel</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Magistrate Judge: Hon. Valerie E.
Torres</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>NOTICE OF PROPOSED SETTLEMENT OF SHAREHOLDER DERIVATIVE </U></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>ACTIONS, HEARING THEREON, AND RIGHT TO APPEAR </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>TO:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>ALL CURRENT RECORD HOLDERS AND BENEFICIAL OWNERS OF COMMON STOCK OF IMMUNITYBIO, INC.
(&#147;IMMUNITYBIO&#148; OR &#147;THE COMPANY&#148;) AS OF <U>&#8195;&#8195;&#8195;&#8195;&#8195;</U>, 2025 (THE &#147;RECORD DATE&#148;). </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">PLEASE TAKE NOTICE that the above-captioned consolidated derivative action and certain other Derivative Matters are being settled on the terms
set forth in a Stipulation and Agreement of Settlement dated May 19, 2025 (the &#147;Stipulation&#148;)<SUP STYLE="font-size:75%; vertical-align:top">1</SUP> of the above-captioned consolidated derivative lawsuit and certain other Derivative
Matters. Under the terms of the Stipulation, as part of the proposed Settlement, and in consideration of the associated releases set forth herein, Defendants shall cause the Board, within thirty (30)&nbsp;days after the Court enters an Order
granting final approval of the Settlement, to adopt, implement, and maintain the corporate governance, oversight, and internal controls reforms set forth in Exhibit A to the Stipulation consistent with the terms and timing set forth therein (the
&#147;Reforms&#148;). The Reforms, which are detailed more fully in the Stipulation and Long Form Notice, are intended to address the claims asserted in the Derivative Matters.
</P><DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The capitalized terms used in this Notice and not otherwise defined are defined in the Stipulation. This Notice
should be read in conjunction with, and is qualified in its entirety by reference to, the text of the Stipulation and its Exhibits, which have been filed with the U.S. District Court for the Southern District of California. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Parties agree that: (i)&nbsp;the Settlement confers a substantial benefit upon
ImmunityBio and its shareholders; and (ii)&nbsp;the Settlement, and each of its terms, is in all respects fair, adequate, reasonable, and in the best interests of ImmunityBio and its shareholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shareholders&#146; Counsel intends to request approval of attorneys&#146; fees and reimbursement of expenses in the amount not to exceed
$2,500,000, inclusive of requested Service Awards for the Shareholders. Defendants are permitted to respond and/or oppose the Fee and Expense Award application. The amount of attorneys&#146; fees and expenses will be within the sole discretion of
the Court. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IF YOU WERE A RECORD OR BENEFICIAL OWNER OF IMMUNITYBIO COMMON STOCK AS OF <U>&#8195;&#8195;&#8195;&#8195;&#8195;</U>,
2025, PLEASE READ THIS NOTICE CAREFULLY AND IN ITS ENTIRETY AS YOUR RIGHTS MAY BE AFFECTED BY PROCEEDINGS IN THE ABOVE-REFERENCED LITIGATION. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On <U>&#8195;&#8195;&#8195;&#8195;&#8195;</U>, 2025, at <U>&#8195;&#8195;&#8195;&#8195;&#8195;</U>, the Court will hold the Settlement Hearing
either in person at the James M. Carter and Judith N. Keep United States Courthouse, Courtroom 2D, 333 West Broadway, San Diego, California 92101 , or by telephone or videoconference (at the discretion of the Court). At the Settlement Hearing, the
Court will consider whether the Settlement is fair, reasonable, and adequate and thus should be finally approved and whether the above-captioned consolidated derivative action should be dismissed with prejudice pursuant to the Stipulation. The Court
also will rule upon Shareholders&#146; Counsel&#146;s request for approval of attorneys&#146; fees and reimbursement of expenses and Shareholders&#146; Service Awards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any Current ImmunityBio Shareholder may, but is not required to, appear in person at the Settlement Hearing. If you want to be heard at the
Settlement Hearing in opposition to the Settlement, Shareholders&#146; Counsel request for approval of attorneys&#146; fees and reimbursement of expenses, or the Service Awards, then you must first comply with the following procedures for objecting.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any objections must be presented in writing and must contain the following information: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notice of intent to appear at the Settlement Hearing; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Your name, legal address, and telephone number; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Proof of being a Current ImmunityBio Shareholder as of the Record Date and representation that you will
continue to own ImmunityBio common stock as of the date of the Settlement Hearing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The date(s) you acquired your ImmunityBio shares and the number of ImmunityBio shares held;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A <U>detailed statement</U> of your specific position with respect to the matters to be heard at the Settlement
Hearing, including a statement of each objection being made; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The grounds for each objection or the reasons for your desire to appear and to be heard. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any counsel retained by a purported objector for the purpose of asserting an objection must make a notice of appearance on the Court at least
fourteen (14)&nbsp;days before the Settlement Hearing. The Court will not consider any objection that does not substantially comply with these requirements. Any written objections must be filed with the Court and sent by hand or by first class mail,
postage pre-paid to Shareholders&#146; Counsel no later than fourteen (14)&nbsp;days prior to the Settlement Hearing at the following address: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center"><B>Shareholders&#146; Counsel:</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Clerk of the Court:</B></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">Justin A. Kuehn</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">United States District Court</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">KUEHN LAW, PLLC</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Southern District of California</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">53 Hill Street, Suite 605</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">333 West Broadway, Suite 420</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">Southampton, NY 11968</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">San Diego, CA 92101</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Telephone: (833) 672-0814</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">justin@kuehn.law</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Court will not consider any objection that is not timely filed with the Court and delivered to
Shareholders&#146; Counsel. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any person or entity who fails to object or otherwise requests to be heard in the manner prescribed above
will be deemed to have waived the right to object to any aspect of the Settlement or otherwise request to be heard (including the right to appeal) and will be forever barred from raising such objection or request to be heard in this or any other
action or proceeding, but shall otherwise be bound by the Judgment to be entered and the releases to be given. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Notice summarizes the Parties&#146; Stipulation. It is not a complete statement of the
events of the Derivative Matters or the Stipulation. You may inspect the Stipulation and other papers at https://ir.immunityBio.com/. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">PLEASE DO NOT CALL, WRITE, OR OTHERWISE DIRECT QUESTIONS TO EITHER THE COURT OR THE CLERK&#146;S OFFICE. Any questions you have about matters
in this Notice should be directed by telephone or in writing to Shareholders&#146; Counsel at the address set forth above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated <U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&#8195;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">BY ORDER OF THE UNITED STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF CALIFORNIA</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT D </B></P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES DISTRICT COURT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SOUTHERN DISTRICT OF CALIFORNIA </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="53%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">IN RE IMMUNITYBIO, INC. SHAREHOLDER DERIVATIVE LITIGATION</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTICE OF PROPOSED DERIVATIVE SETTLEMENT</B></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lead Case No.: 3:24-cv-02014-GPC-VET</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(Consolidated with</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3:25-cv-00416-GPC-VET</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3:25-cv-00423-GPC-VET)</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Judge: Hon. Gonzalo P. Curiel</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Magistrate Judge: Hon. Valerie E.
Torres</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>NOTICE OF PROPOSED SETTLEMENT OF SHAREHOLDER DERIVATIVE </U></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>MATTERS, HEARING THEREON, AND RIGHT TO APPEAR </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>TO:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>ALL CURRENT RECORD HOLDERS AND BENEFICIAL OWNERS OF COMMON STOCK OF IMMUNITYBIO, INC.
(&#147;IMMUNITYBIO&#148; OR &#147;THE COMPANY&#148;) AS OF <U>&#8195;&#8195;&#8195;&#8195;&#8195;</U>, 2025 (THE &#147;RECORD DATE&#148;). </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>PLEASE READ THIS NOTICE CAREFULLY AND IN ITS ENTIRETY. THIS NOTICE RELATES TO A PROPOSED SETTLEMENT AND DISMISSAL OF LITIGATION AND CONTAINS
IMPORTANT INFORMATION REGARDING YOUR RIGHTS. YOUR RIGHTS MAY BE AFFECTED BY THESE LEGAL PROCEEDINGS. IF THE COURT APPROVES THE SETTLEMENT, YOU WILL BE FOREVER BARRED FROM CONTESTING THE APPROVAL OF THE PROPOSED SETTLEMENT AND FROM PURSUING THE
SETTLED CLAIMS. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>IF YOU HOLD IMMUNITYBIO COMMON STOCK FOR THE BENEFIT OF ANOTHER, PLEASE PROMPTLY TRANSMIT THIS DOCUMENT TO SUCH
BENEFICIAL OWNER. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>THE COURT HAS MADE NO FINDINGS OR DETERMINATIONS CONCERNING THE MERITS OF THE DERIVATIVE MATTERS. THE RECITATION
OF THE BACKGROUND AND CIRCUMSTANCES OF THE SETTLEMENT CONTAINED HEREIN DOES NOT CONSTITUTE THE FINDINGS OF THE COURT. IT IS BASED ON REPRESENTATIONS MADE TO THE COURT BY COUNSEL FOR THE PARTIES. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>THE DERIVATIVE MATTERS ARE NOT &#147;CLASS ACTIONS.&#148; THUS, THERE IS NO COMMON FUND
UPON WHICH YOU CAN MAKE A CLAIM FOR A MONETARY PAYMENT. THERE IS NO PROOF OF CLAIM FORM FOR SHAREHOLDERS TO SUBMIT IN CONNECTION WITH THIS SETTLEMENT, AND SHAREHOLDERS ARE NOT REQUIRED TO TAKE ANY ACTION IN RESPONSE TO THIS NOTICE. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notice is hereby provided to you of the proposed Settlement<SUP STYLE="font-size:75%; vertical-align:top">1</SUP> of the above-captioned
consolidated derivative action and certain other Derivative Matters. This Notice is provided by order of the U.S. District Court for the Southern District of California (the &#147;Court&#148;). It is not an expression of any opinion by the Court. It
is to notify current shareholders of the terms of the proposed Settlement of the Derivative Matters. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>I.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>WHY THIS NOTICE HAS BEEN POSTED AND FILED WITH THE U.S. SECURITIES AND EXCHANGE COMMISSION
</B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This notice is intended to notify all ImmunityBio shareholders affected by the settlement of the derivative action
styled <I>In re ImmunityBio Inc. Shareholder Derivative Litigation</I>, Lead Case No.&nbsp;3:24-cv-02014 (S.D. Cal.) (S.D. Cal.) (the &#147;Derivative Action&#148;) and all related Derivative Matters (as defined below) of the Proposed Settlement of
Shareholder Derivative Matters, Hearing Thereon, and Right to Appear (the &#147;Notice&#148;). The following Settling Parties (defined herein) through their respective counsel have agreed upon terms to settle the Derivative Matters and have signed
the written Stipulation setting forth the terms of the Settlement: (i)&nbsp;plaintiffs Gary Van Luven (&#147;Van Luven&#148;), Angelo Barbieri (&#147;Barbieri&#148;), and Bong Shin (&#147;Shin&#148;) (the &#147;Plaintiffs&#148;) and demand-made
shareholders Roland Davies (&#147;Davies&#148;) and Chris Pallas (&#147;Pallas&#148;) (and together with Plaintiffs, the &#147;Shareholders&#148;), derivatively on behalf of ImmunityBio, Inc. (&#147;ImmunityBio&#148; or the &#147;Company&#148;);
(ii)&nbsp;nominal defendant ImmunityBio, a Delaware corporation; and (iii)&nbsp;individual defendants Patrick Soon-Shiong, Richard Adcock, Cheryl L. Cohen, Michael D. Blaszyk, John Owen Brennan, Linda Maxwell, Wesley Clark, Christobel Selecky, Barry
J. Simon, and David C. Sachs (the &#147;Individual Defendants,&#148; together with ImmunityBio, the &#147;Defendants,&#148; and together with ImmunityBio and the Shareholders, the &#147;Parties&#148;). Subject to the approval of the Court and the
terms and conditions expressly provided therein, the Stipulation is intended by the Settling Parties to fully, finally, and forever resolve, discharge, and settle the Released Claims.
</P><DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The capitalized terms used in this Notice and not otherwise defined are defined in the Stipulation and
Agreement of Settlement (&#147;Stipulation&#148;) (dated May&nbsp;19, 2025). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On <U>&#8195;&#8195;&#8195;</U>2025, at <U>&#8195;&#8195;&#8195;</U>, the Court will hold a
hearing (the &#147;Settlement Hearing&#148;). The purpose of the Settlement Hearing is to determine: (i)&nbsp;whether the Settlement of the Derivative Matters on the terms and conditions provided for in the Stipulation is fair, reasonable, and
adequate to ImmunityBio and Current ImmunityBio Shareholders, and should be finally approved by the Court; (ii)&nbsp;whether a Judgment as provided in, and attached as Exhibit E to the Stipulation should be entered; (iii)&nbsp;whether to approve
Shareholders&#146; Counsel request for attorneys&#146; fees and reimbursement of expenses, inclusive of requested Service Awards for Shareholders; and (iv)&nbsp;such other matters as may be necessary or proper in the circumstances. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>II.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>SUMMARY OF THE LITIGATION </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>A.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Background </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ImmunityBio is a vertically integrated biotechnology company developing next-generation therapies and vaccines that bolster the natural immune
system to defeat cancers and infectious diseases. The Company&#146;s lead biologic product, Anktiva, is a novel first-in-class IL-15 agonist antibody-cytokine fusion protein. In May 2023, the Company announced that the FDA had rejected its BLA for
Anktiva, not because of any problems with Anktiva&#146;s safety and efficacy, but because of cGMP deficiencies identified during a pre-license inspection of its CMOs. On April&nbsp;22, 2024, upon the Company&#146;s submission of a second BLA, the
FDA approved Anktiva with BCG for the treatment of BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Derivative Matters allege that from March&nbsp;10, 2021 to May&nbsp;10, 2023, the Individual Defendants&#150;all of whom are current or former Company officers and/or members of the Company&#146;s Board of Directors (the
&#147;Board&#148;)&#150;breached their fiduciary duties to the Company and its shareholders and committed other alleged misconduct by failing to conduct adequate oversight and making or causing the Company to make false and misleading statements
that failed to disclose: (1)&nbsp;current Good Manufacturing Practices (&#147;cGMP&#148;) deficiencies at the Company&#146;s </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">third-party contract manufacturing organizations (&#147;CMOs&#148;) for Anktiva; (2)&nbsp;that one or more
of the Company&#146;s CMOs for Anktiva did in fact suffer from cGMP deficiencies; (3)&nbsp;that the foregoing deficiencies were likely to cause the U.S. Food and Drug Administration (the &#147;FDA&#148;) to reject the Company&#146;s Biologics
License Application (&#147;BLA&#148;) for Anktiva; and (4)&nbsp;that the Company overstated the regulatory approval prospects for the Anktiva BLA. The Derivative Matters allege that, as a result of the foregoing, the Company&#146;s stock price
declined, precipitating the filing of a related federal securities fraud class action lawsuit captioned <I>In re ImmunityBio, Inc. Securities Litigation</I>, No.&nbsp;23-cv-01216 (S.D. Cal.) by a class of ImmunityBio investors against the Company
and certain of its officers (the &#147;Securities Class Action&#148;). </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>B.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Procedural History </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&nbsp;9, 2024, Davies issued a demand to ImmunityBio to inspect the Company&#146;s books and records pursuant to 8 <I>Del. C.</I>
&#167; 220 (&#147;Section 220&#148;) in connection with the alleged misconduct described above. Thereafter, pursuant to a confidentiality agreement, the Company produced non-public, Board-level, internal corporate documents totaling over 600 pages
to Davies that were responsive to his Section&nbsp;220 inspection demand (the &#147;220 Documents&#148;). After reviewing and analyzing the 220 Documents, on September&nbsp;17, 2024, Davies served the Board with a pre-suit demand under Delaware law
requesting that the Board commence an investigation into the wrongdoing described above and alleged in the Derivative Matters, and/or file a lawsuit against the Individual Defendants regarding the same. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;24, 2024, Pallas made a substantially similar demand to inspect the Company&#146;s books and records pursuant to
Section&nbsp;220 in connection with the misconduct described above and alleged in the Derivative Matters. Thereafter, pursuant to a confidentiality agreement, the Company produced the 220 Documents to Pallas. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I></I>On October&nbsp;29, 2024, plaintiff Van Luven filed in the Court a shareholder
derivative complaint on behalf of nominal defendant ImmunityBio against the Individual Defendants, asserting claims for violation of the Securities Exchange Act of 1934 (&#147;Exchange Act&#148;), for breach of fiduciary duty, unjust enrichment, and
waste of corporate assets under Delaware law (the &#147;<I>Van Luven Action&#148;). </I>On February&nbsp;25, 2025, plaintiff Barbieri filed a substantially similar shareholder derivative complaint in the Court on behalf of nominal defendant
ImmunityBio against certain of the Individual Defendants for breach of fiduciary duty and unjust enrichment under Delaware law, and for violations of the Exchange Act (the &#147;<I>Barbieri</I> Action&#148;). On February&nbsp;26, 2025, plaintiff
Shin filed a third substantially similar shareholder derivative complaint in the Court on behalf of nominal defendant ImmunityBio against the Individual Defendants asserting claims for violation of the Exchange Act, and for breach of fiduciary duty,
unjust enrichment, and waste of corporate assets under Delaware law (the &#147;<I>Shin</I> Action&#148;). These lawsuits are predicated on the same underlying factual allegations and alleged wrongdoing as the Securities Class Action.<I> </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;2, 2025, the parties to the <I>Van Luven</I>, <I>Barbieri</I>, and <I>Shin</I> Actions jointly moved to consolidate these actions
and to appoint Kuehn Law, PLLC as Lead Counsel for Plaintiffs, which the Court granted that same day. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>C.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Settlement Negotiations </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Parties, by and through their undersigned attorneys, engaged in months of good-faith, arm&#146;s-length discussions and negotiations with
regard to the possible settlement of the Derivative Matters. On December&nbsp;27, 2024, following initial discussions, certain of Shareholders&#146; Counsel sent a detailed settlement demand to Defendants&#146; Counsel, including numerous proposed
corporate governance reforms. On February&nbsp;14, 2025, Defendants&#146; Counsel responded to the settlement demand with a detailed counteroffer of proposed corporate governance reforms. Shareholders&#146; Counsel and Defendants&#146; Counsel then
continued to negotiate a potential settlement, exchanging numerous proposals and information and engaging in frank discussions regarding the strengths and weaknesses of the claims and defenses at issue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;21, 2025, the Parties reached an agreement as to the material terms of the proposed settlement and executed a confidential
settlement term sheet (&#147;Term Sheet&#148;). Pursuant to the Term Sheet, the Company will adopt the corporate governance reforms (&#147;Corporate Governance Reforms&#148;) described in Section III (below), that were subsequently approved by the
Board on April&nbsp;4, 2025, subject to the Court&#146;s approval. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Parties did not discuss or negotiate the amount or payment of any attorneys&#146; fees
for Shareholders&#146; Counsel prior to executing the Term Sheet containing the Corporate Governance Reforms. In an attempt to facilitate a negotiation of an attorneys&#146; fee award, the Parties agreed, and did, participate in a private mediation
on April&nbsp;23, 2025 overseen by Jed Melnick, Esq., the same JAMS mediator who mediated the resolution of the Securities Class Action. The Parties were unable to reach an agreement as to Shareholders&#146; Counsel&#146;s attorneys&#146; fees. The
Parties have finalized the Stipulation without an attorneys&#146; fees component. Shareholders&#146; Counsel will file a fee and expense application to the Court simultaneously with Plaintiffs&#146; separate motion for final settlement approval, to
which Defendants may respond and/or oppose. The Court will determine whether to approve Shareholders&#146; Counsel&#146;s requested award of attorneys&#146; fees or some other amount the Court deems appropriate. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>III.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>TERMS OF THE PROPOSED DERIVATIVE SETTLEMENT </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The principal terms, conditions and other matters that are part of the Settlement, which is subject to approval by the Court, are summarized
below. This summary should be read in conjunction with, and is qualified in its entirety by reference to, the text of the Stipulation, which has been filed with the Court and is also available for viewing on the Investor Relations page of
ImmunityBio&#146;s website at<U> https://ir.immunityBio.com/</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Settlement and in consideration of the releases
set forth therein, ImmunityBio shall implement the corporate governance reforms, consistent with the terms and timing set forth below and in Exhibit A of the Stipulation and its subparts (the &#147;Reforms&#148;). The Company and its Board
acknowledge and agree that the Settlement and Reforms confer substantial and material benefits on the Company and Current ImmunityBio Shareholders, and that the Derivative Matters and Shareholders&#146; and Shareholders&#146; Counsel&#146;s efforts
were a substantial and material factor in causing ImmunityBio to adopt, implement, and/or maintain the Reforms. Specifically, the Company shall adopt and maintain the below described Reforms for a period of at least four (4)&nbsp;years: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>A.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>New Board Member</B> - On or before December&nbsp;31, 2025, the Board shall refresh itself by appointing one
(1)&nbsp;new independent director to the Board. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>B.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Enhancements to the Disclosure Committee Charter</B> &#150; Within (30)&nbsp;days of Final Approval of the
Settlement, the Board shall amend the Disclosure Committee Charter as set forth in Exhibit A-1 to the Stipulation. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>C.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Enhancements to the Audit Committee Charter</B> &#150; Within (30)&nbsp;days of Final Approval of the
Settlement, the Board shall amend the Disclosure Committee Charter as set forth in Exhibit A-2 to the Stipulation. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>D.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Public Posting of Corporate Governance Guidelines and Board Committee Charters</B> &#150; The Company will
continue to post on the Investor Relations/Governance Documents portion of the Company&#146;s public website the Company&#146;s Corporate Governance Guidelines, Code of Global Business Conduct and Ethics, Audit Committee Charter, Compensation
Committee Charter, Disclosure Committee Charter, Nominating and Corporate Governance Committee Charter, and the Related Party Transaction Committee Charter. If such documents are amended or revised, the Company will post these updated documents on
the Investor Relations portion of the Company&#146;s public website within a reasonable time after they have been adopted. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>E.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Quarterly Board Discussion Concerning Business Topics Relevant to Allegations in Derivative Matters</B>
&#150; Within (30)&nbsp;days of Final Approval of the Settlement, Company management shall ensure that they report to the Board at least quarterly concerning: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company&#146;s compliance with FDA regulations, the Company&#146;s compliance with cGMP, and the
Company&#146;s CMOs&#146; compliance with cGMP, identify any material risks relating thereto, and make any recommendations to mitigate any of these identified material risks; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Whether the Company&#146;s disclosures comport with the Company&#146;s compliance with FDA regulations, the
Company&#146;s compliance with cGMP, and the Company&#146;s CMOs&#146; compliance with cGMP, and identify material risks relating thereto, and whether the Company&#146;s disclosures require modification. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>F.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Annual Legal Department Review and Report on Effectiveness</B> &#150; The Company&#146;s Legal Department
will review and report to the Board of Directors at least annually with respect to the effectiveness of the Company&#146;s policies, procedures, and practices related to compliance with FDA regulations. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>G.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Employee Training</B> &#150; Within ninety (90)&nbsp;days of Final Approval of the Settlement, the Company
shall establish and/or maintain training program(s) that adhere to the following conditions: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company&#146;s Human Resources and Legal Departments shall be charged with primary responsibility for
developing, implementing, and/or maintaining annual employee training program(s) focused on compliance, internal controls policies and procedures, compliance risk assessment, and complaint reporting and investigation. The Company&#146;s Human
Resources and Legal Departments shall be authorized and provided the resources necessary to retain external consultants and vendors as they deem necessary to develop, implement, and/or maintain the training program(s). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The training shall be mandatory, in whole or in part, for Company employees based on their role in the Company
as determined by the Company&#146;s Human Resources and Legal Departments. Training shall be annual for all such persons, and in the event a person is appointed or hired after the annual training for a particular year, a special training session
shall be held for such individual within ninety (90)&nbsp;days of their appointment or hiring. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Training shall include coverage of risk assessment and compliance, the Company&#146;s Code of Conduct, the
Company&#146;s Insider Trading Policy, and all other manuals, policies, rules, or procedures established by the Company concerning legal, ethical, or regulatory standards of conduct applicable to and to be observed in connection with work performed
by such employee for the Company. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The training shall be mandatory for employees involved in (a)&nbsp;preparing the Company&#146;s financial
statements; (b)&nbsp;manufacturing the Company&#146;s products; (c) communicating with the FDA; (d)&nbsp;communicating with the Company&#146;s independent external auditor; and (e)&nbsp;and drafting, disseminating or producing the Company&#146;s
public statements, in each case as appropriate based on their role in the Company as determined by the Company&#146;s Human Resources and Legal Departments. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>IV.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>SHAREHOLDERS&#146; COUNSELS&#146; FEE AND EXPENSE AWARD AND SHAREHOLDERS&#146; SERVICE AWARDS
</B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to discussing attorneys&#146; fees and reimbursement of expenses for Shareholders&#146; Counsel, the Settling
Parties negotiated and agreed upon the Reforms to be adopted as part of the Settlement. Defendants acknowledge that the Settlement confers substantial benefits upon ImmunityBio and Current ImmunityBio Shareholders and, in recognition of those
substantial benefits, that Shareholders&#146; Counsel are entitled to an award of attorneys&#146; fees and expenses. Shareholders&#146; Counsel intend to petition the Court for an award of attorneys&#146; fees and litigation expenses not to exceed
$2,500,000 to Shareholders&#146; Counsel (the &#147;Fee and Expense Award&#148;). Defendants have not and do not agree to a Fee and Expense Award of $2,500,000 or that such an award is appropriate. Defendants are permitted to respond and/or oppose
the Fee and Expense Award application. ImmunityBio and its insurers are responsible for the payment of any Fee and Expense Award, and the Parties agree that no other person or entity shall have any responsibility to contribute to or pay the Fee and
Expense Award. To date, Shareholders&#146; Counsel have not received any payments for their efforts on behalf of ImmunityBio shareholders, nor have Shareholders&#146; Counsel been reimbursed for their out-of-pocket litigation expenses. The Fee and
Expense Amount will compensate Shareholders&#146; Counsel for the substantial benefits achieved in the Derivative Matters, and the risks of undertaking the prosecution of the Derivative Matters on a contingent basis. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Defendants agree not to oppose reasonable service awards in the amount up to $2,500 to each
of the Shareholders to be paid out of the Fee and Expense Amount in recognition of Shareholders&#146; efforts to achieve the Settlement&#146;s benefits to the Company, subject to Court approval (the &#147;Service Awards&#148;). </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>V.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>REASONS AND BENEFITS OF THE SETTLEMENT </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Counsel for the Settling Parties believe that the Settlement is in the best interests of ImmunityBio, and its shareholders. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>A.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Why Did the Shareholders Agree to Settle? </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Shareholders and Shareholders&#146; Counsel brought the claims in good faith and continue to believe that the claims asserted in the
Derivative Matters have merit. However, the Shareholders and Shareholders&#146; Counsel recognize and acknowledge the expense, time, and uncertainty inherent in the continued prosecution of their claims in the Derivative Matters through trial and
any subsequent appeal(s). Shareholders and Shareholders&#146; Counsel also have taken into account the uncertain outcome and the risk of any litigation, especially in complex actions such as the Derivative Matters, as well as the difficulties and
delays inherent in such litigation. The Shareholders and Shareholders&#146; Counsel also are mindful of the inherent problems of proof of, and possible defenses to, the claims asserted in the Derivative Matters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based upon their investigation, Shareholders and Shareholders&#146; Counsel have concluded that the terms and conditions of the Stipulation
are fair, reasonable and adequate to Shareholders, Current ImmunityBio Shareholders, and ImmunityBio, and in their best interests, and have agreed to settle the claims raised in the Derivative Matters pursuant to the terms and provisions of the
Stipulation after considering, among other things: (a)&nbsp;the substantial benefits that Current ImmunityBio Shareholders and ImmunityBio have received or will receive from the Settlement; (b) the attendant risks of continued litigation; and
(c)&nbsp;the desirability of permitting the Settlement </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">to be consummated. In particular, Shareholders and Shareholders&#146; Counsel considered the significant
litigation risk inherent in shareholder derivative litigation. The law imposes significant burdens on plaintiffs for pleading and proving a shareholder derivative claim. While Shareholders believe their claims are meritorious, Shareholders
acknowledge that there is a substantial risk that the Derivative Matters may not succeed in producing a recovery in light of the applicable legal standards and possible defenses. Shareholders and Shareholders&#146; Counsel believe that, under the
circumstances, they have obtained the best possible relief for ImmunityBio and Current ImmunityBio Shareholders. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>B.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Why Did the Defendants Agree to Settle? </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Defendants deny any and all allegations of wrongdoing, liability, violations of law, or damages arising out of or related to any of the
conduct, statements, acts, or omissions alleged in the Derivative Matters, and maintain that their conduct was at all times proper, in the best interests of ImmunityBio and its shareholders, and in compliance with applicable law. They further deny
any breach of fiduciary duties or violation of federal securities laws. The Defendants also deny that ImmunityBio or its shareholders were harmed by any conduct or lack thereof alleged in the Derivative Matters or that could have been alleged
therein. The Defendants assert that, at all relevant times, they acted in good faith and in a manner they reasonably believed to be in the best interests of ImmunityBio and all of its shareholders. Nevertheless, Defendants wish to eliminate the
uncertainty, distraction, risk, burden, and expense of further litigation, and to permit the operation of ImmunityBio without further distraction and diversion of its Board and personnel with respect to the Derivative Matters. The Defendants have
therefore determined to settle the Derivative Matters on the terms and conditions set forth in this Stipulation solely to put the Released Claims (as defined below) to rest, finally and forever, without in any way acknowledging any wrongdoing,
fault, liability, or damages. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>VI.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>SETTLEMENT HEARING </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On <U>&#8195;&#8195;&#8195;&#8195;</U>, 2025, at <U>&#8195;&#8195;&#8195;&#8195;</U>, the Court will hold the Settlement Hearing either in person at the James
M. Carter and Judith N. Keep United States Courthouse, Courtroom 2D, 333 West Broadway, San Diego, California 92101 or by telephone or videoconference (at the discretion of the Court). At the Settlement Hearing, the Court will consider whether the
Settlement is fair, reasonable and adequate and thus should be finally approved and whether the Derivative Matters should be dismissed with prejudice pursuant to the Stipulation. The Court also will rule upon Shareholders&#146; Counsel&#146;s
request for approval of the Fee and Expense Amount to Shareholders&#146; Counsel and Shareholders&#146; Service Awards. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>VII.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>RIGHT TO ATTEND SETTLEMENT HEARING </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any Current ImmunityBio Shareholder may, but is not required to, appear in person at the Settlement Hearing. If you want to be heard at the
Settlement Hearing in opposition to the Settlement, the Fee and Expense Amount or the Service Award, then you must first comply with the procedures for objecting, which are set forth below. The Court has the right to change the hearing dates or
times without further notice. Thus, if you are planning to attend the Settlement Hearing, you should confirm the date and time before going to the Court. CURRENT IMMUNITYBIO SHAREHOLDERS WHO HAVE NO OBJECTION TO THE SETTLEMENT DO NOT NEED TO APPEAR
AT THE SETTLEMENT HEARING OR TAKE ANY OTHER ACTION. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>VIII.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>RIGHT TO OBJECT TO THE SETTLEMENT AND PROCEDURES FOR DOING SO </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You have the right to object to any aspect of the Settlement. You must object in writing, and you may request to be heard at the Settlement
Hearing. If you choose to object, then you must follow these procedures. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>A.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>You Must Make Detailed Objections in Writing </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any objections must be presented in writing and must contain the following information: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notice of intent to appear at the Settlement Hearing; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Your name, legal address, and telephone number; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Proof of being a Current ImmunityBio Shareholder as of the Record Date and representation that you will
continue to own ImmunityBio common stock as of the date of the Settlement Hearing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The date(s) you acquired your ImmunityBio shares and the number of ImmunityBio shares held;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A <U>detailed statement</U> of your specific position with respect to the matters to be heard at the Settlement
Hearing, including a statement of each objection being made; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The grounds for each objection or the reasons for your desire to appear and to be heard. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Court will not consider any objection that does not substantially comply with these requirements. Any counsel retained by a purported
objector for the purpose of asserting an objection must make a notice of appearance on the Court by <U>&#8195;&#8194;&#8195;&#8195;</U>, 2025, which is fourteen (14) days prior to the Settlement Hearing. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>B.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>You Must Timely Deliver Written Objections to the Court and to Lead Counsel for Plaintiffs
</B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">YOUR WRITTEN OBJECTIONS MUST BE FILED WITH THE COURT AND SENT BY HAND OR BY FIRST CLASS MAIL, POSTAGE PRE-PAID TO
SHAREHOLDERS&#146; COUNSEL. THE WRITTEN OBJECTIONS MUST BE FILED WITH THE COURT AND POSTMARKED NO LATER THAN <U>&#8195;&#8194;&#8195;&#8195;</U>, 2025, WHICH IS FOURTEEN (14)&nbsp;CALENDAR DAYS PRIOR TO THE SETTLEMENT HEARING to the following
address: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Shareholders&#146; Counsel:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Clerk of the Court:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">Justin A. Kuehn</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">United States District Court</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">KUEHN LAW, PLLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Southern District of California</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">53 Hill Street, Suite 605</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">333 West Broadway, Suite 420</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">Southampton, NY 11968</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">San Diego, CA 92101</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Telephone: (833) 672-0814</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">justin@kuehn.law</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Court will not consider any objection that is not timely filed with the Court and delivered to
Shareholders&#146; Counsel. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any person or entity who fails to object or otherwise requests to be heard in the manner
prescribed above will be deemed to have waived the right to object to any aspect of the Settlement or otherwise request to be heard (including the right to appeal) and will be forever barred from raising such objection or request to be heard in this
or any other action or proceeding, but shall otherwise be bound by the Judgment to be entered and the releases to be given. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>IX.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>HOW TO OBTAIN ADDITIONAL INFORMATION </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Notice summarizes the Settling Parties&#146; Stipulation. It is not a complete statement of the events of the Derivative Matters or the
Stipulation. Although the Settling Parties believe that the descriptions about the Settlement that are contained in this Notice are accurate in all material respects, in the event of any inconsistencies between the descriptions in this Notice and
the Stipulation, the Stipulation will control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You may inspect the Stipulation and other papers at https://ir.immunityBio.com/. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">PLEASE DO NOT CALL, WRITE, OR OTHERWISE DIRECT QUESTIONS TO EITHER THE COURT OR THE CLERK&#146;S OFFICE. Any questions you have about matters
in this Notice should be directed by telephone or in writing to Shareholders&#146; Counsel at the address set forth above. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>X.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>NOTICE TO PERSONS OR ENTITIES HOLDING OWNERSHIP ON BEHALF OF OTHERS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Brokerage firms, banks and/or other persons or entities who held shares of ImmunityBio common stock for the benefit of others are requested to
immediately send this Notice to all of their respective beneficial owners. If Current ImmunityBio Shareholders have questions or comments about the Settlement, they should follow the procedures listed above. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated <U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&#8195;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">BY ORDER OF THE UNITED STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF CALIFORNIA</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT E </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES DISTRICT COURT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SOUTHERN DISTRICT OF CALIFORNIA </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="53%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>IN RE IMMUNITYBIO,
INC.</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>SHAREHOLDER DERIVATIVE LITIGATION</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No.&nbsp;3:24-cv-02014-GPC-VET</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(Consolidated with</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3:25-cv-00416-GPC-VET</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">3:25-cv-00423-GPC-VET)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>This Document Relates to:</B></P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman"><B>ALL ACTIONS</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>[PROPOSED] FINAL JUDGMENT AND ORDER APPROVING</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>DERIVATIVE SETTLEMENT</B></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Judge: Hon. Gonzalo P. Curiel</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Magistrate: Hon. Judge Valerie E.
Torres</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">3:24-cv-02014-GPC-VET </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[PROPOSED] FINAL JUDGMENT AND ORDER APPROVING DERIVATIVE SETTLEMENT </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, a consolidated shareholder derivative action is pending in this Court titled <I>In
re ImmunityBio, Inc. Shareholder Derivative Litigation</I>, No.&nbsp;3:24-cv-02014-GPC-VET; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, a Stipulation and Settlement
Agreement (the &#147;Stipulation&#148;) was made and entered into as of May&nbsp;19, 2025, by and among: (i)&nbsp;plaintiffs Gary Van Luven (&#147;Van Luven&#148;), Angelo Barbieri (&#147;Barbieri&#148;), and Bong Shin (&#147;Shin&#148;) (the
&#147;Plaintiffs&#148;) and demand-made shareholders Roland Davies (&#147;Davies&#148;) and Chris Pallas (&#147;Pallas&#148;) (and together with Plaintiffs, the &#147;Shareholders&#148;), derivatively on behalf of ImmunityBio, Inc.
(&#147;ImmunityBio&#148; or the &#147;Company&#148;); (ii)&nbsp;nominal defendant ImmunityBio, a Delaware corporation; and (iii)&nbsp;individual defendants Patrick Soon-Shiong, Richard Adcock, Cheryl L. Cohen, Michael D. Blaszyk, John Owen Brennan,
Linda Maxwell, Wesley Clark, Christobel Selecky, Barry J. Simon, and David C. Sachs (the &#147;Individual Defendants,&#148; together with ImmunityBio, the &#147;Defendants,&#148; and together with ImmunityBio and the Shareholders, the
&#147;Parties&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, by order dated <U>&#8195;&#8195;&#8195;&#8195;&#8195;</U>, 2025 (the &#147;Preliminary Approval
Order&#148;), the Court (a)&nbsp;preliminarily approved the Settlement; (b)&nbsp;ordered that notice of the proposed Settlement be provided to ImmunityBio shareholders; (c)&nbsp;provided ImmunityBio shareholders with the opportunity to object to the
proposed Settlement and Shareholders&#146; Counsel&#146;s application for an award of attorneys&#146; fees and litigation expenses (the &#147;Fee and Expense Award&#148;); and (d)&nbsp;scheduled a hearing regarding final approval of the Settlement;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Court conducted a hearing on <U>&#8195;&#8195;&#8195;&#8195;&#8195;</U>, 2025 to consider, among other things,
(a)&nbsp;whether the proposed Settlement on the terms and conditions provided for in the Stipulation is fair, reasonable, and adequate to ImmunityBio and its shareholders, and should be approved by the Court; (b)&nbsp;whether a judgment should be
entered dismissing the claims in the Action with prejudice; and (c)&nbsp;whether the application by Shareholders&#146; Counsel for the Fee and Expense Award should be approved; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">3:24-cv-02014-GPC-VET </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FINAL JUDGMENT AND ORDER APPROVING DERIVATIVE SETTLEMENT </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, it appearing that due notice of the terms of the Settlement and the Settlement
Hearing has been given in accordance with the Preliminary Approval Order, the Parties having appeared by their respective attorneys of record, the Court having heard and considered the submissions presented in support of the proposed Settlement, the
opportunity to be heard having been given to all other persons requesting to be heard in accordance with the Preliminary Approval Order, and the Court having determined that notice of the proposed Settlement was adequate and sufficient, and the
entire matter of the proposed Settlement having been heard and considered by the Court; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IT IS HEREBY ORDERED,</B> this
<U>&#8195;&#8195;&#8195;</U> day of <U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U>, 202_ that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. Unless otherwise
defined herein, all capitalized terms shall have the same meanings as set forth in the Stipulation and the Preliminary Approval Order. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.
The Court has jurisdiction over the subject matter of the Action, and all matters relating to the Settlement of the Action, as well as personal jurisdiction over all of the Parties and each of the Current ImmunityBio Shareholders, and it is further
determined that the Parties and all Current ImmunityBio Shareholders, as well as their transferees, heirs, executors, successors, and assigns, are bound by this Order and Final Judgment (the &#147;Judgment&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">3:24-cv-02014-GPC-VET </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FINAL JUDGMENT AND ORDER APPROVING DERIVATIVE SETTLEMENT </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. The Notice has been provided to Current ImmunityBio Shareholders pursuant to and in the
manner directed by the Preliminary Approval Order, proof of the Summary Notice and Notice were filed with the Court, and full opportunity to be heard has been offered to all Parties and Current ImmunityBio Shareholders. The Court finds that the form
and means of publishing the Summary Notice and Notice were the best practicable under the circumstances and were given in full compliance with the requirements of Rule 23.1 of the Federal Rule of Civil Procedure, the United States Constitution
(including the Due Process Clause), and all other applicable law and rules, and that all Current ImmunityBio Shareholders, as well as their transferees, heirs, executors, successors, and assigns, are bound by this Judgment. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. Based on the record in the Action, each of the provisions of Rule 23.1 of the Federal Rules of Civil Procedure have been satisfied, and the
Action has been properly maintained according to the provisions of Rule 23.1. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. The Court finds that the Settlement is fair, reasonable,
adequate, and in the best interests of ImmunityBio and Current ImmunityBio Shareholders. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. Pursuant to Rule 23.1 of the Federal Rules of
Civil Procedure, this Court fully and finally approves the Settlement in all respects, and the Parties are directed to consummate the Settlement in accordance with the terms of the Stipulation. The Clerk of the Court is directed to enter and docket
this Judgment. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. The Action is hereby dismissed with prejudice as to the Defendants. The foregoing dismissal is without fees or costs,
except as otherwise provided in Paragraph 15 below or as otherwise provided in the Stipulation or the Preliminary Approval Order. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">3:24-cv-02014-GPC-VET </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FINAL JUDGMENT AND ORDER APPROVING DERIVATIVE SETTLEMENT </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. Upon the Effective Date, Shareholders, the Company, the Current ImmunityBio Shareholders,
the Defendants, and all of their respective successors-in-interest, predecessors, representatives, trustees, executors, administrators, heirs, assigns or transferees, immediate and remote, and any person or entity acting for or on behalf of, or
claiming under, any of them, and each of them, shall be deemed to have, and by operation of this Judgment shall have, completely discharged, dismissed with prejudice on the merits, released and settled, to the fullest extent permitted by law, the
Released Claims against the Released Persons and shall be forever barred and enjoined from commencing, instituting, prosecuting, or continuing to prosecute any of the Released Claims against any of the Released Persons. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. As set forth in the Stipulation and Notice, &#147;Released Persons&#148; means ImmunityBio, the Individual Defendants, the Shareholders, and
their respective past, present, or future heirs, trusts, trustees, estates, beneficiaries, distributees, agents, employees, fiduciaries, partners, subsidiaries, affiliates, associated entities, stockholders, principals, officers, directors,
predecessors, predecessors-in-interest, successors, successors-in-interest, assigns, advisors, attorneys, personal or legal representatives, associates and insurers, co-insurers and re-insurers. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. As set forth in the Stipulation and Notice, &#147;Released Claims&#148; means any and all manner of claims, demands, rights, liabilities,
losses, obligations, duties, damages, costs, debts, expenses, interest, penalties, sanctions, fees, attorneys&#146; fees, actions, potential actions, causes of action, suits, agreements, judgments, decrees, matters, issues and controversies of any
kind, nature, or description whatsoever, whether disclosed or undisclosed, accrued or unaccrued, apparent or not apparent, direct or derivative, foreseen or unforeseen, matured or not matured, suspected or unsuspected, liquidated or not liquidated,
fixed or contingent, including known claims and Unknown Claims (as defined in the Stipulation), whether based on state, local, foreign, federal, statutory, regulatory, common, or other law or rule (including claims within the exclusive jurisdiction
of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">3:24-cv-02014-GPC-VET </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FINAL JUDGMENT AND ORDER APPROVING DERIVATIVE SETTLEMENT </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">federal courts), that are, have been, could have been, could now be, or in the future could, can, or might
be asserted, in the Derivative Matters or in any other court, tribunal, or proceeding (a)&nbsp;by the Shareholders or any other Current ImmunityBio Shareholder directly or derivatively on behalf of ImmunityBio, or by ImmunityBio directly, against
any of the Released Persons or (b)&nbsp;by the Released Persons against ImmunityBio or any other Released Person, which, now or hereafter, are based upon, arise out of, or relate to any of the actions or inactions, transactions, occurrences,
statements, representations, misrepresentations, omissions, allegations, facts, practices, events, claims, or any other matters related to: (i)&nbsp;the allegations, claims, and events described in the complaints filed in the Derivative Actions;
(ii)&nbsp;the allegations, claims, and events described in the Demands; and (iii)&nbsp;the Derivative Actions and the institution, prosecution and settlement thereof; provided, however, &#147;Released Claims&#148; does not include, and neither the
Stipulation nor any aspect of the Settlement shall affect claims relating to enforcement of the Settlement, the Stipulation, or any other agreement among any or all of the Parties and relevant insurers in connection with the Settlement. For the
avoidance of doubt, Released Claims do not include the derivative claims asserted on behalf of ImmunityBio, Inc. in an unrelated shareholder derivative lawsuit pending in the Delaware Court of Chancery captioned <I>Carlson v. Soon-Shiong, et
al.</I>, C.A. No.&nbsp;2024-1185-JTL </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. The Parties are hereby authorized, without further approval from the Court, to agree to adopt
such amendments, modifications, and expansions of the Stipulation that are consistent with this Judgment and the Stipulation and that do not materially limit the rights of the Parties or Current ImmunityBio Shareholders under the Stipulation.
Without further order of the Court, the Parties may agree to reasonable extensions of time to carry out any of the provisions of the Stipulation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">3:24-cv-02014-GPC-VET </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FINAL JUDGMENT AND ORDER APPROVING DERIVATIVE SETTLEMENT </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. Nothing in this Judgment shall in any way impair or restrict the rights of any Party to
enforce the terms of the Stipulation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13. Neither this Judgment, nor the Settlement, nor any act or omission in connection therewith shall
be deemed or argued to be evidence of or to constitute an admission or concession by: (a)&nbsp;the Defendants as to (i)&nbsp;the truth of any fact alleged by Plaintiffs, (ii)&nbsp;the validity of any claims or other issues raised, or which might be
or might have been raised, in the Action or in any other litigation, (iii)&nbsp;the deficiency of any defense that has been or could have been asserted in the Action or in any litigation, or (iv)&nbsp;any wrongdoing, fault, or liability of any kind
by any of them, which each of them expressly denies; or (b)&nbsp;Plaintiffs that any of their claims are without merit, that any of the Defendants or Released Persons had meritorious defenses, or that damages or other relief recoverable in the
Action would not have exceeded the terms of the Settlement. The Parties or any Released Persons may file the Stipulation and/or this Judgment in any action that has been or may be brought against them in order to support a claim or defense based on
principles of <I>res judicata</I>, collateral estoppel, release, good faith settlement, judgment bar or reduction, or any other theory of claim preclusion or issue preclusion or similar defense or counterclaim or in connection with any insurance
litigation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">3:24-cv-02014-GPC-VET </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FINAL JUDGMENT AND ORDER APPROVING DERIVATIVE SETTLEMENT </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14. In the event that the Settlement is terminated or the Effective Date otherwise fails to
occur for any other reason, then (i)&nbsp;the Settlement and the Stipulation (other than Section F and Paragraph 3.3 thereof) shall be canceled and terminated; (ii)&nbsp;this Judgment and any related orders entered by the Court in this Action shall
in all events be treated as vacated, <I>nunc pro tunc</I>; (iii)&nbsp;the Releases provided under this Judgment and the Stipulation shall be null and void; (iv)&nbsp;to the extent the Fee and Expense Award has been paid, it shall be repaid to the
persons and entities (including the insurers) who paid on behalf of the Defendants within ten (10)&nbsp;business days after termination of the Settlement; (v)&nbsp;the fact of the Settlement shall not be admissible in any proceeding before any court
or tribunal; (vi) all proceedings in the Action shall revert to their status as of immediately prior to filing of the Stipulation of Settlement; and no materials created by or received from another Party that were used in, obtained during, or
related to settlement discussions shall be admissible for any purpose in any court or tribunal, or used, absent consent from the disclosing Party, for any other purpose or in any other capacity, except to the extent that such materials are otherwise
required to be produced during discovery in any other litigation; (vii)&nbsp;the Parties shall jointly petition the Court for a revised schedule for further proceedings; and (viii)&nbsp;the Parties shall proceed in all respects as if the Settlement
and the Stipulation (other than Section F and Paragraph 3.3 thereof) had not been entered into by the Parties. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15. Shareholders&#146;
Counsel are awarded attorneys&#146; fees and expenses in the sum of $<U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U> (&#147;Fee and Expense Award&#148;), which the Court finds to be fair and reasonable, to be paid in accordance with the
terms of the Stipulation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16. Shareholders are each awarded a service award (&#147;Service Award&#148;) of
$<U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U>, in recognition of their participation and efforts in the prosecution of the Action to be awarded from the Fee and Expense Award. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17. No proceedings or Court order with respect to any Fee and Expense Award shall in any way disturb or affect this Judgment (including
precluding the Judgment from being Final or otherwise being entitled to preclusive effect), and any such proceedings or Court order shall be considered separate from this Judgment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">3:24-cv-02014-GPC-VET </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FINAL JUDGMENT AND ORDER APPROVING DERIVATIVE SETTLEMENT </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">18. Nothing in this Judgment dismisses or releases any claim by or against any Party arising
out of a breach of the Stipulation or violation of this Judgment. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">19. Without affecting the finality of this Judgment in any way, this
Court reserves jurisdiction over all matters relating to the administration, enforcement, and consummation of the Settlement and this Judgment. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">20. There is no just reason to delay the entry of this Judgment as a final judgment in the Action. Accordingly, the Clerk of the Court is
expressly directed to immediately enter this final judgment in the Action. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IT IS SO ORDERED. </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated: <U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&#8195;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">THE HONORABLE GONZALO P. CURIEL UNITED STATES DISTRICT JUDGE</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">3:24-cv-02014-GPC-VET </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FINAL JUDGMENT AND ORDER APPROVING DERIVATIVE SETTLEMENT </B></P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>ibrx-20250808.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241122.1 -->
<!-- Creation date: 8/8/2025 9:44:18 PM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2024"
  xmlns:ibrx="http://www.immunitybio.com/20250808"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.immunitybio.com/20250808"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" namespace="http://xbrl.sec.gov/dei/2024" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2024/naics-2024.xsd" namespace="http://xbrl.sec.gov/naics/2024" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ibrx-20250808_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ibrx-20250808_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.immunitybio.com//20250808/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>ibrx-20250808_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241122.1 -->
<!-- Creation date: 8/8/2025 9:44:18 PM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>ibrx-20250808_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241122.1 -->
<!-- Creation date: 8/8/2025 9:44:19 PM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.immunitybio.com//20250808/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="ibrx-20250808.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.immunitybio.com//20250808/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Aug. 08, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001326110<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug.  08,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ImmunityBio, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37507<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">43-1979754<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3530 John Hopkins Court<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92121<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(844)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">696-5235<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">IBRX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d29656d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com//20250808/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="d29656d8k.htm">d29656d8k.htm</File>
    <File>ibrx-20250808.xsd</File>
    <File>ibrx-20250808_lab.xml</File>
    <File>ibrx-20250808_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d29656d8k.htm": {
   "nsprefix": "ibrx",
   "nsuri": "http://www.immunitybio.com/20250808",
   "dts": {
    "inline": {
     "local": [
      "d29656d8k.htm"
     ]
    },
    "schema": {
     "local": [
      "ibrx-20250808.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/naics/2024/naics-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "ibrx-20250808_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ibrx-20250808_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 22
   },
   "report": {
    "R1": {
     "role": "http://www.immunitybio.com//20250808/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2025-08-08_to_2025-08-08",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d29656d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2025-08-08_to_2025-08-08",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d29656d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.immunitybio.com//20250808/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.immunitybio.com//20250808/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.immunitybio.com//20250808/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.immunitybio.com//20250808/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.immunitybio.com//20250808/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.immunitybio.com//20250808/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.immunitybio.com//20250808/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.immunitybio.com//20250808/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.immunitybio.com//20250808/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.immunitybio.com//20250808/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.immunitybio.com//20250808/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.immunitybio.com//20250808/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.immunitybio.com//20250808/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.immunitybio.com//20250808/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.immunitybio.com//20250808/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.immunitybio.com//20250808/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.immunitybio.com//20250808/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.immunitybio.com//20250808/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.immunitybio.com//20250808/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.immunitybio.com//20250808/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.immunitybio.com//20250808/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.immunitybio.com//20250808/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001193125-25-177024-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-25-177024-xbrl.zip
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MI6+@D6K! /;I$YUC!B\#=19QJ4Q2M_GW3-'SU5@V,1OH]R&SOQ((+@@-P B
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M;^7<T<J86!O(B6GUE(9X0D[].%='UPM0T@U]^^L!":@@=]2-&/E+,8_7K4B
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MVCCYEMIZ2PT)U^*Q%B!F\JSR:^L88;)G^A6IR< 'V+J!R8)!:#XRS,9_ "=
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MQ)7$FWL5Q6O%V4UF!9BA-IO?LO/(A#C74AB_P+RRM2"WN$0FYBH[@N?$+R%
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M;>Q]67/;6)+N.R/X'Q U=R;D"8BEU9:7=K06VE:5+&DDN6MZWD#B4$09!-@
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MV.\"-7P@1)YKREXZ.1IEHFAQR[+'7<:.7@;-U9V]7_%*(G%K"Y.B%6C52!J
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M#\[A0WK*A+B"Q+!5J@58D8E3@.P28<P=N(X3W I5'$Q(!F QVW@<,C/_3>\
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M(9L/H/VA[V:_A0_=O/ NN_UQ!U%QOZ5)]VM?Z>HD/.+O:0P<C8?4R2B7_?$
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MB]!S,Q*GAPI><#W4TI$D1O8=6KWXD;69G6(,%]0Q[O)2KLN-+A,=R;$)QAI
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ME'\U@1=.+2GMHUE^HFNR8FF:M]176@8KE,*9'K=GD))*R*_LH]9@Q@;#2R(
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MTZ?Q[;7VJF!#JWCQU>!52T2$&-?41"9Q;65*NINC3E]7?4W[IRJ.=PE 3 \
M%)ST=/^ 92; SCH,2;5.06$ZNN>?P W*N1-/0IJOIWH8Q#_@0NR TR4$YDQ,
M[$@"ZNPFJ=,^'4^%;ET_E@Y(5#K%A=3X_ ;3F56:!U/0BM1F!EV'CEDR*;=
M--;"9"U"D*CV:E"*-0>!%WICSFX\#3,&#@1V[=-U(-EK;6ZPC-2)<P6C@/'W
M$:S3)*<*>AM8#!FI5+5AXKCX^(>ZU(NI]:X=7G5':0B#HF8&'B6;-G4HW2M7
MU\O1P?UR 3#Z3I972"1R@+VV)_AB2RYU'%YLG8("X&&8RJ3.C]VYEO<'+[MP
M#G.=3W5G4+AOTW95D  1IZX[C;MG.KJ2<"J]<&311DQ)R!8'*S8?J9NFZ(!Z
MLKJ(;3 JNI-E6%9O9!!V'X?*F14!07*EO@IZF'QP$]12[._E*I8=_V7QU7;2
M:TL^/ML<JQ;<C$I$LY&CS2XJ+<Z6$!S^CVOHOEX9NBM#=UD-W;L5/Q+S4;,J
M"CEA,)64@435,=5H,!PSM*VLN_##IO*($XLE#&NAW QL+OL\7;Y1X,\RFC@.
M'U^%WIP9,-*V'LI+E@U1XMC:4CX6RY:P^]LVR&;YJ=M7%SVR7$/X25:[5<U[
M$Z^R-9)MR0^+N=,836IOYA;0:C;J.@Z8SNPB544$V4(BU#M\B..YL-5B6+HL
MEG$&Y?XK_+I"1:]"<J=NZ3.H!BPX)\7V':^?J*EX;X<N5"35=^L;5UP,,<RN
M<2,I.I5U2$6-10H1X^/3BG<\B3&U*2$XB:EV30V-NNV:=DNO$0Z1L-:ISXP#
MM%/2<['7@3T!PNCW$$,1XU:J@D^)XWR:7.B'G!-&RK7%P_(<!&I>Q")@3"R.
MNASI@!'<K@M/R IVN#\C+++9T+C9:GJT7\.YN,R+3FQWF@]1Z-$:"=C3$KUG
M08;,93R:93>IJB_EL4E17&I.:6 3[B.B2,"&M@7@B4:!M(9I1MY2<<!1^%]J
M_KVI+,-.Z>4\S6VCI/C",%?[!R=M/=3!V<51^V(=U)*3_?/+]AO]CYGK+&_*
M+QX/\[=?-G[Q#MLG)^?[1T?'IQ_-WY?G^X?Z;U?EX?E<L'+D_<W[Q=&I(G+Z
MOJ%6O_+@D?[QSG_:15T=E;[<!57J'Z)+P:88O8I5I+7@A?L;][O"K]Q[Y!6W
MV/M>7>JM5YJ4;@*P_P:NB]""]Y%X ;&<"]0O!SF[/VCZ\#\7^#]XEBO:N"_:
MZ"PQ;1R\F=%;;$49#TP9W26FC,,WI1Z *VIX8&H(EY@:CM[HEH^@$6&Y(4I_
MH.RAFH:B\ RG6W*"TXINGBW=M-]PZ4T6*$0-VH1O+4 7#ZY:'Y_")E^=MB\O
MO3\^M2_:9Q]\[_C*.[[T\*^#?[*K[TCC;AF(QM'YP%@'5-<B20EKA]ES/RZ"
M:FMCY5A>.98?T;%LN'>9J9:9;N'5#G.^7ZY?.BQ<$C-T/5?+L%\#QR;F9;[1
MS)9WW4Y9/U@<8/L[?[_S4G].W--.56_)%,GCW6U+WI<F1Y($2T>$;[S/P81O
MT>9KW]O:V-IUIUE:C=RWJHPK#'PP>7?YI48K>+4+C!US\*-N$*\3$;VA'[QY
M]RO\X/UWOWAA%KN)'\UA+G>40;_FOWH?,W6-*3HG&(@>C?*B:'RT@_WN??SN
M <H;X8L3]"#(0 -M:7I[M;GU\EGNSP.&XOYX=_EY_^3D_?')Y=DIW"OZP[N4
M3\].+X]/C\W''_7'9T<7QX>?].>RAF P?.M=Z$<N0=;I!WSOO'78FJ%D3+MS
M=\O'W]@$O;,WZGO[U$D,J&@< 17M@OQXME?K4@5HH?G>'_O>Z[W-C9WU5QO;
MJUMTS[?H2L5JV$\3]09;_KU\,;]+W=[>]OK6+A(F=:J[V]VX^P2O;Y&O_OTV
MO\Y:W710,C"<H5R#:_K-= V5%2W=[U&=!B/0=93W6\O[G&;705(K#;<V-S=W
MMA^:;'XBZ;"YM;6]Z[5C[Q >2%+O0@7QLR7?RR#QCB)0NGSO$.3"UN;VQOKV
MQL;6L]R,1Y(+>[M["\B%[=V-]:WM1Y,+R8!8S$HP_ #$].[XO:YOB2BB^G+-
M01)B;8F'IAN8RVDZ(">O>7DQL?@XZ;;T3)XS11U,WOSPCHH#-<HGWB$H)$$2
M]=(X_%$/8YFO=V63Z[T@>UL[NQL/?;TO@FX?1)=WT?(.)MF4F;S>>+F]\["A
MBO?[L?H+->&K#*O'CX(D]3&CH:H.OWH)__? D_GC[.2#]VG_Y*A]>GG5/C[U
M]H].VA?>!W3?[Y\^])FP!OVI??%_WLG)^9V6^@V^E-T-[P!./5-JI/TH0'K/
MV(]2UI@W-I_E/CR2LOQR\_4"RO+6]NOUG=W7KQ])61X(8_[[;3_H]6O4Y?M^
M80=X;_%E#[F\D>&Q4Q?X[+2W9;XOOXWS491X^RWO]['J)]X:Y@Y0@270SK$B
M>3_H>M@_#=7P%P]-/;]_:7\Z]4[V__"]\Y.3PP>63[O;WB?,0BQ*J)<;N\^6
MT"[3\:@/*L((,S-._^EM;KY^N?<L=^*Q_#G;VPN(J)>OMM8W]C9WODE$W?U>
M_$D\X>]?D2&TXN#VV5Z';Q9:9:CAPYU5R9]CTJ"\CXB__0<HG"?C&Y5H)XH+
M^]"PN1\2;K:Y@INMX&8KN-D*;K9RO,YSO%ZD'2SP<=CR+KO],?Y[)= ?P-M9
MV>5:A^?+K9=[.P]M1AVQ47<R9RY;NSM[KQ[:WWEY^.G+0?OBJMGX[>ST\/=/
M[?:%&\S__>SDH/T(OLBMC8U-[TN"&=:7HY:V];:>,Z@+=,,/6&X=FQJQ0W)G
M<VO[6>[%(UE[.YN["UA[K_;VUG>VMAXK>I_EPB/^GO_Y59M[#[@A8=W[FK4I
M72O_X).3[S3[<GT_N59QB@*E$ZDL6D7I?PYE\2084Y4'[W,+/L[1<_!C'L8R
M7ZK*)D]!9[Y^N??@Z,RK3VWOXNRR36YW[\/QQ6>$4NZW'E@?V][=]2Y;WL<,
M$SL+4/MF0X,3GB79G:2Y1[P56PJ@4K:Q\6H5)7Y(J/WF(B[X5WN[ZULO-Q]+
M*8LS9 M_I_^ELM6K..IR4U1)3QH:/_Q!FEQ[E_TH66E(/X>&=)"IT<@[:H'(
M5MVO*OM1S^+[#[.R$<]P$Q[2<_;IR^?]4]_[>-(^A?^PO^SRJGWX>_OBH;6S
MK9?>'RTP!I)ND(]4UFR BM9ZMI2^GX78%@44XWUO$Q2RE9/L ?6Q[8U%]+&]
MEYN8;+3]2/I8!WG=W_/^&/Z*@]M>E U6&MERTU1)(W-:@\ 3,9J=1\%-I/*5
M7O9SZ&67:M1';>0BNL[2,/\Z^5$/X_LC.]6=>(:[\(\H07@$0EM/I%WR,]R%
MAXQX'W^\.#NZ_/V? MB]J]/P[F_<V]KUVJ"0>A_)69J.L:=H%F(V#X5SMSF<
M^X S^ BO4XEW2 V "2"[N_W0[US;W33%(&"E,V"B>]OKV[N;;B;#0\K7>2I:
M'F9_S^)UQWWU**K:W'G=Q-.F]9Q5@.\?8+J^==C/HMP[#^(X$'7K)T&A;JU0
MJ"L4ZL_03:>\[Z8"_"P"?Y #__*^4@%@9A%ZF."763)EH>JONW>M_HHM%0Y2
M[*&1]KRC*%/=$;;'6<.BKMB Y-5;^A;_N??V!3Y47=4:/^A\P8][TN24OSY,
M!\,@F>B1L+$G-:F@[AU!F Y'U,ES@/&&0)I4VF8/II6#M/*@G<MDYYS9RF;*
M6[AEA+Q9.I*85C!8'>)7YXW4T!Q;29C^']Q=0Y]/J/)N%G6H=SS,BH1#+QUG
MWMK."^8J$Q7 WE'3-VK;0PU:L2];R$U,N*=?H3L-]61*X[';=:;:FK/2@<2>
M\3.M%CV[(/1QRY7N[E=3C8H'KP>-W_!-^ZRPH^K=:C^_?(C+OT]])Z59K]/&
M!QL]8?==A5UDX:)EB>Y$5=,UMC,>>=QVEN4+/-.E!3+-;6]R852^2[P!NEU5
M#VB_[T4C4+5Z7F?2;,#5P[:$^#9L?+:V*1<K@3GC(H=4=GWDA<*H=..?*@=;
MW9@[WIAEO#+MI(]\'GEEKH_Z*,J[<9ICFS?@ZY3B"_\"'7VT%%?J-/7B@+JY
MPM3Q-F'_O+7M#2'D$#0OC]N]1GD^MAU=I;=30-U']&WK<6OU8CNS1>2%SXW0
MW-M&;8'G[R!(97@?RK91'_MS:?UI$[N781V4<%I3K-4%FW/!?I0;MC\.L?G)
MZG)]R^6:MGG3[M76ZEY]Y[WZQQ)>J_-Q!TP([SS-69?IU5M^'\>P:'1R<!M(
MIJ@*[>1+</-<,XH:7H->"$L;4P?!(2S3DX[EQ\F-RE$SNU#<+##_U5GP4=H=
M,Z^!S2BV S7&X<NW\"WOWZWJY.@.I_M6>F3.AOKP0$C7_V.<=N"B'XQS_!Q_
MF(3C+E_W-O"0+CP[Y=;Z-"^5Y-S1LN;[6;+4][@H()$ OJUVRC4_TTU+:0L5
MF(C<A?<J"V FW?JIM+SC'O>;#\T>4U]$Y$S 7.!$,G43Y2KTW0WGPZ0#A$]S
MY8V'(?5+M*-,/=B[G2%V[,1^GVY#RA&0F3!L&$"Z%G>42L 20(> "E?<\&[<
M<!F9X?^,B4+CB3 XO#/C/&<R-M:EN9]7Z1#N))*9NL$ZFL!@]F,,<C#1 0TY
M(ODP#J)!CI[2.@Y9[V;\6503;(E;U4WTQ899 4'1KUE' 39&O;&Q/2[=MDSA
M!2Z:T/!=K# P^2]]:&]^V$Y.ZR_7O6?@2O]IV-KT[F\O9_*\S27D>5=5>=B%
M/^/(=KK^<+2/[:NEIW+NU\G0\F\.QUF&-_ICFH):\#E(QCU0",89,H[S#'6#
M+DQ+_/'=CY_/Q0]N=8K*"Y(1_@[9A3,6E<&._LTSDS[D,NKAYS/M7:],#]_H
M>Q%RT*@WT1W1@4D!-\NB_*O;&)VM'9[8(/BJZ.E,P9"HL0BSQV;6T2BZ1IV)
MNU,W&ZRGR$LB%99>,:VGWDJ'N)?+MK6$E^V/OJ+VZ#7T'1K]G"\3"CS39_X;
M+FC%#*F_ E-NF[X[<)NF_\Y<GX6NSNUB:\_4O\812/]!&L*EZ3IMW&?;E:NK
M,EO=7D:?WGZ28!G\$\0%@:X\!$6.U, +L/_@1T@U%ZSZ@2K9UC%*TKV7RM&@
MZ;BR$+)9,[N:.D6V$,TV6FU 6Q-/^,[!Q1C"$_J'JK 56L<N6[4I&+41^A=
M8>^J$&\7W\2AD;\9V^TX[AR>LC)O[WK?EO'"M>&,TXE2Z*&)R)A]^GM4M$=A
M4@KMT=?W9(]6?>/<[#I?P%)ED[WHA1(+-1\%G3C*^V5DAC?2&PNSNLZ"P5K^
M@@W9("3(AMQ@%RZ2A!'-Z,WJBCT[4^L39C>!D,O3<=85YWI9BN1"=!WE=?LP
M(^#7Q*&'633 BJ,H'(!\HDX41W!UP-QO-D)UH^)T" 3F6Q@1_54B6/;XDAA6
MFCG4T7 O[8ZQ<3S<%"LI8&ST ."5(_,LC:W8$4EC)8\C8%!-]((\!^F%\V*I
M1-_CK$1*:E]T1.[<Z%HTP6F;V&PLO(O!>-1/,SC#4$_R)D+/,U[,S R2*/C?
M'#<8[BRHL7B[@<^9Y>;C>*1;]W@@BD.2WSE[K$*E!L41Y$2<XZB<!4V@9O-7
MZN_SLQ2O7%(PE M/A@$HBA.\>6!1I;!%0$#P;R1SGX!^6E+IZYQ[G4!N+M!7
ME'D9_DJH31YN-@)$#2*:"N1OZ'4F=6;:0LRJ974+>^&8P>#L\!,*_@Q5EI.M
MRG><]=H;<B'+=R#O/8%9<5BH#VIR:*,P>EBS330^[434!;TU\Q#E""_P4'F.
MW">1\P W:3;,%/LJ#FD FEQD>W1)-*A>+V&E(<KT/%GEH)G":U8.G@>]MMO+
M>&V+M!\EW7@<@MS&*"IL"!),2?A9V2<BM<X;(P%B"0C7^W>.:9<SO'XA>5E1
M$$_X?N%<4O*^H/<TB-$H-.9A-J;"1UA"Q8AKJ^%6N($+M*2,'M]3&)S&?U#L
MEFQ&; L.0P"[RD*Z)UT=S#:894)3)V1\P@5,.[G*;A3Q G@V41P^)DWG-LV^
M(E- =#-&F6%"=$V-QM)+"WZEJ1?O1XP-O5K%AIX#-]M91FXV6PFA:V?5#%#4
MTUAN\%H@8G*8H6J@S?,2RT)K/4')#((8B_&1 O'66^O(CXNAGCKD1I8B4\'?
M=.4W&)89)^0XAM\8#_J'HWUX*)S]4&ET%\=M-/\  3AI]I98UYJ2 ?&/, /5
MA&RL, +V;@ US%AAGK*(JJ>.\2=V"TB[4P%PN"ZH;FA4D)<###X,+\U7Y[Q[
MU.;NQ4'T/0SPO__[O\N.D<?$D$F I')H[+PE!V_0_9JDM[$*KRUHH2[_0,=:
M5 _!E2(5;?JFZ1SBFQ*O/I4Q\R6/DV4YE] HB4F*M+"LI,0@D(\=%+\C5'LY
M<"DA&KQ/;#)T P2R%.Z527!RS50P#FKL5,DUTA$D6;7.0!*;>OHT.BI1O<A"
M>=WM1C28O*4#>@@[&> ?>0F_Q:8#6_8Z\54[JG]$2;_W+"3]8R:ROOOROOV_
MGXX/CJ^\3<E://BFS,7OG,?QY\]?3H^O_GEP?.9[QZ>'+6_.1!YH/XZ.+P]/
MSBZ_7+2]P[//GX^OKMKPKT_[%W">\Z:TN7<OI0(.WI]_N3@_NVSCZRHN[SMR
M]IUOX>S#<39,<Y/E:(&QQ.,%K.HD:L*4S><XZ=D9IN7?(:-R?Q7E'&T3:PT?
MUTP1O;<P:)0@#V4@K]A'1I@[H7*PF.)(8PWE.8DODG$T$*FC&6P_4CVOS1ET
M()3.>KVHBV7FUNQLVV?N3 D(3+_ZH/4T_2O/^=$'YT?X&[!.TVL.]5O%J@UT
M;W^B,H0-H.R1\7+WO?I7S<9U&L2%VA)WTOV)D_WM%\JG[_4PSUD/4TZ]'WEA
M"CJ80I89HO%<*#*1,^/@DA4+S@:8(YPD 1E9Q :CP@BFJ,B3K,A;BUY\TZ)8
M+.*)ND0JD(VPI(5J38F),F\V>A'H2'=\YP-N@J'.+ZW+EG<)%R.+1CIRT?ZK
MVP^2:T&],P98B/ZR?2BD6MG#)S[6;SC3Z;/I];@,Q;O+JXOCW]OOQXGF5\Y6
MZ6UJ-O:[%&S=?+V]XY/%PG!^'R8E ]R9VJ*<8'89#4.^J9RR O+Q .2"B=\P
M?;%)%!!2/Q8]L@OS#+"\.9A,4;XTE">V8Q2)\<B>.?=&6?MTZJT"*M0WR[<8
M:+ :R3.'&CCL%N;L(Y[$(C_0M(,QK:U)ID?-[[M@<LBO>'XTH*?'X^'J#%?T
M>"+/PVSK)!UY<02BDS$FQ246TK7+B+!L?*U#9APKZ\81;@@Z\2-R8-XOXI1L
MC$"@ 47.\ $&9,L+)[4?@AR.\E'&RY#Q/ASMNV(SAS5C  *5;M!^K5,4=RBG
M;=%"'_:\!^NA. XP&MA=W+UOXLXM4$& RXXS/"\-E* T>5%YC'-9E!QVZ80J
MASGZ;/CQ9IC"$XY'F Y<!W=KG+0EJ; .J@E,0T=Q;4Q7+K)+*J,^ZF,VZY"J
M5J"./*]ZU;WII%8;_MS^?-"^N/QT?$ZE;\XN/NZ?'O\?U<*IU5@?(X)38B(U
M1LKZYES?WA.[1G=FN49G8ZF6&,LA%RDJ!DS@NB%2R>#U!'# ZCU=P:H&S!<O
M)T9$>7#P6T8)L2Z<CZ^O$0=AH$K,%^Y-=P!YXC =KSAZ61=87%G":E(XLE7O
MR_H ^8XB!O@'Y*\$YH+2[8)%3;-AVK-L;Z_O;6Z!?K&]L[[S<F?KE2[80]LI
M8&$&5!HK*4I$ML!D!=%LT[RH$PI'D1EH*@D#N/D.QLNUNKKZT)<DNOO,><.R
M8C?*0I;!6V0EL3L>)CSSBI%=7:<YW]>-_Z@2T!)B3U<0E O[L<:X\>>P@[7R
M3%,J(T!ZXVT$HKT0C*#$F#DCGH/&0>D%4\R'^]J$P_:9:S61RP,V?N;<7I2G
M9$!I?.+-QB&>].Q!&.)2'LF:S ZD#[FL(:)1>L]\WXW4X99["%5PR'>@%*IM
MH*^M=5R:T($T>!L&NB3U'37H&RL8''B@";@5TK#Y)67Z^MY%K76K,YU]',#O
MRV>!!I!9?67*I:"<7[[.W[V$\#Z68$^G> "HL-_WC)G!"Z:Q8K\\A(\C'8_H
ME81",:$T2MT'M@S<C=VL^8A3,7#)2.0J,W#Q  ;.$C59!^N2S1V@7ACN_BE2
M!XJ1H*R]5%/-(<I\#M^" 18Z$%()XM;^0I<OK*OQ(-S(=Y4[.*/[YB+.\+W[
M'?ON]P"C9\6+0- B >?B(2?=: @D$T=!A$##CAK=*I64;[B$:Y=&4I6.$"45
M5H($@FTV7)!WV13WK"E^OW-BPQZSF]RI:4\=>0F"+CKPK)>&,=;D+Y:B'>*B
MZ$KY(<%;XG,W01:E8ZS;)P47,-:2([&'%J'0;!2#PC\5]FOS642$5[;.8K;.
M4@)>,7Y)131K="2CM2:IUU.W.L=K#O_N9QAGK>.E0"OW)K&P'J[+M=;NES7N
M3-6 RNO=+J]51P6T8TA*"1C4"U7MS731&<=)CK":H/OU.@--*"PY6"L>]@6E
MVL,*-0H,5]U.SCF7)X8BISRGBL7VO=/RJY&T:?,1*QJA Z1^/K#-?N@[8?E#
M&P$1+Z(S[5;!AN,+RO=1<I>FP1Z;#5N0Y[ZUQ)D4R8LZ \N8<9.R)E^^^*Q"
MBO^8CW$C+E42(70./O&L)@:,Z,+"T/=[/5" \Z)#(])%PC)=) PC)PG%,^Y;
M^3=6,&%'/?,:E_!=K*E 3'/_GK??6FB@-+'MY$ZA8$95*LW-O@9XM$[FC6^2
M<1DVHOZ"4QV5!47I#16_BN_4&G2SY/V2\=U"YRT:=L "$=M2Q@D:PM8&HUEC
MMLCO:L_&#8R2*R<!T[,$3R3JJKR 5%B92!#>@ $"HPV""<I)H$H=*T7T#@(F
MISD@?&W.V&N.-J.;MXB)H"YP&(^(DRCP>N$\-"DN2RV:9Z[@+6,.P"%%=@R,
M3*YP/QK.4/<JV/-YSNZIZL8]<^)Z(QIODKTU<$MB[.-"\&Q9?#T$0]NEOI>R
MT*)\1K<B%5U!*T[OB*:__^CVPEB"^Q,Z^U^N/IU='%_]LZ#FU4!-5_SEP?G+
M_5XF#,M;+7DAQN6>]X-SKOM=[0R/]A[SLF\<^ K9H\-%!=1E<+M5J  Z_5)?
M,#A4AL"B<$I*G$G9@*<BA!P!;^Y&&*!?QUIVA,XQX(0,?HOQ@FMT-LU;;3[*
MHJ_J_;OQ>S*DQ_"X_N@A+)^:%)P'.Q&;[.44)FL5^==*6?JYF-G6W9G9-VEA
M3\*[BH"$OA@.]N*; B?-1HZ>=2YB&18-'VVJ2*9721=""P]8#A59E]PO_$57
M27X[Q^;F@#YM^,J6*'-PIO6Y#PM<S(?6KQY?K;(:G;/XB_;E^=GIY?'!\<GQ
MU7'[<G%,^G34-X$@'1VNJ)Z_L5T 'R^'YWZ@]GN%919OR".)X!D2V,-N;5H,
M-1M%.?2M>/HB3&4JUB3@,F5!CJ'SJ7#%*'GC G17LN^Y(V+;&B^I(=^%$F,Z
M*NS@0@MH!:X>YN)$&9;.SC"G(OS]1X+6@BK$H#:]B0N5R%VLUD6!*TX^-;A'
MZ+ S[G7$LLYV?UA?HOM>DU1MBC3I5QO.Q%YL0NH+P >82)E!U*?1W'/$9.&
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MF133[@/K++IG6F!K2#KOHGEU5"&!712)GR>7=?,Y!)M7_.FY\">XKB96$D]
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MR;5LDTUPQ/X.7.H/TP%QZ@@I$%==1F6#X=^P9=U5T;I[N&.OE_..'6L0W:&
MXJ9Z7G5VEELE>AZA^T+E_ YC9]XI*XQ#6"'(B:#+, '&#X")B?W-IB!4R^#
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M'<$[R?B(:>:):OZN3YH;-M)$%FE@0>K.C0R:JXNK$V6J$PZ6QZTJ7J$CJZ:
MD]^'L:1J^-A^<<ZE9V99E,W4L%G>@$XE?GGU_5"R(@V$BH%G=#&=94H8M:L
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M$BW4(MB3B-J+ KD<>07Z+APN=&^1_)3"S_*S*WP#;-U53FU5G[\Z.C<_.JS
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MKJRT;N#2RA?>%;EA1QS4(^H@ !*,HY$'\BB8\_0W?_.]K8VM5SXZ+BGR>)'
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MJB3*5?QR'&+_P@F*]AP+E1&=/PWRD6"B2?:':K-HNE=416DE/-0SCRJ&9G5
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M]PNPM()7N->S!:()91(<L<X0TVS4 =/R46> 6;E?#! 7.2C'ME<"-69-V 3
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MWB$>/H1#QE7D!'%)14#RL?-DN=NXH?&S-(AG*A)$NS<*YBM'P3T["G:?KZ/
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MLU"\^J(B^ YL-^ZXD(MM7 <J^(RZ,LT#*5@3B3T%!2VNJ<Z\6$#<$85=;M0
MJ"Q]*;H9AY/*RKP%S22+ 6;9;4(#M)*'7-.J.I:VT'QTD*5FU,/5,J.R9")]
MRJ?Y3'(A",=VA&CPJ!6M42+3F+.8J->$1*(QR1UKN";,!7'0Y#52BXCTA? S
MP=QR!;'N-K<99+TV#O+)S&&4ABM^OQ'!S<V?P93Y832L:V)#SQB9W0H ';2:
M75B7^U.8;J4@=6+O]]/W__XO;S9_>_6N\A\$]E:PIB"S;G2U218B'PN*E**W
MXR#DU-8P(K:-!A4GFX@1]C&X0&#NHX:W*XA[P+ ^8A;IN7?<\/X(PZEW"D(
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MJRP+S0C&ZAV*YA4U/1@UO7J&U-3$J-9(65XZ0P=C64@I1%.9M/'TM#^T*FE
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M%5X3Y()KC2 2MED%R$M 6@-4$6> 6VR]#'+S_MV0/N7!4L_-1'5O2_)F3D<
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M+I/;J&\W;&\%T?-!%!;IXV#Z*P+BYO[>?N%0I] 1QA:F^*Y(%ZQWJ2+AK<I
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M,CDV-39D.&LN:'1M4$L! A0#%     @ VH,(6Y:IDZ(Z,   M/(  !
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H>"TR,#(U,#@P.%]P<F4N>&UL4$L%!@     &  8 ? $  'XD 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>d29656d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ibrx-20250808.xsd" xlink:type="simple"/>
    <context id="duration_2025-08-08_to_2025-08-08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
        </entity>
        <period>
            <startDate>2025-08-08</startDate>
            <endDate>2025-08-08</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2025-08-08_to_2025-08-08" id="ixv-281">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2025-08-08_to_2025-08-08"
      id="Hidden_dei_EntityCentralIndexKey">0001326110</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2025-08-08_to_2025-08-08" id="ixv-292">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2025-08-08_to_2025-08-08" id="ixv-293">2025-08-08</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2025-08-08_to_2025-08-08" id="ixv-294">ImmunityBio, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2025-08-08_to_2025-08-08" id="ixv-295">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2025-08-08_to_2025-08-08" id="ixv-296">001-37507</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2025-08-08_to_2025-08-08" id="ixv-297">43-1979754</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2025-08-08_to_2025-08-08" id="ixv-298">3530 John Hopkins Court</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="duration_2025-08-08_to_2025-08-08" id="ixv-299">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2025-08-08_to_2025-08-08" id="ixv-300">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2025-08-08_to_2025-08-08" id="ixv-301">92121</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2025-08-08_to_2025-08-08" id="ixv-302">(844)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2025-08-08_to_2025-08-08" id="ixv-303">696-5235</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2025-08-08_to_2025-08-08" id="ixv-304">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2025-08-08_to_2025-08-08" id="ixv-305">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2025-08-08_to_2025-08-08" id="ixv-306">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2025-08-08_to_2025-08-08" id="ixv-307">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2025-08-08_to_2025-08-08" id="ixv-308">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2025-08-08_to_2025-08-08" id="ixv-309">IBRX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2025-08-08_to_2025-08-08" id="ixv-310">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2025-08-08_to_2025-08-08" id="ixv-311">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
